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CHAPTER 1                             
INTRODUCTION 
 
PARTIALLY BASED ON DEVELOPING UNIVERSAL INFLUENZA VACCINES:  
HITTING THE NAIL, NOT JUST ON THE HEAD  
 
Wiersma LC, Rimmelzwaan GF, de Vries RD 
 
Vaccines, 2015 Mar 26;3(2):239-62  
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10 | Introduction 
 
During the three years in which this thesis was conceived, two major zoonotic respiratory 
viruses emerged: Middle East Respiratory Syndrome (MERS) coronavirus (CoV), which 
originated in dromedary camels, and Influenza A/H7N9 virus, which originated in poultry. 
This gives some indication of the high rate of emergence of novel viruses the world is 
currently facing, at least in part, due to changes in the structure and demographics of 
human populations and our behaviour [1, 2]. A particularly important aspect in the case of 
these two zoonotic viruses is the intensification of livestock production [3]. Camel 
populations in Saudi Arabia alone were estimated at almost 300,000, on a population of 
only 30 million (FAOSTAT 2013). Even more mind-boggling are the statistics on poultry in 
China, with an estimated 5 billion live chickens for 1.35 billion inhabitants (FAOSTAT 
2013), i.e. there are approximately 3.7 times more chickens than people in China. Close 
interaction with these livestock species, in for example backyard flocks, live poultry 
markets or camel slaughterhouses, camel sporting events, and even camel beauty 
pageants, provide ample opportunity for viruses to cross the species barrier.  The high 
human population densities and the frequency of travel in turn provide fertile ground for 
a pandemic if these pathogens acquire the ability to efficiently spread from human to 
human, as happened in 2009 for Influenza A/H1N1 virus. Fortunately so far, neither 
A/H7N9 virus nor MERS-CoV is capable of wreaking such havoc, but it is not clear whether 
we will remain so lucky. It is therefore essential that we elucidate host/pathogen 
interactions with the ultimate goal of creating effective prevention and intervention 
strategies. For elucidating host/pathogen interactions as well as testing candidate 
vaccines, animal models that mimic human disease as closely as possible are 
indispensable. In this introduction, an overview will be given of the general characteristics, 
the existing animal models and the current advances in vaccine development for both 
human influenza A and coronaviruses.  
 
BACKGROUND  
 
INFLUENZA VIRUSES 
 
Influenza viruses are enveloped, single-stranded, negative-sense RNA viruses that belong 
to the family of Orthomyxoviridae and are divided into three types: A, B and C. Influenza C 
viruses are rarely isolated and disease caused by these viruses is usually limited to mild 
symptoms in children [4, 5]. Influenza B viruses have no animal reservoir, unlike influenza 
A viruses, and predominantly infect humans. Influenza B can be divided into two 
i
i
i
i
i
i
i
i
Introduction | 11 
 
Ch
ap
te
r 1
 phylogenetic lineages: Yamagata 16/88-like and Victoria 2/87-like [6]. These viruses have 
lower mutation rates [7], but also contribute to seasonal influenza activity considerably 
(van de Sandt et al 2015, Future Microbiology, in press).  This thesis, however, will focus 
on Influenza A viruses which can infect many different species and are responsible for 
substantial morbidity and mortality during seasonal epidemics. Furthermore, a zoonotic 
spillover event of influenza A could potentially be the cause of a novel pandemic. The 
influenza A genome consists of 8 segments encoding 11 major proteins: Polymerase basic 
(PB)2 protein, PB1 and PB1-F2 proteins, Polymerase Acidic (PA) protein, Haemagglutinin 
(HA), Nucleoprotein (NP), Neuraminidase (NA), Matrix (M)1 and M2 proteins, non-
structural (NS)1 and nuclear export (NE) proteins and these viruses are further divided 
into subtypes based on the surface glycoproteins HA and NA. According to the HA 
designation, viruses are classified into two groups. H1, H2, H5, H6, H8, H9, H11, H12, H13, 
H16, H17 and H18 are considered group 1 HAs and H3, H4, H7, H10, H14 and H15 belong 
to group 2 HAs.  
 
Both seasonal and pandemic influenza viruses can have huge public health consequences. 
In 2003 in the United States alone the total annual economic burden of seasonal influenza 
was estimated to be $87.1 billion [8]. Introduction of novel subtypes of influenza A virus 
into the human population may lead to pandemic outbreaks, as has happened three times 
in the previous century: in 1918 (Spanish flu, caused by A(H1N1) viruses), in 1957 (Asian 
flu, caused by A(H2N2) viruses) and in 1968 (Hong Kong flu, caused by A(H3N2) viruses). 
The most recent influenza pandemic in 2009 was caused by an H1N1 influenza A virus of 
swine origin [9]. Each of these pandemic outbreaks of influenza was associated with 
excess morbidity and mortality. On several occasions, zoonotic transmission of avian 
influenza A viruses from birds to humans of subtypes H5N1 [10, 11] H7N9 [12], H9N2 [13], 
H6N1 [14], H7N3 [15, 16] and H10N8 [17] has occurred, sometimes leading to fatal 
disease. Although thus far human-to-human transmission remains limited for these 
subtypes, infections with H5N1 and H7N9 viruses in particular constitute a pandemic 
threat [18]. It has been demonstrated recently that only a limited number of mutations in 
the HA and the viral polymerases are required to make airborne transmission of highly 
pathogenic avian influenza A viruses of the H5N1 subtype possible [19-21]. Indeed, some 
of these adaptive mutations were already found in circulating H5N1 viruses [22]. Influenza 
viruses can acquire additional genetic changes rapidly, either by mutation or by 
reassortment with viruses adapted to replicate in mammalian hosts [23]. 
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CORONAVIRUSES 
 
Coronaviruses are enveloped, single stranded, positive-sense RNA viruses with the largest 
genome of all RNA viruses: 26-32 kb. They belong to the family Coronaviridae and 
comprise four genera: α, β, γ and δ coronaviruses. A wide range of birds and mammals are 
susceptible to these viruses, and they are known to cause predominantly gastrointestinal 
and/or respiratory disease. However in humans they appear to be exclusively respiratory 
pathogens, with only few reports of associated gastrointestinal disease [24].   
Coronaviruses attach to cells via the spike (S) protein, a characteristically shaped 
transmembrane peplomer that gives the viral surface the crown-like morphology to which 
the virus lends its name and which largely determines the viral host range. The S protein 
plays a key role in inducing both cellular and humoral immunity and consists of two 
subunits: the S1 subunit contains a receptor-binding domain (RBD) that engages the host 
receptor and the S2 subunit that mediates fusion between the viral and host cell 
membrane [25]. Once the virus has entered the cytoplasm, RNA dependent RNA 
polymerase is produced. This polymerase subsequently transcribes negative sense RNA 
that is used as a template to produce either progeny genomes or subgenomic RNA 
encoding the various viral proteins. Coronavirus genomes consist of six to ten open 
reading frames (ORFs) that encode the structural proteins (Spike (S), Envelope (E), 
Membrane (M), Nucelocapsid (N) and, depending on the virus, hemagglutinin esterase 
(HE)) the replicase proteins, and variable numbers of accessory proteins. When 
transcription and translation of viral elements is complete, the genome is packaged into a 
helix with the N protein and enveloped by a host-derived membrane containing M, E, S 
and sometimes HE viral proteins [26].  
To date, there are six coronaviruses that are known to infect humans (HCoVs). Two are 
alphacoronaviruses (NL63 [27] and 229E [28] viruses) and the remainder are 
betacoronaviruses (HKU1 [29], OC43 [30], Severe Acute Respiratory Syndrome (SARS) [31] 
and Middle Eastern Respiratory Syndrome (MERS) [32] coronaviruses). All human 
coronaviruses except SARS-CoV and MERS-CoV are known to cause seasonally recurring 
infections of predominantly the upper respiratory tract, rarely progressing to more severe 
disease in the form of pneumonia.  SARS-CoV emerged in 2002 and caused an outbreak 
that was relatively quickly contained and affected a limited number of people (8,000 
confirmed cases, approximately 770 fatal [33]) but that nonetheless had an enormous 
economic impact, with global economic losses estimated at close to $40 billion in 2003 
[34].  MERS-CoV continues to circulate at the time of writing and has been shown to infect 
1638 people, claiming 587 lives (WHO). 
i
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 Both SARS-CoV and MERS-CoV are zoonotic and appear to have originated in bats, as they 
are closely related to bat coronaviruses HKU4-CoV and HKU5-CoV [35]. However humans 
were not found to be infected with SARS-CoV directly through bats, but rather via an 
intermediate animal reservoir, the palm civet [36]. Much effort concentrated on finding 
the animal reservoir for MERS-CoV has led to the dromedary camel as the most likely 
culprit [37, 38]. Like MERS-CoV and SARS-CoV, there is some evidence that NL63 also 
originally emerged from a bat reservoir [39] but it is now effectively transmitted and 
maintained within the human population without an intermediate host. 
Overall, coronaviruses mutate more slowly than influenza viruses due to numerous RNA 
enzymes that improve the fidelity of the RNA dependent RNA polymerase [40]. However, 
in addition to point mutations, like influenza viruses, they are able to recombine, 
especially in the context of a co-infection [41, 42]. Both of these mechanisms, especially 
when considering genetic changes in the receptor binding domain (RBD) of the S protein, 
may explain how new coronaviruses are able to emerge from animal reservoirs [40].  
 
 
 
ANIMAL MODELS 
  
 
Animal models, despite their limitations, are still the mainstay of research into 
pathogenesis and replication kinetics of many viral diseases, as well as providing the only 
way of pre-clinically testing prevention/intervention methods. Ideally, a model should 
reproduce all the hallmarks of the human disease as faithfully as possible in an 
immunocompetent animal that has been administered a realistic quantity of unadapted 
virus via an appropriate inoculatory route. However, the extent to which an animal model 
represents its human counterpart is often difficult to ascertain in the absence of accurate 
descriptions of human disease. This has especially proved an issue for MERS-CoV, as its 
geographical origin (i.e. the Middle East) precludes autopsies on deceased patients for 
cultural reasons. Lack of an appropriate animal model is a substantial obstacle in the 
development of intervention strategies, as will be discussed subsequently under the 
heading vaccine development.  
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INFLUENZA VIRUSES 
 
Animal models for influenza have been repeatedly and extensively reviewed [43-46]. A 
wide range of species has been assessed for suitability but only few species are routinely 
used and these are discussed below. 
 
Ferrets 
Ferrets are considered the gold standard animal model for influenza as the hallmarks of 
human disease are most closely mimicked in this species. They are susceptible to many 
unadapted human influenza viruses (both A and B) as well as some avian and swine 
influenza A viruses. The distribution of the α2,3-linked (avian) and  α2,6-linked 
(mammalian) sialic acid (SA) influenza virus receptors closely resembles that of humans; 
i.e. α2,6 is more abundant in the upper respiratory tract and α2,3 is more abundant in the 
lower respiratory tract [47]. The pathology induced by the different influenza subtypes 
mirrors this receptor distribution; as for humans, fully mammalian adapted subtypes 
cause predominantly transient upper respiratory tract infections and avian viruses such as 
H5N1 cause more severe, lower respiratory tract pathology [23]. Clinical signs in ferrets 
roughly resemble human "flu-like symptoms" and include fever, malaise, anorexia, 
yawning, sneezing and nasal discharge and congestion.  A salient difference is that ferrets 
appear to develop neurological symptoms/invasion of the central nervous system more 
frequently than humans, although this effect does appear to be subtype and dose 
dependent. Ferrets develop neutralizing antibodies in response to infection but 
unfortunately detailed studies of cellular correlates of protection in this species are largely 
lacking because both inbred animals and reagents are not available. However, depletion of 
alveolar macrophages was shown to cause higher viral loads and more prominent 
inflammatory infiltrates [48] and heterosubtypic immunity following natural infection has 
also been demonstrated [49, 50]. Ferrets are also known to efficiently transmit influenza 
virus, both directly (contact transmission) and indirectly (airborne transmission) [51].  
 
Mice 
Although ferrets may be the gold standard, mice clearly afford some practical advantages 
including cost, ease of handling and husbandry, availability of reagents and a wide range 
of genetic backgrounds.  However, mice are generally not susceptible to unadapted 
human influenza viruses and develop lower respiratory tract disease that is rather 
dissimilar to that caused by the homologous virus in humans. SA receptor distribution of 
the mouse has rarely been reported and existing reports are incongruent, possibly 
i
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 indicating that different mouse strains express SA's differently [52, 53].  Clinical signs in 
mice are generally more severe than in humans and lack the febrile nature. They include 
marked anorexia, lethargy, hunching, labored breathing, fur ruffling, huddling, 
hypothermia and dehydration. Although clearly this model is not a faithful reproduction of 
the disease in humans, one big advantage, apart from cost and ease of handling, is that it 
allows for more detailed study of cellular immunity to influenza virus infection. A vast 
amount of information has accumulated on this topic, and summarized in numerous 
reviews, including [54]. Another potential issue of the mouse is that transmission of 
influenza viruses is, at best, inefficient in this model [55]. Considering the obvious 
limitations, one may ask; if murine disease appears to be so dissimilar from humans, to 
what extent is information gained from this model useful? This has been further discussed 
in more detail in [56].  
 
Guinea pigs 
Guinea pigs are highly susceptible to unadapted human influenza viruses, as well as avian 
and swine viruses [55], and they have therefore frequently been used as an animal model 
for influenza virus infection. Guinea pigs were shown to express α2,3- and   α2,6-SA 
receptors in the nasal cavity and the trachea, whereas in the lungs, the α2,3-SA receptor is 
most widely present [57]. The pathogenesis of influenza in guinea pigs depends on the 
inoculatory route, as will be discussed further in Chapter 2 of this thesis. When inoculated 
intranasally, as is most commonly done, infection appears to be limited to the upper 
respiratory tract [58]. Clinical signs in this model again are rather unlike to those in 
humans as they are generally very mild and, in contrast to ferrets and mice, lethal 
infection is rarely observed. They are however, commonly used as a model for 
transmission as (like ferrets) they readily transmit influenza viruses, but (in contrast to 
ferrets) they are smaller, easier to handle and less costly. Although some work has been 
carried out on the innate immune response of guinea pigs to influenza virus infection, 
little is known about cellular immunity. In this thesis, the isogenic (strain 2) guinea pig 
model will be further discussed as a potentially unique way of studying cellular immunity 
and its effect on (airborne) transmission. The isogenic guinea pig model derives its 
uniqueness from the fact that it combines the advantages of the ferret (transmission) and 
the mouse model (isogenicity). This way, the effect of cellular immunity on transmission 
can be studied for the first time.  
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CORONAVIRUSES 
 
Unfortunately, finding an appropriate animal model for human coronaviruses has proved 
to be more troublesome than for influenza. Interest in developing animal models for 
seasonally circulating human coronaviruses such as OC43-CoV, 229E-CoV, HKU1-CoV and 
NL63-CoV has been very limited. 229E-CoV has only  been studied in (double) transgenic 
mice [59]. OC43-CoV has also been studied in mice, but not as a representative of human 
respiratory infection but rather to asses the neural pathology and neuroinvasion [60, 61]. 
Neither HKU1-CoV nor NL63-CoV have been tested in animal models, although serological 
investigation on captive rhesus macaques suggests that these animals can be naturally 
infected with NL63-CoV during their lifespan [62].  We report for the first time on infection 
of macaques with NL63-CoV in Chapter 6.  
Significantly more effort has focused on developing animal models for MERS-CoV and 
SARS-CoV than for the other human coronaviruses, but the models developed to date are 
disappointingly far from the 'gold standard' (reviewed in detail in [45] and [63] 
respectively). The most commonly used species are briefly discussed below, and non-
human primate models for coronaviruses are also the subject of Chapter 6. 
 
Non-human primates 
Cynomolgous macaques appear to be susceptible to infection with MERS-CoV, SARS-CoV 
and NL63-CoV, however, disease in young immunocompetent animals is mild and 
transient (Chapter 6). Similar results have been found by several other groups using rhesus 
macaques as a model for MERS-CoV, [64, 65]. Receptor distribution for SARS-CoV and 
NL63-CoV (ACE2) and MERS-CoV (DPP4) in macaques mimics human receptor distribution 
[66, 67] rather well: ACE2 is present throughout the respiratory tract whereas DDP4 is 
present only in the lower respiratory tract (Chapter 6). This receptor distribution and the 
associated tissue tropism explains (at least in part), why MERS-CoV transmits poorly 
between humans compared to SARS-CoV and NL63-CoV; its prediliction for the lower 
respiratory tract likely decreases virus excretion. For SARS-CoV, the model that most 
faithfully represents human disease is the aged macaque [68], however use of this model 
is very limited due to ethical, logistical and financial constraints, which is also why this 
model has not yet been used for MERS-CoV. However the aged macaque model may 
prove to reflect disease in humans more accurately than young immunocompetent 
individuals as MERS-CoV causes severe disease predominantly in middle aged individuals 
with co-morbidities. In addition to macaques, the common marmoset was identified as a 
promising and more practical non-human primate model in which severe lethal disease 
i
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 was reported [69], however these findings were subsequently refuted by another group 
[70]. 
 
Mice and other small animals 
Although young immunocompetent mice naturally show only moderate susceptibility to 
SARS-CoV and no susceptibility to MERS-CoV, various adaptations have been devised to 
allow their use. Such adaptations are justified by the fact that this model shows obvious 
ethical, practical and financial advantages over the non-human primates discussed above. 
Engineering mice so that they express human DPP4 renders them susceptible to infection 
with MERS-CoV and induces a severe and fatal respiratory disease [71]. To allow for 
improved infection of SARS-CoV in the murine model, either older animals are used [72], 
or the virus can be adapted to the murine host by serial passaging [73]. Although 
questions may be posed regarding the extent to which such adapted models remain 
representative of disease in humans, considering the relative lack of suitable alternatives, 
they are presently the most commonly used model to study these viruses. In addition to 
the mouse model, SARS-CoV has also been studied successfully in ferrets [74-76]. Due to 
the same differences in DPP4 that preclude infection of non-adapted mice, of the other 
small animals that were inoculated with MERS-CoV, only the rabbit was productively 
infected. However, infection of rabbits was asymptomatic and limited to the upper 
respiratory tract, and as such the pathogenesis appears to resemble the disease in camels 
rather than humans [77]. 
 
VACCINE DEVELOPMENT 
 
 
Evidently the purpose of developing animal models is not only to understand viral 
replication kinetics, pathogenesis and immune responses, but ultimately to use this 
information for the development of effective intervention strategies. Although vaccine 
approaches for influenza are far more abundant than for coronaviruses, the holy grail of 
influenza vaccine development, a universal vaccine, remains elusive [78]. Coronavirus 
vaccine development has been plagued in part by the difficulties in finding appropriate 
animal models, as discussed above, and in part by the lack of incentive for the 
pharmaceutical industry to go through the costly development of a vaccine for a disease 
that affects a relatively low number of people [79].  
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INFLUENZA VIRUSES 
 
Most existing influenza vaccines are produced using labor intensive and time-consuming 
production methods that rely on the availability of embryonated chicken eggs. In the face 
of an outbreak caused by a novel emerging subtype, these methods suffer from logistical 
problems that preclude an adequate response. The delayed availability of sufficient 
numbers of vaccine doses may have disastrous consequences for public health. As will be 
discussed in this review, the limitations of the current vaccines highlight the pressing need 
for game-changing vaccines that induce long-lasting immunity against a wide range of 
influenza viruses.  
Currently used vaccines to protect against seasonal and pandemic influenza virus 
infections predominantly aim at the induction of antibodies directed at specific sites on 
the highly variable head domain of the HA surface glycoprotein and to a lesser extent, the 
NA glycoprotein [80]. Since the error rate of influenza virus is high due to low fidelity of 
the RNA polymerase complex, mutations in the viral genome can accumulate quickly, 
under selective pressure e.g. exerted by virus neutralizing antibodies induced by previous 
infections or vaccinations. Vaccines that induce HA globular head-specific antibodies will 
become less effective when mutations in HA accumulate to such an extent that vaccine-
induced HA-specific antibodies can no longer recognize their target, a process known as 
antigenic drift. Currently used vaccines are generally trivalent; they contain components 
of two influenza A strains (H1N1 and H3N2) and one influenza B strain. The strains used in 
seasonal vaccines are selected annually approximately eight months before the start of 
the seasonal vaccination campaign. Selection of vaccine components is based on 
prediction of strains likely to circulate in the subsequent influenza season. Although some 
methods, such as mathematical modeling of influenza virus evolution [81], have been 
developed to aid this prediction, the recommendation of the best possible vaccine strains 
remains difficult [82]. When vaccine strains do not match the epidemic strains, this can 
potentially lead to higher morbidity and mortality [83]. 
Different formulations of inactivated vaccines are used for parenteral administration: 
whole virion, split virion and subunit vaccines. Split virion and subunit vaccines, initially 
developed to overcome adverse reactions associated with whole virion vaccines [84], 
were shown to be of comparable immunogenicity but were less reactogenic than whole 
virion preparations. Since the 70's, inactivated trivalent split virion vaccines have most 
commonly been used as seasonal vaccines. Paradoxically, the efficacy of these vaccines in 
age groups that are most at risk (the young and the elderly) is actually lower than for 
healthy adults [85-88]. 
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 An alternative to the inactivated formulations is live attenuated influenza vaccines (LAIV) 
that are produced by reassortment of gene segments encoding the desired HA and NA 
glycoproteins and those of a cold adapted (attenuated) strain. As these vaccines are 
administered intranasally they can induce mucosal immunity, in addition to systemic 
antibody and T cell responses, more closely mimicking the immune response induced after 
natural influenza virus infection. Because of low immunogenicity of inactivated vaccines in 
children, LAIV may be better suited to protect this age group [89]. Indeed it was shown 
that after intranasal administration of LAIV to children between 3-17 years of age, 
significant increases in B-cell and T-cell responses could be induced that were sustained at 
least 1 year after vaccination [90, 91]. However, whether universal vaccination of all 
immunologically naive children is in fact an advisable strategy remains a topic of debate. 
Vaccination of children at risk of developing severe complications due to influenza is of 
course highly recommended, vaccination of otherwise healthy children not at risk for 
developing severe complications with inactivated vaccines may interfere with 
development of heterosubtypic immunity that is otherwise induced following natural 
infections [92, 93].  
Even though in some situations, such as childhood vaccination, LAIV may have advantages 
over TIV [94], they suffer from similar problems regarding production. Like inactivated 
vaccines, the production process of LAIV is still predominantly egg-based and difficult to 
scale-up. Vaccine-induced antibodies are also directed mostly against the head domain of 
HA and thus at risk of losing effectiveness in the face of antigenic drift or shift. In addition, 
LAIV production has some challenges of its own like the incompatibility of certain HA and 
NA combinations with the backbone virus to create a replication competent vaccine virus 
[95].  
Clearly, currently available influenza virus vaccination strategies leave a lot to be desired. 
The induction of strain-specific antibodies directed to the head domain of the HA may be 
efficacious if the vaccine strains match the anticipated epidemic strains. In case of 
antigenic drift or in the case of a pandemic outbreak caused by newly emerging influenza 
viruses, the availability of vaccines that induce more broadly protective immunity is 
desirable to overcome this important public health issue. Such vaccines should induce 
antibodies against more conserved proteins or regions thereof and activate other arms of 
the immune system, like cell-mediated immune responses to conserved proteins. In other 
words, such vaccines should hit the nail (but not just on the head). 
Numerous approaches have been employed to develop these elusive universal vaccines. 
They have been outlined and discussed in more detail in [78]. Briefly, compared to current 
regimens, novel approaches to vaccination against influenza can be improved in two 
i
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important ways, either by inducing more broadly protective immune responses or by 
decreasing the time of production using novel vaccine platforms.  
 
 
Figure 1 Schematic representation of possible immunological correlates of protection. Numerals in red 
show various immunological correlates of protection as indicated below. (A) Cartoon of an influenza virion, 
showing the hemagglutinin (HA) surface glycoprotein (stem and head), the neuraminidase (NA) surface 
glycoprotein, the matrix 2 (M2) ion channel, the matrix 1 (M1) structural protein and the ribonucleoproteins 
(RNPs: the combination of genomic RNA, viral polymerases PA, PB1 and PB2 and nucleoproteins (NP)). 
Antibodies directed against HA can either target the globular head (1A) or stem region (1B). (B) Interference 
of production of progeny virus by infected cells by various immunological correlates of protection, including 
(1) antibodies against HA head, interfering with binding or HA stem, potentially interfering with post-entry 
functions of HA, like endosomal membrane fusion; (2) antibodies against NA, limiting the production of 
progeny virus; (3) antibodies against M2e, HA or NA, followed by ADCC through CD16 signaling in NK cells (or 
phagocytosis, not shown); (4) virus-specific CD4+ T lymphocytes; and (5) virus-specific CD8+ T lymphocytes 
that possess cytolytic activity. 
 
Inducing broadly protective immune responses 
The influenza genome encodes 11 major proteins on 8 segments of RNA: HA, NA, NP, M1, 
M2, NS1, NS2, PA, PB1, PB1-F2 and PB2. These proteins are variably conserved among 
avian and human virus isolates and this information may be of use when attempting to 
identify conserved targets required to make a universal vaccine. A large study that 
analyzed more than 36,000 sequences of virus isolates collected over the past 30 years 
showed that PB1-F2, NA, M2, NS1 and NS2 proteins contain no sequences that were 
completely conserved in at least 80% of the viruses. However, comparison of the 
sequences of PB2, PB1, PA, NP, and M1 proteins showed that 55 sequences of 9-58 amino 
acids were completely conserved in at least 80%, or even as much as 95 to 100%, of the 
avian and human influenza A virus isolates and, although HA is generally considered to be 
highly variable, there was one 9 amino acid sequence that was conserved in all type A 
viruses [96].  
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 When humoral immunity is induced, resultant antibodies can exert their effects by directly 
neutralizing virus particles, but can also mediate a number of non-neutralizing 
immunologic functions, including blocking of fusion between the viral and endosomal 
membrane, innate immune system activation, complement-mediated lysis, phagocytosis 
and antibody dependent cell-mediated cytotoxicity (ADCC). Broadly protective antibodies 
currently under investigation include those specific for membrane proteins such as M2, 
NA and HA. The latter deserves special mention as some exciting breakthroughs have 
been made very recently. In contrast to the head, the stem of the HA protein is highly 
conserved and the development of vaccines using so-called 'headless HA' have been the 
focus of intense research. However, until recently the instability of the stem in absence of 
the head posed a serious limitation on this vaccine candidate. Using very different 
methods but with similar results, two different groups were able to stabilize headless HA 
immunogens that induced broadly cross-reactive antibodies. In one study, vaccination 
completely protected mice and partially protected ferrets [97] and in the other, mice were 
protected from lethal infection and macaques showed decrease in fever after sublethal 
challenge [98].  
Antibodies can also be directed at more highly conserved internal proteins. These are 
generally non-neutralizing and therefore alone they may not be sufficient to provide 
broad immunity, but evidence is mounting that they are of importance in conjunction 
with, for example, cell mediated immunity [99, 100]. 
Although cell mediated immunity (CMI) to influenza virus infections does not prevent 
infection, it can significantly decrease viral shedding, reduce disease severity and 
mortality. As T lymphocytes (CD4+ or CD8+) tend to preferentially recognize the more 
conserved internal proteins such as the nucleoprotein and matrix 1 (M1) protein, there is 
a greater potential for broad responses [101]. Indeed, CMI has repeatedly been shown to 
contribute to responses to both homologous and heterologous virus challenge [102-105]. 
Protection against virus of heterologous subtypes is known as heterosubtypic immunity 
[106], and it has been demonstrated that T cells play a crucial role in its development in 
animal models such as mice [107], ferrets [108] and macaques [109, 110]. In humans, a 
protective role of pre-existing virus specific CD8+ and CD4+ T cells has also been 
demonstrated against experimental infections [111, 112] and natural infection with the 
pandemic virus of 2009 [113-115]. Studies employing adoptive transfer of T cells from 
primed donor to naive recipient mice have contributed to our understanding of the 
function of both CD4+ and CD8+ cells in protection [116]. The isogenic guinea pig model 
that is discussed in Chapter 2, 3 and 4 is a new model that will allow for such adoptive 
transfer studies and additionally allows for investigation into the effect of CMI on 
transmission. 
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Novel vaccine platforms 
With progressively improved knowledge of the protective antigenic targets described 
above and the advent of new techniques, an ever-increasing number of platforms for the 
generation of a universal vaccine are becoming available. These techniques can be 
employed in numerous ways to deliver the desired antigens. Additionally, these systems 
often allow for different routes of administration, which in turn can steer the type of 
immune response induced. Novel platforms offer promise for both of the two 
improvements of influenza vaccines; induction of more broadly protective immunity and 
reduced production time.  
Novel approaches include viral vectors (further discussed below), DNA vaccines that 
employ DNA plasmids encoding influenza viral antigens, virus-like particles (VPLs) that 
serve as vehicles for antigens and virosomes that are essentially empty influenza virus 
envelopes that lack genetic material. A common limitation of some of these novel 
platforms, but also of existing influenza vaccines, remains limited immunogenicity. 
Adjuvants such as aluminium salts have been used to boost immunogenicity of human 
vaccines for decades, but novel approaches include improved adjuvants. Besides solely 
increasing immunogenicity, adjuvants can play an important role in facilitating increased 
speed of vaccine availability, because less viral antigen is required per dose (dose-sparing) 
meaning that more doses can become available in short period of time. Adjuvants may 
also help to broaden the humoral immune response [117] and some, such as ISCOMS have 
even been shown to result in increased virus specific CD8+ T-cell responses as was 
demonstrated in animal models and in clinical trials [118-121]. 
One novel approach, viral vectors, will be discussed in more detail as it was evaluated for 
efficacy in the ferret model in Chapter 5 of this thesis. Viral vectors are recombinant, non-
influenza viruses engineered to express influenza viral proteins. There are several 
advantages of using (attenuated or replication deficient) viral vectors as vaccine platforms 
for universal vaccines. As previously mentioned, cellular immune responses appear to play 
a pivotal role in protection from influenza infection, especially when a broad 
(heterosubtypic) immunity is desired. Subunit proteins, and whole or split inactivated 
viruses, often induce antibody and CD4+ T-cell responses due to exclusive antigen 
presentation by MHC class II. The advantage of using viral vectors is that they drive de 
novo synthesis of proteins in infected cells and facilitate endogenous antigen processing 
and presentation by both MHC class I and II molecules, thus inducing the complete 
spectrum of cellular and humoral immune responses. Additionally, they may stimulate 
mucosal immunity (depending on the route of administration) and thus function much like 
the existing LAIV vaccines, but without many of the safety or production issues. Viral 
vectors may actually be able to act as their own adjuvants as the immune system can 
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 mount a response to both the protein of interest and the vector. Consequently, these 
vaccines even have the potential to be used as bivalent vaccines, protecting against the 
vector itself as well as the transgenic influenza virus protein(s). Conversely, this may 
require that the host is immunologically naive for the vector, as pre-existing immunity to 
the vector could potentially interfere with induction of immunity against the foreign 
protein of interest. Other concerns with some of the vectors, for example the use 
Newcastle disease virus, include the possibility of recombination and reversion to 
virulence in chickens [122]. 
DNA viruses such as adenovirus [123], herpesvirus [124], baculovirus [125] and poxvirus 
[126] have been used for the generation of recombinant influenza virus vaccines. RNA 
viral vectors, including paramyxovirus, flavivirus, retrovirus, coronavirus, alphavirus, 
bunyavirus and rhabdovirus [127-129], have also been considered for expression of 
influenza virus proteins. To date, vectors expressing influenza virus HA genes are most 
commonly used but recently other antigens such as NP and M1 have also been employed, 
either alone or in combination with HA. Notably, Price et al have shown that immunization 
with a mixture of adenoviruses expressing NP and M2 confers heterosubtypic immunity 
[130], and can even reduce transmission in a mouse model [131]. The simultaneous 
expression of surface and internal proteins has the potential to induce both humoral and 
cell mediated immunity, therefore making these platforms interesting candidates for the 
development of universal vaccines. 
One particularly promising candidate for universal influenza vaccine production is the 
Modified Vaccinia Ankara (MVA) vector [132, 133]. MVA is avian adapted and does not 
produce infectious progeny upon infection of most mammalian cells [134]. It does, 
however, express early, intermediate and abundant late gene products in these cells, 
therefore making it both safe and effective. Of importance, potentially pre-existing 
immunity to the MVA vector induced after vaccinia virus vaccination against small pox 
before 1975, or after repeated vaccination with the vector, does not interfere with 
immunogenicity [135]. Many different influenza virus proteins have been expressed in 
MVA vectors; including HA of pandemic H1N1, H7N9 (Chapter 5) and H5N1 [136-140], HA 
combined with NP [135] and NP combined with M1 [141]. Interestingly, it was shown that 
priming with an adenoviral vector with NP and M1 followed by an MVA-NP-M1 boost, 
provided better heterologous protection than using either vector alone [142]. 
Recombinant MVAs have been evaluated in clinical trials and were shown to be effective, 
safe and practical alternatives to current vaccination strategies [143, 144]. Therefore MVA 
is considered as a promising alternative vaccine platform for universal influenza vaccine 
development. 
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CORONAVIRUSES 
 
Although progress has been made, at present there are no licensed vaccines for SARS-CoV 
or MERS-CoV. The previously discussed limitations of the available animal models have 
had significant effects on the development of effective prevention and intervention 
strategies.  A brief overview of the basic principles of adaptive immunity to coronaviruses 
and how this knowledge has so far been employed in the quest for efficacious coronavirus 
vaccines will be given below.  
 
Humoral and Cell Mediated Immunity  
As is the case for influenza, coronavirus surface proteins are attractive targets for the 
induction of humoral immunity. Studies with SARS-CoV have shown that the S protein is a 
promising vaccine target as it induces high titers of neutralizing antibodies in sera of 
recovered patients [145] and in animal models [146]. However, neutralizing antibodies 
appear short lived in recovered patients and display narrow specificity for the viral strain 
that elicited them [147]. In addition, when inducing humoral immunity to coronaviruses, 
special attention must be paid to a phenomenon known as antibody dependent 
enhancement (ADE). For SARS-CoV it was shown that immunizing ferrets with an MVA-
vectored, full-length S protein resulted in hepatic necrosis and enhancement of disease 
[148]. It is postulated that the full-length S protein may contain non-neutralizing epitopes 
that induce increased uptake of virus and can cause severe immunopathology [148, 149]. 
Therefore attempts were made to identify only the epitopes that induce high levels of 
neutralizing antibody. They were mapped to the RBD domain in vitro [150, 151] and were 
shown to induce protective antibodies in the mouse model [152]. In the case of MERS-
CoV, experiments in mice have so far shown that MVA vectored full-length S protein 
induced high levels of neutralizing antibodies that did not appear to enhance disease 
[153].  
Relatively little is known about the T cell response to human coronaviruses, and most that 
is known has been learned from SARS-CoV (reviewed in [154]). Importantly for vaccine 
development, in contrast to the relatively short-lived humoral immune response, cellular 
immunity appears longer lived [155].  Both SARS-CoV and MERS-CoV initially cause marked 
leukopenia and in SARS-CoV infected patients with severe disease this was shown to delay 
the development of the adaptive immune response and resulted in prolonged clearance 
[156]. Several SARS-CoV T cell epitopes on the S and N proteins have been identified using 
peripheral blood monocytes (PBMCs) obtained from recovered patients [157, 158] and 
these proteins are both capable of inducing CD4+ and CD8+ T-cell responses. Equally, 
numerous CD4+ and CD8+ T-cell epitopes have been identified on S and N proteins in mice 
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 [154] and T cell responses have been shown to contribute to increased clearance and 
decreased clinical disease. Notably, adoptive transfer experiments of SARS-CoV specific 
CD4+ and CD8+ cells in mice accelerated viral clearance and reduced symptoms in 
challenged recipient mice [159].  
Although information on immune responses is relatively limited, it appears clear that both 
S and N are capable of inducing potentially protective humoral (S) and cellular (S and N) 
immune responses and should therefore be considered the most attractive vaccine 
candidates.  
 
Vaccine platforms  
The available options for vaccine development for coronaviruses parallel those discussed 
for influenza and include inactivated or live-attenuated, subunit, DNA, VLPs and viral-
vectored vaccines. Also, different adjuvants, including alum and MF59, have been tested 
to enhance immunogenicity of these vaccines. However all strategies have so far proven 
less successful than for their influenza counterparts. 
It has been shown in several animal models that it is possible to induce potent immune 
responses against SARS-CoV using inactivated or live attenuated (especially E attenuated 
[160]) vaccines [161-166]. However, the potential of attenuated vaccine strains to revert 
to virulence makes them less suitable, especially for use in immunosuppressed individuals, 
which for MERS-CoV would be the target population. Also, Th2 immunopathology 
suggestive of hypersensitivity associated with eosinophilic infiltration has been observed 
with SARS-CoV inactivated whole virus vaccine in ferrets and nonhuman primates, which 
warrants caution when further development of such vaccine candidates is considered 
[167]. However this may have merely been an effect of the adjuvant as recently a new 
formulation of inactivated whole-virus with a novel delta inulin-based polysaccharide 
adjuvant was shown to provide protection without inducing such eosinophilic 
immunopathology in the murine model [168]. 
As previously mentioned, subunit vaccines based on well-defined immunogenic epitopes 
of the RBD and excluding potentially ADE-inducing non-neutralizing epitopes of the S 
protein may be attractive vaccine candidates for both SARS-CoV and MERS-CoV [169-171]. 
DNA vaccines encoding SARS-CoV S protein have been shown to induce both humoral 
immunity and CMI and they have proven effective in the mouse model [172] and have 
progressed to Phase I clinical trials [155].  However, immunogenicity of such vaccine 
formulations remains relatively low [72].  
VLPs can be generated in various mammalian and plant expression systems and one of the 
most successful coronavirus VLP formulations to date has been chimeric and consisted of 
i
i
i
i
i
i
i
i
26 | Introduction 
 
E, M and N proteins of mouse hepatitis virus-CoV and SARS-CoV S protein. It was effective 
at inducing neutralizing antibodies and protecting from mice challenge [173].  
MVA, Vesicular Stomatitis virus, adenovirus, rhabdovirus and attenuated parainfluenza 
virus have been assessed as potential vectors for S, N and M proteins in the development 
of viral vectored vaccines against SARS-CoV. Although efficacy at inducing both humoral 
and cell mediated immunity of such vaccines has been shown [169], as mentioned above; 
attention must be paid to the exact formulation of the vectored antigen to avoid induction 
of ADE. Also, pre-existing immunity to the vector may pose problems, as can be the case 
for adenovirus [174]. For MERS-CoV, MVA [153, 175] and adenoviruses [176, 177] appear 
to be promising candidates. The advantage of such viral vectored vaccines is that, as is 
shown in Chapter 5, they allow for rapid deployment in the face of a newly emerging 
pathogen. 
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 OUTLINE OF THIS THESIS 
 
The objective of the work presented in this thesis was to improve understanding of, and 
response to, emerging zoonotic respiratory viruses. To this end, various animal models 
were employed to represent respiratory viral infections in humans. The introduction 
serves to provide a background on the currently available animal models and (potential) 
vaccine strategies for human influenza and coronavirus infections.  
 
For the work presented in this thesis, animal models were used in three distinct ways, 
underlining that the choice of animal model depends largely on the research question. In 
Chapter 2-4 a new isogenic guinea pig model was developed that provides unique features 
compared to established influenza virus models. The baseline parameters of influenza 
infection in this model were assessed to determine its suitability for use to simultaneously 
study transmission and cell mediated immunity to influenza infections. In Chapter 5, an 
established model was used to test a novel intervention strategy for an emerging 
influenza subtype. We showed that the modified vaccinia ankara (MVA)- H7 vaccine is 
effective against the newly emerging influenza A/H7N9 virus in the ferret model and that 
it satisfies one of the main aims of the novel influenza vaccines: rapid availability. Finally in 
Chapter 6, a new model was explored to gain understanding of the pathogenesis of a 
recently emerged coronavirus.  Cynomolgous macaques were used to study underlying 
mechanisms that appear to restrict MERS-CoV replication in some hosts and data was 
compared to two other coronaviruses SARS-CoV and NL63-CoV.  
 
In the summarizing discussion (Chapter 7), further attention is paid to the parallels and 
differences between coronaviruses and influenza viruses, what questions remain to be 
answered and how we may hope to answer them. 
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PATHOGENESIS OF INFECTION WITH 2009 PANDEMIC H1N1 INFLUENZA       
VIRUS IN ISOGENIC GUINEA PIGS AFTER INTRANASAL OR 
INTRATRACHEAL INOCULATION 
 
Wiersma LC, Vogelzang-van Trierum SE, van Amerongen G, van Run P, Nieuwkoop NJ, 
Ladwig M, Banneke S, Schaefer H, Kuiken T, Fouchier RA, Osterhaus AD, Rimmelzwaan GF 
 
The American journal of pathology, 2015. Mar;185(3):643-50 
i
i
i
i
i
i
i
i
30 | H1N1 Influenza Virus Infection in Isogenic Guinea Pigs 
 
ABSTRACT 
 
To elucidate the pathogenesis and transmission of influenza virus, the ferret model is 
typically used. To investigate protective immune responses, the use of inbred mouse 
strains has proven invaluable. Here, we describe a study with isogenic guinea pigs, which 
would uniquely combine the advantages of the mouse and ferret models for influenza 
virus infection. Strain 2 isogenic guinea pigs were inoculated with H1N1pdm09 influenza 
virus A/Netherlands/602/09 by the intranasal or intratracheal route. Viral replication 
kinetics were assessed by determining virus titers in nasal swabs and respiratory tissues, 
which were also used to assess histopathologic changes and the number of infected cells. 
In all guinea pigs, virus titers peaked in nasal secretions at day 2 after inoculation. 
Intranasal inoculation resulted in higher virus excretion via the nose and higher virus titers 
in the nasal turbinates than intratracheal inoculation. After intranasal inoculation, 
infectious virus was recovered only from nasal epithelium; after intratracheal inoculation, 
it was recovered also from trachea, lung, and cerebrum. Histopathologic changes 
corresponded with virus antigen distribution, being largely limited to nasal epithelium for 
intranasally infected guinea pigs and more widespread in the respiratory tract for 
intratracheally infected guinea pigs. In summary, isogenic guinea pigs show promise as a 
model to investigate the role of humoral and cell-mediated immunities to influenza and 
their effect on virus transmission. 
 
INTRODUCTION 
 
Influenza viruses are an important cause of respiratory tract infections in humans. 
Seasonal influenza A/H1N1, A/H3N2 and B-viruses cause epidemics in the human 
population annually [178]. Occasionally, novel antigenically distinct influenza viruses cause 
pandemic outbreaks with increased morbidity and mortality. The last pandemic occurred 
in 2009 and was caused by A/H1N1 viruses of swine origin [179, 180]. Furthermore, 
zoonotic transmissions of avian influenza virus of various subtypes (e.g H7N9 and H5N1) 
have been reported, and may cause relatively large numbers of fatalities [12, 181, 182]. 
To obtain understanding of these viruses regarding pathogenesis, virulence, 
transmissibility and immunity, various animal models are being employed [46, 55, 58, 
183]. Commonly, infection of ferrets is considered the preferred animal model for human 
influenza virus infections, as the pathogenesis in ferrets most closely resembles that 
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observed in humans [55, 184]. Additionally, ferrets and humans show similarities in 
receptor distribution in the respiratory tract, thus allowing for virus replication in the 
upper and/or lower respiratory tract, depending on the origin of the viruses tested and 
the route of inoculation [185, 186]. Since virus replication in the ferret upper respiratory 
tract is considered indicative for transmissibility of influenza viruses between humans, 
ferrets are also used for transmission studies [55, 58].  Other species that may be used to 
study transmission include (outbred) guinea pigs [58, 187] and, as recently identified, the 
common marmoset [188].  
The animal models mentioned above each have their advantages and limitations. It has 
proven difficult to correlate parameters of cellular immunity with pathogenesis and 
transmission in these animal species.  
For investigating (cellular) immunity to influenza virus infections inbred mouse strains 
have commonly been used, in part because many reagents are available for the 
identification and isolation of cells of the murine immune system. These models have 
provided a wealth of information on immune function [54]. The use of inbred animals also 
allows performing adoptive transfer experiments with isolated T or B lymphocyte 
populations or other cells of the immune system to assess their contribution to protective 
immunity [116]. However, mice transmit influenza viruses inefficiently and it is doubtful 
whether the pathogenesis of infection resembles that of humans [58].   
The choice of animal model for any given study should therefore be selected based on the 
research question. Ideally, an animal model is used that combines the advantages of the 
ferret and the mouse model. Therefore, we were interested in using inbred guinea pigs 
(Cavia porcellus). We used strain 2 guinea pigs; a designation that follows the principles 
devised by geneticist Sewall Wright, a pioneer in animal (specifically guinea pig) 
inheritance patterns. Currently the only inbred strains still available are strain 2 and strain 
13.  It has already been demonstrated that transfer of lymphocyte populations is possible 
in these animals [189, 190]. In addition, sufficient immunological reagents are available to 
identify and isolate lymphocyte subsets [191]. Other advantages of the use of (isogenic) 
guinea pigs is that they are susceptible to both unadapted avian and human influenza 
viruses and can be used to investigate transmissibility of these viruses in relation to the 
presence of (cellular) immunity [58]. 
Typically, guinea pigs are inoculated with influenza virus by the intranasal (IN) route [55, 
58], presumably because of the ease of administration. Intratracheal (IT) inoculation 
through intubation has been described [192] but is challenging because the diameter of 
the trachea is small and the cervicocranial anatomy of the guinea pig precludes simple 
visualization of the larynx via the mouth. To overcome these obstacles, inoculation with 
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virus by the IT route can be performed transcutaneously (surgically), which has been used 
previously with inactivated influenza virus [193] and other pathogens [194].  
The aim of the present study was to investigate the pathogenesis of influenza virus 
infection in inbred strain 2 guinea pigs and to compare different routes of inoculation, as it 
has been shown in ferrets that the route of inoculation has a profound effect on the 
pathogenesis [186].  
For infection of isogenic strain 2 guinea pigs, we used 2009 pandemic A/H1N1 influenza 
virus, which has continued to circulate as a seasonal virus since 2009. 
Although studies have been conducted into its transmission [195], knowledge about 
pathogenesis and virus replication kinetics of this virus strain in particular, and influenza 
viruses in general, is still limited in guinea pigs [196]. 
In order to pave the way for new lines of research into viral transmission and cellular 
immunity, this study was performed to assess replication kinetics and pathogenesis of 
influenza A(H1N1)pdm09 virus infection via IN or IT inoculation in strain 2 isogenic guinea 
pigs. 
 
MATERIALS AND METHODS 
 
Animals and experimental design 
All experiments were performed in accordance with an animal experimentation protocol 
approved by an independent Animal Welfare Committee (DEC Consult) and in compliance 
with national and European legislation. Twenty-two female, 12-16 week old (320-520 
grams) isogenic strain 2 guinea pigs were purposely bred at the Federal Institute for Risk 
Assesment (BfR) in Berlin, Germany. Before the start of the experiment, animals were 
tested for the presence of serum antibodies to circulating influenza viruses A/H1N1, 
A/H3N2 and B/Yamagata-like using epidemic and corresponding vaccine strains with the 
haemagglutination inhibition assay, as described [197]. Influenza virus specific antibodies 
were not detected in any of the animals.  
Animals were housed in groups of 4 or 6 per negatively pressurized BSL3 isolator unit at 
the animal facilities of the Erasmus Medical Center, on a 12-hour light/dark cycle and with 
ad-libitum access to food and water.  
Twelve animals were inoculated by the IN route under ketamine and medetomidine 
anesthesia by instilling 150 μL of virus per nostril (total volume 300 μL per guinea pig, 
containing 2 x 106 tissue culture infectious dose (TCID50) of influenza virus 
A/Netherlands/602/2009) with the animal in an upright position. The anesthetic was 
antagonized with atipamezole and during recovery of the animals, the head and nose 
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were kept slightly elevated with respect to the rump to prevent the inoculum from flowing 
out of the nostrils. Nasal, pharyngeal and rectal swabs were taken daily and animals were 
weighed prior to inoculation on day 0 and on days 1, 2, 3, 4 (n=12) and 7 (n=6) post-
inoculation (p.i.) under isofluorane anesthesia (4% induction, 2% maintenance). On day 4 
and 7, 6 animals were sacrificed by exsanguination under anesthesia with ketamine and 
medetomidine and autopsy was performed. 
Ten animals were inoculated via the IT route. To this end, animals were anesthetized with 
ketamine and medetomidine, and 500 μL PBS containing 2 x 106 TCID50 of virus was 
injected transcutaneously (surgically) directly into the trachea, while the animal was in 
dorsal recumbency. The anesthetic was antagonized with atipamezole and during 
recovery animals were again positioned with their heads slightly elevated with respect to 
the rump to prevent the inoculum from flowing out via either the pharyngeal or nasal 
cavity. Nasal, pharyngeal and rectal swabs were taken daily. Nasal swabbing was 
performed by inserting a thin (urethral) swab carefully into the nasal vestibule. Rectal and 
pharyngeal swabbing was performed by inserting the swab ca. 3 cm until slight resistance 
was felt, the swab was carefully twisted several times and retracted.  Animals were 
weighed and swabbed prior to inoculation on day 0 and on days 1 (n=10), 2 (n=8), 3 (n=6), 
4 (n=4) and 7 (n=2) p.i. under isofluorane anesthesia. On day 1, 2, 3, 4 and 7 p.i., two 
animals were sacrificed per time point by exsanguination as described above and 
autopsies were performed. 
 
Virus preparation 
Influenza virus A/Netherlands/602/2009 (A(H1N1)pdm09) was propagated in confluent 
Madin-Darby Canine Kidney (MDCK) cells. Culture supernatants were harvested after the 
appearance of cytopathic changes, cleared by low-speed centrifugation and stored at 
−80°C.  The  virus   titer  was  determined   in  MDCK  cells  as  described  previously[198]. Virus 
was diluted in Phosphate Buffered Saline (PBS) to the desired concentration of 2 x 106 
TCID50 per 300 μL for IN and 500 μL for IT inoculation.   
 
Pathological examination and Immunohistochemistry 
Autopsies were carried out according to standard procedures. The trachea was clamped 
before opening the thorax and inflated lungs were visually inspected to assess the 
percentage of pulmonary tissue affected. Samples of nasal turbinate, nasal septum, 
trachea, tracheobronchial lymph node, bronchus, lung, cerebrum (including the olfactory 
bulb), cerebellum, heart, liver, kidney, spleen, duodenum and colon were fixed in 10% 
neutral-buffered formalin. For improved histological assessment, the entire right lung was 
inflated with formalin prior to fixation. Formalin-fixed tissues were paraffin embedded, 
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sectioned at 4 μm and stained with haematoxylin and eosin (HE) for histological 
evaluation. For immunohistochemical (IHC) evaluation, antigen was retrieved using 0.1% 
protease in PBS at 37ºC for 10 minutes and tissues were stained with an 
immunoperoxidase method using a monoclonal antibody against influenza nucleoprotein 
(to assess influenza antigen distribution) or against major basic protein antibody, clone 
BMK-13 (AbD Serotec, for identification of eosinophils). For IHC, IgG2a isotype controls of 
each tissue and a positive control (for influenza) were included. All slides were evaluated 
by light microscopy without knowledge of the identity of the animals. Cranial and caudal 
lung lobes were sectioned both longitudinally and cross-sectionally and HE stained slides 
were semi-quantitatively assessed using previously described criteria [199]. 
Influenza antigen IHC was semi-quantitatively evaluated without knowledge of the 
identity of the animals by visually estimating the number of infected cells.  
 
Assessment of virus titers in tissues and swabs 
Nasal, pharyngeal and rectal swabs were stored at -70°C in transport medium (Hanks' 
balanced salt solution with 0.5% lactalbumin, 10% glycerol, 200 U/ml penicillin, 200 μg/ml 
streptomycin, 100 U/ml polymyxin B sulfate, 250 μg/ml gentamicin, and 50 U/ml nystatin 
(ICN Pharmaceuticals, Zoetermeer, Netherlands)). Samples of nasal turbinates, trachea, 
lung, cerebrum (including olfactory bulb), cerebellum, liver, spleen, lung, duodenum and 
colon were stored at -70°C. For determination of viral titers in tissue, tissues were 
weighed and homogenized (FastPrep-24 homogenizer (MP Biomedicals, Eindhoven)) in 
transport medium and cleared of tissue debris by centrifugation (1 min at 10000 rotations 
per minute (rpm)). Tenfold serial dilutions of swabs and processed tissue samples were 
used to infect MDCK cells in quadruplicate. On day 5 post-infection of cells, 
haemagglutination activity of the culture supernatants was assessed to demonstrate the 
presence of progeny virus [198]. Mean tissue culture infectious dose 50 (TCID50 expressed 
per milliliter for swabs and per gram for tissue samples) was calculated using the 
Spearman-Karber standard equation.   
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RESULTS 
 
Clinical signs 
Animals displayed few clinical signs. Two days p.i., recovery from isofluorane anesthesia 
was slower for all animals and animals in the IT inoculated group additionally displayed 
ruffled fur and slightly decreased activity. From day 0 to day 1 animals displayed modest 
mean weight loss of 5.4% and 4.4% for the IT and IN inoculated animals, respectively. 
 
Virus replication 
Two days p.i,, virus titers in the nasal swabs reached a peak in all animals. By day 7 p.i., 
infectious virus was no longer detectable in the nasal swabs(<0.75 TCID50/ml (10log)). 
After IN inoculation, higher virus titers were observed in nasal secretions than after IT 
inoculation (peak titers of 4.2 (standard deviation (SD) 1.2) and 2.5 (SD 1.5) TCID50/ml 
(10log) - Figure 1). Pharyngeal swabs were intermittently positive for all animals but did 
not show a clear pattern of virus excretion (data not shown). Infectious virus was not 
detected in any of the rectal swabs.  
In all animals that were inoculated via the IN route, infectious virus was detected in the 
nasal turbinates on day 4 p.i. (n=6) with virus titers  ranging from 3.0 to 5.9  TCID50/gr 
(10log) (mean 4.1 TCID50/gr (10log) SD 1.2). At this time point, virus could not be isolated 
from remaining tissues, with the exception of the cerebrum of one out six animals, with a 
titer of 2.5 TCID50/gr (10log) (data not shown).  
 
 
Figure 1 Viral load in nasal swabs after 
intranasal or intratracheal inoculation with 
influenza A(H1N1)pdm09 virus. Intranasal n=12 
for day 0-4, n=6 day 7 p.i.. Intratracheal n=10 
for day 0-1, n=8 day 2, n=6 day 3, n=4 day 4, 
n=2 day 7 (dashed line indicates limit of 
detection < 0.75 TCID50 /ml (10log)) 
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To investigate the kinetics of virus replication in various tissues after IT inoculation, ten 
strain 2 guinea pigs were inoculated and at various time points p.i., two animals were 
sacrificed. Based on the results obtained after IN inoculation, autopsies at earlier time 
points (days 1, 2 and 3) were included.  Widespread virus replication was observed (Figure 
2) with infectious virus detected in the nasal turbinates on days 1, 2, 3 (n=2 out of 2 
animals) and 4 p.i. (n=1/2) (mean peak virus titer on day 1;  8.1 TCID50/gr (10log) SD 1.7), 
trachea on day 1 (n=2/2) and 2 p.i. (n=1/2) (mean peak virus titer on day 1; 4.6  TCID50/gr 
(10log) SD 0.6), lung on day 1, 2, 3 (n=2/2) and 4 (n=1/2) (mean peak virus titer on day 1;  
6.7  TCID50/gr (10log) SD 0.4) and cerebrum on day 1 (n=1/2) and 2 (n=2/2) p.i. (mean peak 
virus titer on day 2; 3.7 TCID50/gr(10log) SD 0.1). 
 
 
Macroscopic and Microscopic findings 
Macroscopically, lungs of IN inoculated animals showed multifocal small areas of 
consolidation affecting <15% of lung tissue. At day 4 and 7 p.i., a moderate quantity of 
mucopurulent exudate was present in the nasal cavity and the mucosa showed diffuse 
hyperaemia.  
Lungs of IT inoculated animals were visibly more severely affected, with up to 30% of 
tissue showing randomly distributed, well-demarcated, firm, dark red foci in pulmonary 
parenchyma (Figure 3). Within the nasal cavity, especially posteriorly, a large quantity of 
mucopurulent exudate was present from day 2 to 7 p.i. and the mucosa was diffusely 
hyperaemic. Other tissues showed no notable macroscopic changes. 
Figure 2 Tissue viral load after 
intratracheal inoculation with 
influenza A(H1N1)pdm09 virus, 
n=2 per time point (dashed line 
indicates limit of detection <0.75 
TCID50/gr(10log)).  
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Figure 3 Macroscopic photo of guinea pig lung. (A) Normal guinea pig lung (B) Guinea 
pig lung at 2 days after intratracheal inoculation; arrowheads indicate multiple areas of 
consolidation, asterisk shows heart (not present in control). 
 
 
Figure 4 Histopathology (Haematoxylin & Eosin (HE)) of nasal epithelium and trachea (x40) and bronchiole and 
alveoli (x20). (A) Intratracheal inoculation 4 d.p.i. (B) Intranasal inoculation 4 d.p.i. (C) Intratracheal inoculation 7 
d.p.i. (D) Intranasal inoculation 7 d.p.i.. Inflammatory changes are more pronounced after intratracheal 
inoculation. 
i
i
i
i
i
i
i
i
 
Figure 5 Histopathology (HE) of respiratory tissues (x20) after intratracheal inoculation at days 1 (A), 2 (B), 3 (C), 4 (D) and 7 (E) post inoculation. 
Acute inflam
m
atory changes and necrosis are m
ost prom
inent at days 2 and 3 post-inoculation. 
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Histological evaluation of tissues from IN inoculated animals revealed moderate 
inflammation of the nasal epithelium and mild inflammation in the remaining respiratory 
tract, with an inflammatory infiltrate composed predominantly of polymorphonuclear 
cells morphologically consistent with eosinophils, fewer heterophils and, especially in the 
pulmonary parenchyma, mononuclear cells morphologically consistent with macrophages.  
On days 4 and 7 p.i., all respiratory tract tissues and particularly alveoli from IT inoculated 
animals showed more widespread and more severe inflammation of the alveolar walls and 
respiratory epithelium (and, where present, the submucosa), than those of IN inoculated 
animals (Figure 4). After IT inoculation, the extent of acute inflammation was most 
marked around day 2 and 3 p.i. (Figure 5) and infrequently accompanied by intra-alveolar 
oedema and deposition of fibrin. Pyknosis, karyorrhexis and karyolysis (necrosis), 
flattening (attenuation) and/or loss of cilia of epithelial cells of nasal cavity, bronchi(ioli) 
and alveoli were more frequently observed with this route of inoculation than with IN 
inoculation. Necrotic debris frequently accumulated in alveolar and airway lumina and on 
nasal epithelium. Some type II pneumocyte hyperplasia was seen in the alveoli by day 7 
p.i. (regeneration).  
Other tissues examined, including the cerebrum, showed no notable microscopic changes 
apart from one IN inoculated animal that showed perivascular cuffing with mononuclear 
cells (ca. 5 cells thick) in the olfactory lobe at day 7 p.i.. However, this animal showed no 
detectable virus titers or antigen positivity by IHC in the brain. 
 
Immunohistochemical findings 
After IN inoculation, moderate numbers of viral antigen positive cells were detected in the 
nasal epithelium at day 4 and, to a lesser extent, day 7 p.i.. Virus-infected cells were not 
detected in any other (respiratory) tissues (data not shown). 
After IT inoculation, moderate numbers of virus-infected (epithelial) cells were detected 
by IHC in all respiratory tissues (Figure 6). Nasal epithelium showed a peak in positivity at  
day 2 p.i. with a steady decline on day 3 and 4, and was negative by day 7. Trachea was 
antigen positive on day 2 p.i. only. Bronchi(oli) showed peak positivity on day 1, followed 
by a steady decline on day 2, 3 and 4 and by day 7, antigen was no longer detectable. 
Antigen in alveoli also peaked at day 2 p.i. and thereafter declined steadily with only a few 
cells positive by day 7. The number of virus-infected cells in the respiratory tract therefore 
roughly correlated with the virus titers that were measured in the respective tissues 
(Figure 2). 
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Cell types that showed intranuclear antigen were epithelial cells of the upper respiratory 
tract and airways, and type II pneumocytes and alveolar macrophages in the pulmonary 
parenchyma (see inset Figure 6). These cells were identified based on their location and 
morphology. Other tissues inspected, including the cerebrum, showed no virus antigen 
positivity.  
Major basic protein antibody (clone BMK-13) was used to definitively distinguish 
eosinophils from heterophils. In respiratory tissues, the predominant polymorphonuclear 
cell type present was confirmed to be eosinophils (Figure 7).   
 
 
Figure 6 Immunohistochemistry (IHC) of respiratory tract tissues after intratracheal 
inoculation (x20). (A) 1 d.p.i. (B) 2 d.p.i. (C) 3 d.p.i. (D) 4 d.p.i.. Intranasal inoculation resulted 
in infection of cells in the nasal epithelium only (results not shown).  
 
 
 
Figure 7 Immunohistochemistry of 
inflammatory infiltrate surrounding a 
bronchus (*) at day 2 post-intratracheal 
inoculation (A) x20, (B) cells at higher 
magnification. Arrowheads show 
eosinophils with granules that stain 
positive (brown) with major basic 
protein antibody (BMK-13), arrows 
show heterophils. 
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DISCUSSION  
 
In the present study we investigated virus replication and pathogenesis of infection with 
A(H1N1)pdm09 influenza virus in strain 2 isogenic guinea pigs after intranasal (IN) or 
intratracheal (IT) inoculation. For both inoculation routes, virus excretion from the nose 
peaked around day 2 p.i., although after IN inoculation higher virus titers were observed in 
the nose swabs than after IT inoculation. After IN inoculation, virus replication in the 
respiratory tract was restricted to the nasal epithelium. In one animal virus was also 
detectable in the cerebrum on day 4 p.i.. In contrast, IT inoculation appeared to result in 
more widespread replication. On days 1, 2, 3 and 4 p.i., infectious virus was not only 
detected in the nasal epithelium, but also in the lungs and on days 1 and 2 in the trachea 
and the cerebrum. Due to the limited breeding capacity at present and restrictions 
imposed by the ethical committee, it was not possible to test virus replication in the 
respective organs at earlier time points after IN inoculation. It therefore remains unclear 
whether the virus replicated in the respective respiratory tissues before day 4 p.i.. 
Previous studies do not consistently report spread of influenza viruses to the lower 
respiratory tract after IN inoculation but the histological lesions observed in the lungs of 
the IN inoculated guinea pigs were consistent with those previously described for 
infection with influenza viruses of other subtypes [196, 200-202]. However, in the present 
study we could not confirm viral replication (by detection of infectious virus or infected 
cells) in tissues other than the nasal epithelium after IN inoculation.  
For IT inoculation, the immunohistochemistry results (Figure 6 and 7) corresponded with 
the virus titers in the respective tissues (Figure 2), confirming the presence of virus in 
epithelial cells of the nasal turbinates, trachea, bronchi(oli), alveoli and in pulmonary 
macrophages between day 1 and 4 p.i.. Low virus titers were detected in the cerebrum at 
day 1 (n=1/2) and 2 (n=2/2), however no antigen positive cells were detected by IHC. No 
histological changes were noted in the cerebrum of any of the animals apart from one IN 
inoculated animal that showed minimal histological changes in the olfactory lobe at day 7 
p.i., but did not show detectable viral titers or viral antigen positivity. The relevance of this 
finding and the potential importance of the olfactory route of entry into the guinea pig 
central nervous system therefore remains unknown.  
Interestingly, IT inoculation resulted in effective spread of replicating virus to both the 
upper and lower respiratory tract. In ferrets, IT inoculation with 2009 pandemic A(H1N1) 
virus typically results in viral replication predominantly in the lower respiratory tract [140, 
184, 203]. If IT inoculation becomes the preferred route of inoculation for guinea pigs, this 
is especially relevant for future transmission studies. For both routes of inoculation, the 
trachea appeared to be relatively spared. Histological lesions in the trachea were mild, 
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replicating virus was only demonstrated in 3 out of 10 IT inoculated animals and IHC was 
positive in only 1 animal. This may be explained by the relatively small number of cells 
available for infection in the trachea compared to the lower respiratory tract.  
Overall, histological lesions corresponded generally with those reported in the few 
pathogenesis studies previously conducted in guinea pigs [196, 200-202] and consisted of 
rhinitis, tracheitis, bronch(iol)itis and alveolitis with mild (IN inoculation) and moderate (IT 
inoculation) infiltrates consisting of numerous eosinophils, fewer heterophils, and in the 
lower respiratory tract, macrophages. Epithelial attenuation and necrosis was noted 
multifocally throughout the respiratory tract and was more marked especially in the lower 
respiratory tract after IT inoculation.  
In two of the previous guinea pig influenza studies that report on viral pathogenesis, the 
authors comment on the presence of neutrophils [201, 202]. Guinea pig 
polymorphonuclear cells that correspond to neutrophils are more correctly referred to as 
heterophils [204]. Guinea pig heterophils and eosinophils are easily confused at first 
glance due to the presence of a segmented nucleus and abundant eosinophilic 
cytoplasmic granules in both cell types. They can be distinguished to some extent on the 
basis of nuclear and granule morphology; heterophils are slightly smaller, have a more 
segmented nucleus and fewer and smaller cytoplasmic granules than eosinophils. 
However, when an inflitrate is composed of only one of these two cell types, these relative 
distinguishing features are less useful and so additional methods may become of interest, 
especially considering that the functional differences of these cell types parallel those in 
other species. Major Basic Protein is a constituent of eosinophil granules [205] and here 
we show that antibody directed against this protein (clone BMK-13) can be used to 
definitively distinguish eosinophils from heterophils. To our knowledge, there is no 
existing literature using this method in guinea pigs, and we hereby recommend its use in 
cases where accurate description of the inflammatory infiltrate is of importance. Using 
major basic protein antibody immunohistochemistry, we found that eosinophils were the 
predominant polymorphonuclear cell type in airway infiltrates of infected animals. Tang et 
al also report the presence of eosinophils in the airways of infected animals and speculate 
that this finding is suggestive of airway hypersensitivity [201]. Inbred guinea pigs have 
previously been shown to mount a delayed hypersensitivity response to influenza A 
infections using nasal washes and peritoneal exudates [206], a finding that would be 
consistent with these observations. However, the exact significance of this finding in the 
pathological response to influenza remains to be elucidated. 
In summary, we have explored, for the first time, infection of isogenic strain 2 guinea pigs 
with pandemic H1N1 influenza virus as an influenza animal model. The IT and IN route of 
inoculation were compared and for both procedures, productive infection of the upper 
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respiratory tract was achieved, with a peak in viral replication around day 2 p.i.. IT 
inoculation appeared to result in more widespread viral replication and associated 
histological lesions in both the upper and lower respiratory tract whereas after IN 
inoculation hisotpathological changes were more restricted to the nasal cavity. Thus, 
compared to IN inoculation, the pathogenesis of infection of guinea pigs after IT 
inoculation may mimic viral pneumonia in humans more closely. However, IT 
administration is a technically more demanding procedure. In addition to these findings, 
we presented a novel way to accurately distinguish heterophils from eosinophils in guinea 
pig formalin-fixed, paraffin embedded tissue sections using major basic protein antibody 
(BMK-13). 
The use of this particular inbred strain of guinea pigs seems a promising model for human 
infections with influenza virus. Furthermore, it would allow investigation of virus specific 
cellular immunity and identification of immune correlates of cross-protection against 
influenza virus infection by adoptive transfer of selected lymphocyte subsets. Since guinea 
pigs transmit influenza virus efficiently, the model also allows studying the impact of 
immunity on virus transmission. 
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ABSTRACT 
 
Since 2013, avian influenza viruses of subtype H7N9 have been transmitted from poultry 
to humans in China and caused severe disease. Concerns persist over the pandemic 
potential of this virus and further understanding of immunity and transmission is required. 
The isogenic guinea pig model uniquely would allow for investigation into both. Eighteen 
female isogenic guinea pigs 12-16 weeks were inoculated intratracheally with either 
A/H7N9 virus (n=12) or PBS (n=6) and sacrificed on days 2 and 7 post-inoculation. Nasal 
and pharyngeal swabs were taken daily to assess viral replication kinetics and necropsies 
were performed to study pathogenesis. All animals showed peak virus titers in nasal 
secretions at day 2 post-inoculation and by day 7 post-inoculation infectious virus titers 
had decreased to just above detectable levels. At day 2, high virus titers were found in 
nasal turbinates and lungs and moderate titers in trachea and cerebrum. At day 7, 
infectious virus was detected in the nasal turbinates only. Histology showed moderate to 
severe inflammation in the entire respiratory tract and immunohistochemistry (IHC) 
demonstrated large numbers of viral antigen positive cells in the nasal epithelium at day 2 
and fewer at day 7 post-inoculation. A moderate number of IHC positive cells was 
observed in the bronchi(oli) and alveoli at day 2 only. This study indicates that isogenic 
guinea pigs are a promising model to further study immunity to and transmission of H7N9 
influenza virus. 
 
INTRODUCTION 
 
In 2013, the first human cases of infection with avian influenza viruses of subtype H7N9 
were reported in China. As of February 23rd, 2015 a total of 571 laboratory-confirmed 
infections have been reported to WHO, of which 212 had a fatal outcome [207]. Infections 
have thus far been the result of direct transmission from birds predominantly and only a 
few human-to-human transmission clusters have been reported [208-210]. Although 
recent studies have shown that adaptation of the virus incurs a fitness cost in ferrets 
[211], concerns persist over the probability that the virus will acquire the necessary 
mutations for sustained human-to-human transmission. As this subtype has not previously 
circulated in the human population, humoral immunity is virtually absent and the impact 
of a pandemic could therefore be substantial. Both viral transmission and the effect of 
pre-existing (cellular) immunity are crucial elements in determining the pandemic 
potential of H7N9 influenza virus. Therefore, further investigation into both these factors 
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is of key importance. Typically, the ferret model is used to investigate certain aspects of 
influenza virus infections such as pathogenesis and transmission [212-214]. However, 
possibilities to study virus-specific immunity and its effect on pathogenesis and 
transmission are limited.   
Isogenic guinea pigs have recently been identified as a model for studying influenza 
viruses [215] and may offer some advantages over the ferret model. Guinea pigs have 
been used as models for influenza virus transmission [187, 216] and strain 2 (isogenic) 
guinea pigs additionally offer the possibility for more in depth study of cellular immunity 
through adoptive transfer of immune cell subsets [190, 193].  
Another advantage of this model is that guinea pigs have been shown to be susceptible to 
unadapted mammalian and avian influenza viruses [187]. Avian influenza viruses bind 
predominantly  to  α-2,3-linked sialic acid (SA) receptors and mammalian influenza viruses 
preferentially  bind  α-2,6-linked SA receptors [217].   In  guinea  pigs,  both  α-2,3-linked and  
α-2,6-linked SA receptors are abundantly present in the nasal cavity and trachea, whereas 
α-2,3-linked SA receptors predominate in the lungs [57]. Similarly in humans, the upper 
airways  express  relatively  more  α-2,6-linked SA receptors and the lower airways express 
more  α-2,3-linked SA receptors [218]. H7N9 is a virus of avian origin and therefore binds 
more  readily  to  α-2,3-linked SA receptors, and the overall pattern of H7N9 attachment in 
guinea pig tissue was found to be similar to that observed in humans. In both species, the 
virus attached (albeit to a slightly different extent) to ciliated epithelial cells in the nasal 
turbinates, trachea, and bronchus, ciliated and nonciliated cells in the bronchioles, and 
both type I and type II pneumocytes in the alveoli [219]. Although the ferret is one of the 
most commonly used animal models for influenza virus infection and transmission, the 
attachment pattern of H7N9 virus was rather dissimilar to humans [219] and use of guinea 
pigs may therefore offer an additional advantage for studying this particular viral subtype.  
In this study we determined the virus replication kinetics and pathogenesis of 
intratracheal influenza A H7N9 virus infection in strain 2 isogenic guinea pigs to assess the 
suitability of this model for future transmission and immunity studies. 
 
MATERIALS AND METHODS 
 
Virus preparation 
Influenza virus A/Anhui/1/2013 was propagated in embryonated chicken eggs three times 
and confluent Madin-Darby Canine Kidney (MDCK) cells once. Culture supernatants were 
harvested after the appearance of cytopathic changes, cleared by low-speed 
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centrifugation   and   stored   at   −70°C.   MDCK   cells   were   used   to   determine   virus   titre,   as  
described[198]. Virus was diluted in Phosphate Buffered Saline (PBS) to the desired 
concentration, 2 x 106 TCID50 per 500 μL,  for  intratracheal  inoculation.   
 
Animals and experimental design 
The animal experimentation protocol was approved by an independent animal welfare 
committee (DEC Consult) and experiments were performed in compliance with national 
and European legislation. The Federal Institute for Risk Assessment (BfR) in Berlin, 
Germany provided eighteen 12-16 week old (320-600 grams) isogenic strain 2 guinea pigs. 
Animals were tested prior to the start of the experiment for presence of antibodies to 
circulating influenza viruses A/H1N1, A/H3N2 and B/Yamagata-like and their respective 
vaccine strains using the haemagglutination inhibition assay, as previously described 
[197]. No antibodies against these viruses were detected in any of the animals.  
Three groups of 6 animals were held in biosafety level 3 conditions at the animal facilities 
of the Erasmus Dierexperimenteel Centrum, on a 12-hour light/dark cycle with ad-libitum 
access to food and water.  
Intratracheal inoculation was performed under ketamine and medetomidine anesthesia 
on  all  18  animals  by  injecting  500μL  of  either  2  x  106 tissue culture infectious dose (TCID50) 
H7N9 virus A/Anhui/1/2013 (n=12) or Phosphate Buffer Saline (PBS) (n=6) 
transcutaneously (surgically) directly into the trachea, with the animal in dorsal 
recumbency. The anesthetic was antagonized with atipamezole and during recovery 
animals were placed with the head slightly elevated to prevent loss of the inoculum. 
Nasal, pharyngeal and rectal swabs were taken daily and animals were weighed on day 0, 
1 and 2 (n=18), 3, 4 and 7 (n=9) post-inoculation (p.i.) under isofluorane anesthetic. On 
day 2 and day 7 p.i., 6 animals from the virus infected group and 3 animals from the PBS 
control group were anesthetized with ketamine and medetomidine, exsanguinated and 
necropsied. 
 
Pathological examination and Immunohistochemistry  
Necropsies were conducted following standard procedures. Before opening the thoracic 
cavity, the trachea was clamped to prevent deflation of lungs and allow for accurate visual 
assessment of the percentage of lung tissue affected. Nasal turbinates, nasal septum, 
trachea, tracheobronchial lymph node, bronchus, lung, olfactory bulb, cerebrum, 
cerebellum, liver, heart, kidney, spleen, duodenum and colon were sampled and fixed in 
10 % neutral buffered formalin. Prior to fixation, the right lung was inflated with formalin 
to improve histological assessment.  
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Formalin   fixed   tissues  were  embedded   in  paraffin  and   cut   to   4   μm.  For  histological  and  
immunohistochemical evaluation, tissue was stained with either haematoxylin and eosin 
(HE), or with an immunoperoxidase method using a monoclonal antibody against influenza 
nucleoprotein, respectively. IgG2a isotype controls of each tissue and a positive control 
were included for the immunoperoxidase method. Identity of the animals was concealed 
prior to evaluation of the slides and lung lobes were sectioned according to a standard 
protocol to avoid bias. HE stained slides were semi-quantitatively evaluated using 
standardized criteria [199] and IHC slides were assessed semi-quantitatively by visually 
estimating the proportion of cells that showed a positive nuclear stain. 
 
Assessment of virus titers in swabs and tissue 
All swabs were stored at -70 °C in transport medium (Hanks' balanced salt solution with 
0.5  %   lactalbumin,  10  %  glycerol,  200  U/ml  penicillin,  200  μg/ml  streptomycin,  100  U/ml  
polymyxin  B   sulfate,   250  μg/ml  gentamicin,  and   50  U/ml  nystatin   (ICN  Pharmaceuticals,  
Zoetermeer, Netherlands)). Tissue samples of cerebrum (including olfactory bulb), 
cerebellum, nasal turbinates, trachea, lung, liver, spleen, duodenum and colon were 
stored at -70 °C.  
In order to determine virus titers in tissues, samples were weighed and homogenized 
(FastPrep-24 homogenizer (MP Biomedicals, Eindhoven)) in the aforementioned transport 
medium and centrifuged. MDCK cells were infected with tenfold serial dilutions of 
supernatant of swabs and processed tissue samples (in quintuplicate for respiratory and 
central nervous system tissue samples and nasal swabs and in quadruplicate for samples 
from PBS inoculated animals, remaining tissues and pharyngeal and rectal swabs). 
Haemagglutination activity of the culture supernatants of MDCK cells was assessed on day 
5 after inoculation to demonstrate the presence of virus [198]. The Spearman-Karber 
standard equation was used to calculate the tissue culture infectious dose 50 (TCID50 
expressed per milliliter for swabs and per gram for tissue samples). 
 
RESULTS 
 
Infection with H7N9 virus resulted in minor clinical signs  
Animals displayed few clinical signs. On day two, the group inoculated with virus showed 
ruffled fur, decreased activity and animals were slower to recover from isofluorane 
anesthetic. From day 0 to day 1 virus inoculated animals showed minimal weight loss 
(1.6%) compared to the PBS group. A small amount of serous nasal exudate was only 
observed upon anesthesia with isofluorane in all animals. 
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Virus replicated in the entire respiratory tract and peaked at day 2 post -inoculation 
All animals showed a peak in viral titer in nasal secretions at day 2 p.i. (mean titer 3.0 
TCID50/ml (10log) standard deviation (SD) 1.8) (p.i.) and by day 7 p.i., only two out of six 
animals still showed detectable titers (2.3 and 2.1 TCID50/ml (10log)), detection limit <0.5 
TCID50/ml (10log)) (Figure 1 (A)). Pharyngeal swabs were intermittently positive for all 
virus infected animals but no clear pattern of virus excretion was observed. Infectious 
virus was not isolated from any of the rectal swabs.  
 
 
 
 
Figure 1 (A) Tissue viral load after IT inoculation with influenza A/H7N9. Cerebrum day 2 p.i., Lung day 2 
p.i., Trachea day 2 p.i., Nasal turbinates day 2 p.i. and Nasal turbinates day 7 p.i. (dashed line indicates limit 
of detection < 0.5 TCID50 per gram (10log)). (B) Viral load in nasal swabs after IT inoculation with influenza 
A/H7N9 virus. For day 0, 1 and 2: n=12, for day 3, 4 and 7: n=6 (dashed line indicates limit of detection < 0.5 
TCID50  per milliliter (10log)).  
 
 
 
At day 2 p.i., infectious virus was isolated from nasal turbinates (mean titer 8.0 TCID50/gr 
(10log) SD 0.7, n= 6/6), trachea (3.0 TCID50/gr (10log) SD 1.7, n= 5/6), lung (5.6 TCID50/gr 
(10log) SD 1.2, n= 6/6) and cerebrum (3.8 TCID50/gr (10log) SD 0.4, n=5/6) (Figure 1 (B)). 
Virus could not be isolated from remaining tissues, with the exception of one animal that 
showed low titers in kidney (2.7 TCID50/gr (10log)) and liver (2.5 TCID50/gr (10log)) at day 
2. By day 7 p.i., virus could be isolated only from nasal turbinates (3.5 TCID50/gr (10log) SD 
1.9, n= 5/6) (Figure 1 (B)).  
All PBS inoculated animals tested negative for viral excretion.  
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Infection with H7N9 causes rhinitis, tracheitis, bronch(iol)itis and brochointerstitial 
pneumonia 
Macroscopically, lungs of virus inoculated animals showed multifocal to coalescing well-
demarcated areas of hyperaemia and consolidation affecting up to 30% of lung tissue. On 
day 2, and to a lesser extent day 7, a moderate quantity of mucopurulent exudate was 
present in the nasal cavity of all infected animals, especially caudally, and the mucosa was 
diffusely hyperaemic.  
Histological evaluation of tissues of infected animals revealed moderate to marked 
inflammation of the epithelium and submucosa of the nasal cavity, trachea and bronchi, 
with an inflammatory infiltrate composed predominantly of eosinophils and fewer 
heterophils. (FIgure 3 A, B, C) Epithelial cells of the nasal cavity, and to a lesser extent, the 
trachea and bronchi frequently showed karyopyknosis, karyorrhexis and karyolysis 
(necrosis) (Figure 3). In the nasal cavity this was multifocally associated with formation of 
a necropurulent exudate, especially on day 2 p.i. (Figure 2 and 3). The lumen of smaller 
airways frequently contained necrotic debris and flocculent eosinophilic material (mucus). 
Pulmonary parenchyma showed multifocal to coalescing areas of dense cellular infiltrates 
consisting of eosinophils, heterophils and macrophages in the walls and lumen of alveoli, 
frequently accompanied by epithelial cell necrosis (Figure 3D). 
Lesions in the respiratory tract were of similar nature on both day 2 and day 7 p.i., 
however on day 2 they were generally more severe and on day 7, there was evidence of 
moderate mononuclear cell infiltration around the airways and type II pneumocyte 
hyperplasia in the alveoli (regeneration) (Figure 2). The cerebrum (including the olfactory 
bulb) and the cerebellum showed no macroscopic or histopathological changes.  
Tissues collected from PBS inoculated animals showed minimal to mild presence of 
eosinophils in the epithelium and, where present, submucosa, throughout the respiratory 
tract. One animal showed mild focal pyogranulomatous tracheitis with intralesional 
bacteria at day 2 p.i., likely as a consequence of the inoculation. 
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Figure 2 Haematoxylin and Eosin (HE) stain (x20). Respiratory tissues of A/H7N9 inoculated animals and PBS 
inoculated control animals at day 2 (top two rows) and day 7 (bottom two rows) post-inoculation (A) Nasal 
turbinates (B) Trachea (C) Bronchi (D) Alveoli. 
 
 
 
 
Figure 3 Hematoxylin and eosin (HE) 
(40×). Close up of histopathological 
lesions in respiratory tissues of A/H7N9 
inoculated animals day 2 post-
inoculation. Arrowheads indicate 
necrosis, arrows indicate heterophilic 
and eosinophilic inflammatory cells, 
asterisk indicates macrophages: (A) 
nasal epithelium showing a layer of 
exudate composed of inflammatory 
cells and necrotic debris; (B) trachea 
showing inflammatory infiltrates in the 
epithelium and submucosa; (C) 
bronchiole showing inflammatory 
infiltrates predominantly in the 
submucosa; (D) alveoli showing 
thickened alveolar septae with 
inflammatory infiltrates and necrosis. 
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Virus-infected cells were detected in the entire respiratory tract at day 2 
Moderate numbers of viral antigen positive cells were found only in the nasal epithelium, 
bronchi(oli) and alveoli 2 days p.i.. On day 7 p.i., antigen positive cells were found in nasal 
epithelium only (Figure 3). No viral antigen was detected in any other tissues, including 
the olfactory bulb. 
 
 
Figure 12 Immunohistochemistry (IHC) (x20) A/H7N9 inoculated animals at day 2 (top row) and day 7 
(bottom row) post-inoculation (A) Nasal turbinates (B) Bronchi (C) Alveoli. 
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DISCUSSION  
 
The present study shows the virus replication kinetics and pathogenesis of influenza 
A/H7N9 virus infection in strain 2 isogenic guinea pigs after intratracheal inoculation.   
At day 2 p.i., virus inoculated animals showed a peak in viral titers in nasal secretions, 
infectious virus was isolated from nasal turbinates, trachea, lung and cerebrum and viral 
antigen was demonstrated in nasal turbinates, bronchi and alveoli by IHC. By day 7, 
infectious virus and viral antigen was only found in nasal turbinates and mean infectious 
virus titers in nasal secretions had decreased to just above detectable levels. Histology 
showed moderate to severe acute necrotizing rhinitis and (broncho)interstitial pneumonia 
and mild to moderate tracheitis. 
Although infectious virus was found in the cerebrum at day 2, no viral antigen was 
detected by immunohistochemistry in the olfactory bulb or other central nervous tissues 
at this time point, nor were any histopathological changes noted. The ability of this virus 
to infect the brain of these guinea pigs therefore remains uncertain. 
Virus replication kinetics correspond to previous reports of H7N9 virus infection in 
outbred guinea pigs, where peak virus titers also occurred at day 2 [216]. However in that 
particular study, animal numbers were low and inoculation was intranasal rather than 
intratracheal. Although they found infectious virus in the lungs, virus infected cells were 
not demonstrated in the airways or alveoli using IHC. The study in these outbred animals 
also showed a predominantly mononuclear inflammatory reaction in the respiratory tract, 
especially later in infection, which we did not observe in our model [216].  
The ferret model is still considered to best mimic the pathogenesis of influenza infections 
in humans and when compared to intratracheal H7N9 virus infection in ferrets, the guinea 
pig model shows similar pathogenesis and replication kinetics. H7N9 virus reaches higher 
titers and persist longer in the nasal turbinates of guinea pigs than ferrets and, in contrast 
to ferrets, submucosal glands are not affected. For similar inoculatory doses, ferrets 
generally show more prominent clinical signs and a higher percentage of lung tissue 
affected than strain 2 guinea pigs as a result of H7N9 virus infection [213, 214].  
The distribution of the virus in the respiratory tract resembles what was shown by virus 
binding [219] and what would be expected knowing receptor distribution in the guinea 
pig; namely that it is found in both the upper and lower respiratory tract.  
Histopathological changes following intratracheal H7N9 inoculation were more severe, 
necrotizing and widespread than after intratracheal inoculation with H1N1pdm09 virus in 
this strain of guinea pigs [215]. H7N9 virus infected animals also showed higher average 
peak viral titers and more prolonged virus shedding from the nose than H1N1pdm09 
infected animals [215].  
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This experiment confirms that the use of this strain of isogenic guinea pigs is very useful 
for investigating influenza viruses with pandemic potential, including the newly emerging 
H7N9 viruses. The model allows simultaneously examination influenza virus pathogenesis, 
immunity, and transmission. 
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ABSTRACT 
 
Heterosubtypic immunity is defined as immune-mediated (partial) protection against an 
influenza virus induced by an influenza virus of another subtype to which the host has not 
previously been exposed. This cross-protective effect has not yet been demonstrated to 
the newly emerging avian influenza A viruses of the H7N9 subtype. Here, we assessed the 
induction of protective immunity to these viruses by infection with A(H1N1)pdm09 virus in 
a newly developed guinea pig model. To this end, ten female 12-16 week old strain 2 
guinea pigs were inoculated intratracheally with either A(H1N1)pdm09 influenza virus or 
PBS (unprimed controls) followed 4 weeks later with an A/H7N9 influenza virus challenge. 
Nasal swabs were taken daily and animals from both groups were sacrificed on days 2 and 
7 post inoculation (p.i.) with A/H7N9 virus and full necropsies were performed. Nasal virus 
excretion persisted until day 7 in unprimed control animals, whereas only two out of 
seven H1N1pdm09-primed animals excreted virus via the nose. Infectious virus was 
recovered from nasal turbinates, trachea and lung of all animals at day 2 p.i., but titers 
were lower for H1N1pdm09-primed animals, especially in the nasal turbinates. By day 7 
p.i., relatively high virus titers were found in the nasal turbinates of all unprimed control 
animals but infectious virus was isolated from the nose of only one of four H1N1pdm09-
primed animals. Animals of both groups developed inflammation of variable severity in 
the entire respiratory tract. Viral antigen positive cells were demonstrated in the nasal 
epithelium of both groups at day 2. The bronchi(oli) and alveoli of unprimed animals 
showed a moderate to strong positive signal at day 2, whereas H1N1pdm09-primed 
animals showed only minimal positivity. By day 7, only viral antigen positive cells were 
found after H7N9 virus infection in the nasal turbinates and the lungs of unprimed 
controls. Thus infection with H1N1pdm09 virus induced partially protective 
heterosubtypic immunity to H7N9 virus in (isogenic) guinea pigs that could not be 
attributed to cross-reactive virus neutralizing antibodies. 
 
INTRODUCTION 
 
 
In addition to the enormous public health burden of seasonal influenza viruses, newly 
emerging and pandemic viruses pose a constant threat. In 2009, an influenza A(H1N1) 
(H1N1pdm09) virus of swine-origin emerged in humans [180], caused a worldwide 
pandemic and has continued to circulate [220]. In 2013, H7N9 virus crossed the species 
barrier from poultry in China and new cases are still being reported [207]. In such 
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situations, when an influenza virus of a novel subtype is introduced into a naive 
population, specific immunity to the new virus is limited. However, it has long been 
recognized that infection with an influenza virus of one subtype can confer a certain 
degree of protection to infection with a virus of another subtype [221]. This type of cross-
protection is known as heterosubtypic immunity and, although it generally does not offer 
sterile protection, it can contribute significantly to decreasing disease severity and virus 
shedding [106]. Besides antibody mediated immunity, cell mediated immunity, particularly 
mediated by CD8+ cytotoxic lymphocytes (CTLs), has repeatedly been demonstrated to 
contribute to heterosubtypic immunity to influenza virus infections (reviewed in [222]). 
Heterosubtypic immunity has been demonstrated in several species including mice [102, 
107], macaques [109, 110], ferrets [108], pigs [223, 224], ducks [225, 226], chickens [227, 
228], cotton-rats [229] and has also been confirmed following natural infection in humans 
[113]. Previous infection with H3N2 has been shown to have an effect on viral 
transmission of pandemic H1N1 virus in outbred guinea pigs [195] but to date, the 
existence of heterosubtypic immunity has not been ascertained in (isogenic) guinea pigs 
and, although it has been speculated that prior infection with H1N1pdm09 would provide 
a certain degree of protection against H7N9 infection [230], this combination of viruses 
has never been studied in an animal model.  
Strain 2 isogenic guinea pigs have recently been identified as a model for influenza virus 
infection [215]. The fact that these guinea pigs are inbred, and therefore isogenic, offers 
exciting new possibilities to study immune mediated mechanisms of protection against 
influenza virus infections. For example, adoptive transfer experiments can be conducted 
by isolating lymphocytes from a donor that has been infected with an influenza virus to a 
naive recipient, that is subsequently challenged with a heterologous virus subtype, as has 
been performed in mice [116, 231]. In addition, guinea pigs, like ferrets, may transmit 
influenza viruses efficiently and therefore this model would offer the unique possibility to 
study the effect of cell-mediated immunity on transmission of influenza viruses. Reagents 
for studying cell-mediated immunity in guinea pigs are more abundantly available than 
those for ferrets [191, 232].  
To explore the induction heterosubtypic immunity in strain 2 isogenic guinea pigs, animals 
were intratracheally inoculated with H1N1pdm09 virus or PBS as a control. Four weeks 
later, H1N1pdm09 primed and unprimed animals were challenged with H7N9 virus. Virus 
titers, as well as histopathological and immunohistochemical parameters were compared 
between the two groups. 
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MATERIALS AND METHODS 
 
Virus preparations 
H7N9 influenza virus A/Anhui/1/2013, isolated from a fatal human case and kindly 
provided by the WHO Pandemic Influenza Preparedness (PIP) framework, was propagated 
in embryonated chicken eggs three times and confluent Madin-Darby Canine Kidney 
(MDCK) cells once. Influenza virus A/Netherlands/602/2009 (A(H1N1)pdm09) was 
propagated in confluent MDCK cells twice. After the appearance of cytopathic changes, 
culture supernatants were harvested, cleared by low-speed centrifugation and stored at 
−70°C.  Virus  titer was determined in MDCK cells, as described [198]. Virus was diluted in 
Phosphate Buffered Saline (PBS) to 2 x 106 tissue culture infectious dose (TCID50) per 
500μL,  for   intratracheal  inoculation.  The  choice  of  dose  and  inoculatory  route  was  based  
on previous experiments with H1N1pdm09 in isogenic guinea pigs [215].  
 
Animals and experimental design 
Experiments were performed in compliance with national and European legislation and an 
independent animal welfare committee (DEC Consult) approved the animal 
experimentation protocol. The Federal Institute for Risk Assessment (BfR) in Berlin, 
Germany supplied ten 12-16 week old (320-600 grams) female isogenic strain 2 guinea 
pigs. A haemagglutination inhibition assay was performed as previously described [197] to 
test for the presence of antibodies to circulating influenza viruses A/H1N1, A/H3N2 and 
B/Yamagata-like and their respective vaccine strains. All animals were found to be 
negative for antibodies to influenza prior to the start of the experiment.  
Two groups, one group of 3 and one group of 7 animals, were housed in two separate 
glove boxes (biosafety level 3 conditions) at the animal facilities of the Erasmus 
Dierexperimenteel Centrum, on a 12-hour light/dark cycle with ad-libitum access to food 
and water. 
All 10 animals were anesthetized with ketamine and medetomidine and inoculated 
intratracheally by keeping the animals in dorsal recumbency and injecting a total volume 
of  500μL  transcutaneously  directly  into  the  trachea.  The  anesthetic  was  antagonized  with  
atipamezole, and animals were placed with their heads slightly elevated to prevent loss of 
the inoculum. 
The group of 3 animals received Phosphate Buffer Saline (PBS) followed 4 weeks later by 2 
x 106 TCID50 influenza virus A/Anhui/1/2013 (H7N9) (further referred to as unprimed 
animals). The group of 7 animals received 2 x 106 TCID50 H1N1pdm09 virus 
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A/Netherlands/602/09 followed four weeks later by 2 x 106 TCID50 of the H7N9 virus  
(further referred to as H1N1pdm09-primed animals).  
After inoculation with H1N1pdm09, nasal swabs were taken on day 2 to verify that all 
animals were indeed productively infected. On day 0, 1, 2, 3, 4 and 7 after H7N9 
inoculation, all animals were weighed and nasal, pharyngeal and rectal swabs were taken 
under isofluorane anesthesia. Animals were anesthetized with ketamine and 
medetomidine, exsanguinated and necropsied on day 2 post inoculation (one unprimed 
animal and three H1N1pdm09-primed animals) and on day 7 p.i. (2 unprimed and four 
H1N1pdm09-primed animals). Unless otherwise specified, days p.i. refers to time points 
after inoculation with H7N9 virus. 
 
Assessment of virus titers in swabs and tissue 
All swabs were stored at -70°C in transport medium (Hanks' balanced salt solution with 
0.5%   lactalbumin,   10%   glycerol,   200  U/ml   penicillin,   200  μg/ml   streptomycin,   100 U/ml 
polymyxin  B   sulfate,   250  μg/ml  gentamicin,  and   50  U/ml  nystatin   (ICN  Pharmaceuticals,  
Zoetermeer, Netherlands)). Tissue samples of cerebrum (including olfactory bulb), 
cerebellum, nasal turbinates, trachea, lung, liver, spleen, duodenum and colon were 
stored at -70°C.  
Virus titers in tissues were determined by weighing and homogenizing samples (FastPrep-
24 homogenizer (MP Biomedicals, Eindhoven)) in the transport medium, followed by 
centrifugation. MDCK cells were infected with tenfold serial dilutions of supernatant of 
swabs and processed tissue samples (in quintuplicate for respiratory and central nervous 
system tissue samples and nasal swabs and in quadruplicate for remaining tissues and 
pharyngeal and rectal swabs). Haemagglutination (HA) activity of the culture supernatants 
of MDCKs was assessed on 5-7 days after infection to demonstrate the presence of virus 
[198]. The tissue culture infectious dose 50 (TCID50 expressed per milliliter for swabs and 
per gram for tissue samples) was calculated using the Spearman-Karber standard 
equation. The detection limit was <0.5 TCID50/ml. 
 
Virus Neutralization 
In order to detect virus-neutralizing antibodies, heat inactivated sera from day 0 and day 
28 p.i. with H1N1pdm09  and day 2 and 7 p.i. with H7N9 virus were prepared in 60 μl 
volumes of 2-fold serial dilutions starting at 1:10. Virus (H1N1pdm09 and H7N9) was 
diluted to 20 TCID50/ml   in   infection   medium   (Lonza   BioWhittakker   Modifed   Eagle’s  
Medium   (EMEM),   with   Earle’s   Balanced   Salt   Solution,   HEPES,   Sodium   Bicarbonate, 200 
U/ml   penicillin,  200  μg/ml   streptomycin,   L-Glutamine, 10% fetal calf serum and trypsin) 
and 50 μl was added to all wells containing antibody dilutions and incubated at 37ºC for    
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2 hours. MDCK cells were washed and the virus-serum mixture was transferred onto the 
cells and incubated overnight at 37 ºC. The next day, medium was removed and replaced 
with 200 μl of infection medium. Cells were incubated for 5-7 days after which an HA 
assay was performed [198].  
 
Pathological examination and Immunohistochemistry  
Standard necropsy procedures were followed. The trachea was clamped before opening 
the thoracic cavity to prevent deflation of lungs, and allow for accurate visual assessment 
of pulmonary tissue. Nasal turbinates, nasal septum, trachea, tracheobronchial lymph 
node, bronchus, lung, olfactory bulb, cerebrum, cerebellum, liver, heart, kidney, spleen, 
duodenum and colon were sampled and fixed in 10 % neutral buffered formalin. Prior to 
fixation, the right lung was inflated with formalin to improve histological assessment.  
Paraffin  embedded,   formalin   fixed   tissues  were  cut   to  4  μm.  For  histological  evaluation,  
tissue was stained with haematoxylin and eosin (HE). For immunohistochemical 
evaluation, tissue was stained with an immunoperoxidase method using a monoclonal 
antibody against influenza nucleoprotein. IgG2a isotype controls were used for each tissue 
and one postive control was included. Animals were anonymized before evaluation of the 
slides and lung lobes were sectioned according to a standard protocol to avoid bias. 
Standardized criteria were used to semi-quantitatively evaluate HE stained slides [199] 
and IHC slides were assessed by visually estimating the proportion of cells that showed a 
positive nuclear stain. 
 
 
RESULTS 
 
Clinical signs 
All animals displayed limited clinical signs upon challenge infection with H7N9 virus. On 
day two, animals from both groups showed ruffled fur, decreased activity and were slower 
to recover from isofluorane anesthetic. A small amount of serous nasal exudate was only 
observed upon anesthesia with isofluorane in all animals. Most animals showed a small 
decrease in body weight (< 5%) from day 0 to day 2 p.i. 
 
Virus titers 
Unprimed animals showed peak virus titers in nasal swabs at day 2 p.i. (mean 102.5 
TCID50/ml SD 0.8), on day 3 and 4 p.i. titers dropped below detectable levels and by day 7 
p.i. virus was again detectable (101.9 TCID50/ml SD 0.28). 
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H1N1pdm09-primed all animals were productively infected with pH1N1, as confirmed by 
virus excretion in nasal swabs on day 2 following inoculation. Following H7N9 inoculation, 
only two animals showed detectable virus titers in nasal secretions. One animal showed 
detectable virus on day 1 (102.7 TCID50/ml) and day 2 (10
2.3 TCID50/ml), the other was 
positive on day 3 (102.7 TCID50/ml) and day 4 (10
2.3 TCID50/ml) and virus was not detected in 
any animal on day 7. All other animals in this group were uniformly negative for virus in 
nasal secretions (Figure 1). 
 
 
 
 
 
 
 
 
 
 
Pharyngeal swabs showed intermittent low viral titers for all virus infected animals but no 
clear pattern of virus excretion was demonstrated.  
Infectious virus was isolated from the one unprimed animal that was sacrificed at day 2 
p.i., from nasal turbinates (107.6 TCID50/gr), trachea (10
5.0 TCID50/gr), lung (10
5.2 TCID50/gr) 
and cerebrum (102.0 TCID50/gr). From the two animals that were sacrified on day 7 p.i., 
virus was isolated from nasal turbinates (mean 104.9 TCID50/gr SD 0.9, n= 2/2) and 
cerebrum (102.3 TCID50/gr SD 0.4, n= 2/2). Virus was not isolated from remaining tissues. 
Infectious virus was isolated from H1N1pdm09-primed animals at day 2 p.i., from nasal 
turbinates (104.6 TCID50/gr SD 1.4, n= 3/3), lung (10
4.1 TCID50/gr SD 0.5, n= 3/3), trachea 
Figure 1 Viral load in nasal swabs (TCID50 per milliliter (log10)) after 
inoculation with A/H7N9/Anhui/1/2013 influenza virus. Individual 
unprimed animals are shown in black squares and the black line 
represents the average  (day 0-2 p.i. n= 3, day 3-7 p.i. n= 2) Individual 
H1N1pdm09-primed animals are shown in grey circles and the red 
line represents the average (day 0-2 p.i. n= 7, day 3-7 p.i. n= 4) (limit 
of detection < 0.5 TCID50 /ml (log10)).  
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(103.4 TCID50/gr SD 0.6, n= 3/3) and cerebrum (10
2.0 TCID50/gr SD 1.8, n= 2/3). The one 
animal that shed virus from the nose on day 1 and 2 had significantly higher virus titers in 
the nasal turbinates at day two than the animals that showed no nasal shedding at this 
time point (106.1 TCID50/gr compared to 10
4.4 and 103.3 TCID50/gr).  By day 7 p.i., virus could 
be isolated from nasal turbinates of only one animal (103.1 TCID50/gr, n= 1/4), which was 
the same animal that showed nasal shedding on day 3 and 4. Virus could not be isolated 
from remaining tissues. Although virus titres in all respiratory tissues at day 2 p.i. and 
nasal turbinates at day 7 p.i. were visibly lower in H1N1pdm09 primed animals than in 
unprimed animals (and historical H7N9 controls, see accompanying paper), small sample 
sizes precluded statistical analysis (Figure 2). 
 
 
 
 
 
 
Virus Neutralization 
Sera from unprimed animals did not neutralize either H1N1pdm09 or H7N9 virus at any 
time point. Pre-infection sera from H1N1pdm09-primed animals did not neutralize 
H1N1pdm09 virus but sera obtained at day 28 p.i. displayed virus neutralizing antibody 
titers ranging from 1:40 to 1:160.  These sera failed to neutralize the H7N9 virus. 
 
 
 
Figure 2 Viral load in respiratory tract tissues (TCID50 per 
gram tissue (log10)) after inoculation with A/Anhui/1/2013 
(H7N9) influenza virus. Titers in trachea, lung and nasal 
turbinates of unprimed animals (white bars) and H1N1pdm09-
primed animals (black bars) at 2 and 7 days post-inoculation 
(dpi). (limit of detection < 0.5 TCID50 /ml (log10))  
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Figure 3 Haematoxylin and Eosin (HE) stain (x20). Histopathological changes in respiratory tissues of 
unprimed (PBS + H7N9), H1N1pdm09-primed (H1N1 + H7N9) and mock infected (PBS) animals at 2 
and 7 days post-inoculation (dpi) with influenza A/H7N9/Anhui/1/2013 virus. Arrowheads show 
inflammatory infiltrates and necrosis, arrows show inflammatory cells and debris in bronchiolar 
lumina, and asterisks indicate peribronchiolar lymphocytic infiltrates. 
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Macroscopic and Microscopic findings 
Macroscopically, lungs of virus inoculated animals showed multifocal to coalescing well-
demarcated areas of hyperaemia and consolidation affecting 20-30% of lung tissue in 
unprimed animals, and 10-20% of lung tissue in H1N1pdm09-primed animals. On day 2, 
and to a lesser extent day 7, moderate (unprimed) or small (H1N1pdm09-primed) 
quantities of mucopurulent exudate were present in the nasal cavity, especially caudally, 
and the mucosa was diffusely hyperaemic.  
For unprimed animals, the epithelium and submucosa of the nasal cavity, trachea and 
bronchi revealed varying severity of inflammation, with an inflammatory infiltrate 
composed predominantly of eosinophils and fewer heterophils. Necrotic epithelial cells 
were frequently observed in the nasal cavity, and to a lesser extent, the airways. On day 2 
p.i. multifocal necropurulent exudate covered parts of affected nasal epithelium. Lumina 
of smaller airways were frequently filled with necrotic debris and eosinophilic material. 
Alveoli showed multifocal areas of densely cellular infiltrates consisting of eosinophils, 
heterophils and macrophages in the walls and lumen of alveoli, frequently accompanied 
by epithelial cell necrosis. Lesions were of similar nature on both day 2 and day 7 p.i., 
however on day 2 lesions were generally more severe and necrotizing and on day 7, there 
was more evidence of mononuclear cell infiltration around the airways in the 
H1N1pdm09-primed animals. 
Although the nature of the lesions was the same for both groups, the H1N1pdm09-primed 
group was less severely affected and showed fewer lesions in the lungs (Figure 3) 
The cerebrum (including the olfactory bulb) and the cerebellum showed no macroscopic 
or histopathological changes in any of the animals.  
 
Detection of virus-infected cells 
Unprimed animals showed moderate numbers of viral antigen positive cells in the nasal 
epithelium, bronchi(oli) and alveoli at 2 days p.i.. On day 7 p.i., small numbers of antigen 
positive cells were found in nasal epithelium and lung. H1N1pdm09-primed animals 
showed moderate amounts of viral antigen in the nasal epithelium at day 2 p.i. and nearly 
no antigen in airways or alveoli. By day 7 p.i., H1N1pdm09-primed animals were uniformly 
negative for viral antigen (Figure 4).  
No viral antigen was detected in any other tissues, including the olfactory bulb, in any of 
the groups. 
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Figure 4 Influenza virus immunohistochemistry (IHC) (x20).  Respiratory tract tissues of unprimed (PBS 
+ H7N9), H1N1pdm09-primed (H1N1 + H7N9) and mock infected (PBS) animals at 2 days post-
inoculation (dpi) with influenza A/H7N9/Anhui/1/2013 virus.  
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DISCUSSION  
 
In the present study we demonstrate that a prior infection with a A(H1N1)pdm09 
influenza virus can induce heterosubtypic immunity to challenge infection with an avian 
influenza virus of the H7N9 subtype in isogenic guinea pigs.  
Similar observations were made in others studies that demonstrated that infection with 
seasonal influenza viruses afforded mice and ferrets protection against infection with 
highly pathogenic avian influenza viruses of the H5N1 subtype [50, 107, 108]. 
Of interest, in humans prior infections with heterosubtypic strains of influenza virus also 
have an impact on susceptibility to infection with a pandemic influenza virus of a novel 
subtype, as was demonstrated by Epstein et al. This study showed that subjects who 
experienced H1N1 influenza virus infection prior to the 1957 pandemic were less likely to 
develop symptomatic influenza caused by the pandemic strain of the H2N2 subtype [233]. 
It was suggested that cellular immunity played a role in the observed protection.  
One of the hallmarks of heterosubtypic immunity is that, in most cases, sterile immunity is 
not achieved but the extent of viral shedding from the respiratory tract is reduced. This 
suggests that the extent of virus transmission between individuals will also be reduced, 
although this never has been studied properly.  
During the last decade, the quest for universal influenza vaccines has spurred the 
elucidation of immune correlates of protection that contribute to heterosubtypic 
immunity. Antibodies have been identified that are specific for conserved proteins such as 
the M2 protein or conserved regions of an otherwise variable protein, such as the stem 
region of the HA molecule (reviewed in [234]). It has been demonstrated that after passive 
administration or hyperimmunization these antibodies can be broadly protective against 
infection with influenza viruses of various subtypes. However, after infection these 
antibody responses are subdominant and other correlates of protection may be more 
important for infection-induced heterosubtypic immunity. In the present study, serum 
obtained after infection with the A(H1N1)pdm09 strain neutralized the homologous strain 
but failed to neutralize the A(H7N9) virus. Most likely, cross-reactive T cells contributed to 
protective immunity, which concurs with the observation of mononuclear cell infiltrates 
surrounding airways of H1N1pdm09-primed guinea pigs.  Indeed in mouse, ferret  and 
macaque models heterosubtypic immunity correlated with the induction of cross-reactive 
T cells  [116, 235] [107, 236]. It is important to note that virus-specific CD8+ T cells display 
a high degree of cross-reactivity and T cells induced after infection with seasonal human 
influenza viruses can recognize cells infected with avian influenza viruses of the H5N1 
subtype [103, 237] and the H7N9 subtype [104] or swine-origin viruses such as 
H1N1pdm09 viruses [105].  By performing adoptive transfer of T cells obtained from mice 
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that experienced an influenza virus infection it was demonstrated that indeed T cells can 
confer protective immunity [116, 231]. Of interest, during the 2009 pandemic it was also 
demonstrated that the frequency of pre-existing virus-specific CD8+ T cells inversely 
correlated with disease severity caused by infection with the A(H1N1)pdm09 viruses [113]. 
However, the correlation with viral shedding was not studied, but this has been 
established previously after experimental infection of subjects that lacked antibodies 
against the strain that was used for infection [112]. In our study, protection against the 
development of severe disease was observed. Not only did the H1N1pdm09-primed 
guinea pigs show less viral shedding from the upper respiratory tract, they also showed 
lower virus titers, less severe histopathological lesions and less widespread distribution of 
viral antigen positive cells in the respiratory tract than the unprimed control animals.  
This study shows that infection with a A(H1N1)pdm09 virus induced protective immunity 
against challenge infection with the newly emerging avian viruses of the H7N9 subtype in 
guinea pigs. For this purpose we used isogenic strain 2 guinea pigs, which offers some 
important advantages. The use of these animals would allow the elucidation of correlates 
of protection more precisely by adoptive transfer of antibodies or subsets of lymphocytes. 
Since the guinea pig is a preferred species to study transmission of influenza viruses, the 
impact of immunity induced by prior infection and individual arms of the immune system 
on transmission can also be investigated, and will be the subject of future experiments. 
This model may help advancing our understanding of influenza dynamics in the human 
population.      
i
i
i
i
i
i
i
i
 
 
 
 
 
 
  
i
i
i
i
i
i
i
i
CHAPTER 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A SINGLE IMMUNIZATION WITH MODIFIED VACCINIA VIRUS ANKARA-BASED 
INFLUENZA VIRUS H7 VACCINE AFFORDS PROTECTION IN THE INFLUENZA 
A(H7N9) PNEUMONIA FERRET MODEL 
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ABSTRACT 
 
Since the first reports in early 2013, >440 human cases of infection with avian influenza 
A(H7N9) have been reported including 122 fatalities. After the isolation of the first 
A(H7N9) viruses, the nucleotide sequences became publically available. Based on the 
coding sequence of the influenza virus A/Shanghai/2/2013 hemagglutinin gene, a codon-
optimized gene was synthesized and cloned into a recombinant modified vaccinia virus 
Ankara (MVA). This MVA-H7-Sh2 viral vector was used to immunize ferrets and proved to 
be immunogenic, even after a single immunization. Subsequently, ferrets were challenged 
with influenza virus A/Anhui/1/2013 via the intratracheal route. Unprotected animals that 
were mock vaccinated or received empty vector developed interstitial pneumonia 
characterized by a marked alveolitis, accompanied by loss of appetite, weight loss, and 
heavy breathing. In contrast, animals vaccinated with MVA-H7-Sh2 were protected from 
severe disease. 
 
INTRODUCTION 
 
In spring of 2013, avian influenza A viruses of the H7N9 subtype caused an outbreak of 
severe respiratory illness in humans in China. These viruses re-emerged in the winter of 
2013-2014 to cause a second outbreak [238-240]. So far, more than 440 human cases 
have been reported of which 122 had a fatal outcome [241]. Based on the absence of a 
multi-basic cleavage site in the viral hemagglutinin and the phenotype of the virus in the 
intravenous pathogenicity index test (IVPI), the H7N9 virus is categorized as a low 
pathogenic avian influenza virus [12]. Despite the low pathogenic phenotype, the virus is 
able to attach to the lower respiratory tract in humans and H7N9-infected patients 
present at the hospital with severe respiratory illness [238, 242]. Furthermore, it was 
demonstrated that intratracheal inoculation of ferrets with an influenza A/H7N9 virus 
causes severe broncho-interstitial pneumonia [213]. More widespread circulation of these 
viruses is feared and therefore there is interest in the development of vaccines that could 
prevent infection or mitigate disease severity.  
The conventional production of such (pre)pandemic vaccines fell short during the last 
pandemic (H1N1) in 2009 [243, 244]. The evaluation of (pre) pandemic vaccines against 
avian influenza viruses of the H5N1 and H7N9 subtypes indicated that these vaccines are 
poorly immunogenic and the use of adjuvants is required to improve their immunogenicity 
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[245, 246]. However, the use of adjuvants may have some limitations and adverse side 
effects [247].  
These issues underscore the need for new production platforms with capacity to produce 
large quantities of efficacious vaccines in a short period of time [248]. So far, various H7 
vaccine candidates have been evaluated for their immunogenicity and protective capacity 
with variable success [249-257]. Recombinant DNA technology may facilitate the 
production of purified recombinant viral proteins, DNA vaccines, but also viral vectors 
such as MVA [253-256, 258].  
MVA is a highly attenuated and replication-deficient orthopoxvirus that is biologically and 
genetically well-characterized, has successfully been developed as next generation 
smallpox vaccine as well as having been evaluated as a viral vector for numerous 
prophylactic and therapeutic vaccines [259, 260]. Recombinant MVA has also been tested 
extensively as a vaccine candidate against various influenza viruses [132]. Recently it was 
shown that influenza H5N1 vaccines based on the MVA technology were found to be safe 
and immunogenic in mice, chickens and macaques.  Currently, a prototype MVA-H5 
vaccine is under clinical development in a phase I/IIa clinical trial [137, 261-264]. In 
addition, MVA-based universal influenza vaccines, that elicite heterosubtypic-immunity, 
are in various stages of development [135, 265-267]. 
Here we evaluate the first H7N9 viral vector vaccine, based on Modified Vaccinia virus 
Ankara (MVA), in a ferret model for influenza A/H7N9 virus induced pneumonia. The 
immunogenicity and protective capacity of the vaccine was investigated after a single and 
two immunizations. To assess the possibility for dose sparing also a 100-fold lower vaccine 
dose was investigated.  
 
 
MATERIAL & METHODS 
 
Vaccine construction  
The HA gene sequence of influenza virus A/Shanghai/2/2013 (GISAID accession number: 
EPI439502(H7-Sh2) was codon optimized for stable insertion and expression in the context 
of vaccinia virus MVA. Silent mutations were introduced in H7-Sh2 to remove runs of four 
or more G/C and stop signal sequences (TTTTTNT) for early MVA-specific transcription. 
The tailor-made H7-Sh2 sequence with HpaI and NotI  restriction  sites  added  to  the  5’and  
3’  termini  was  obtained  as  synthetic  gene  (Baseclear,Leiden,  the  Netherlands) and cloned 
into the MVA vector plasmid pMKIIIred [268] under control of the synthetic promoter 
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psynII  and containing the mCherry sequence as marker gene, resulting in pMKIIIred-H7 
(Figure 1) [269]. Subsequently, chicken embryo fibroblasts (CEF) cultured under serum-
free conditions in VP-SFM medium (Life technologies, Breda, The Netherlands) were 
infected with MVA and transfected with pMKIIIred-H7 DNA using Fugene HD (Promega, 
Leiden, The Netherlands) to generate recombinant MVA containing the H7-Sh2 sequence 
and mCherry as a fluorescent marker. Recombinant viruses were clonally isolated in 
plaque passages on CEF screening for foci of red fluorescent cells. Finally, the mCherry 
marker gene was removed from the viral genomes due to a second step of intragenomic 
homologous recombination resulting in the final marker-free recombinant MVA-H7-Sh2. 
To generate vaccine preparations MVA-H7-Sh2 was purified by ultracentrifugation 
through sucrose, resuspended in physiological saline and stored at -80⁰C.   Virus  
amplifications, titrations, and quality control experiments were performed as described 
previously [268]. Expression of the H7 protein was confirmed using immunocytochemistry 
and Western blot analysis as described previously using a hyperimmune rabbit serum 
against influenza virus A/Seal/Massachussets/1/80 (Figure 1F) [268]. 
 
 
 
 
 
 
 
 
Figure 1 Construction of the MVA-H7-Sh2 vector (A-E) 
and H7 protein expression (F). The HA gene sequence 
of influenza virus A/Shanghai/2/2013 (H7-Sh2) was 
codon-optimized, obtained as synthetic gene (A) and 
cloned between the flank 2 and flank 1 regions of the 
MVA vector plasmid pMKIIIred under control of the 
PsynII promoter and containing the mCherry sequence 
as marker gene, resulting in pMKIIIred-H7 (B). 
Subsequently, chicken embryo fibroblasts (CEF) were 
infected with MVA (C) and transfected with pMKIIIred-
H7 DNA using Fugene HD (Promega, Leiden, The 
Netherlands) to generate  recombinant MVA containing 
the H7-Sh2 sequence and mCherry as a fluorescent 
marker, inserted in the MVA genome through 
homologous recombination (D). Finally, the mCherry 
marker gene was removed from the viral genome due 
to a second step of intragenomic homologous 
recombination resulting in the final marker-free 
recombinant MVA-H7-Sh2 (E). H7 protein expression 
was confirmed by Western blot analysis of cell lysates 
from MVA-H7-Sh2 infected Baby Hamster Kidney cells 
(BHK-21) using a hyperimmune rabbit serum against 
influenza virus A/Seal/Massachussets/1/80 and a Goat 
anti-Rabbit IRDye Infrared antibody (Westburg BV, 
Leusden, The Netherlands) (lanes: c=negative control, 
1=MVA-H7-Sh2 1:50, 2=MVA-H7-Sh2 1:10, 3=MVA-H7-
Sh2 undiluted)(F). 
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Animals 
Twenty-eight healthy female ferrets (Mustela Putorius furo) of around 12 months of age 
were used and assigned to experimental groups as indicated below. Before use the 
absence of antibodies against Aleutian disease virus and seasonal influenza viruses was 
confirmed. The animals were housed under standard conditions, provided with 
commercial food pellets and water ad libitum and placed in BSL-3 isolator units just before 
challenge inoculation with H7N9 virus. An independent animal ethics committee (DEC 
consult) approved the experimental protocol before the start of the experiment.  
 
Immunization and challenge infection 
Animals were immunized once (group A, n=6) or twice (group B, n=6) intramuscularly with 
MVA-H7-Sh2 at 108 plaque forming units (pfu) per dose and an interval of 3 weeks. Empty 
vector control (wildtype MVA (wtMVA) at a dose of 107 pfu) (group C, one immunization 
n=3, group D two immunizations, n=3) and PBS (group E, n=4) were used as negative 
control immunizations. To assess the possibility of dose sparing also a group of ferrets was 
immunized twice with 106 pfu MVA-H7-Sh2 (Group F, n=6). Before each immunization and 
before the challenge, blood was drawn from the animals to test for the induction of 
influenza virus specific antibodies. Four weeks after the last immunization the animals 
were inoculated under anesthesia (ketamine/medetomidine (reversed with atipamezole), 
with 3 ml containing 105.5 TCID50 influenza virus A/Anhui/1/2013 (H7N9) by the 
intratracheal route. This virus was isolated from a fatal human case in China and kindly 
provided under conditions of the Pandemic Influenza Preparedness (PIP) Framework. The 
virus was passaged three times in embryonated chicken eggs and passaged once in Madin 
Darby Canine Kidney (MDCK) cells. The infectious titer was determined as described 
previously and expressed as tissue culture infectious dose 50% (TCID50) [198]. The 
challenge dose was based on the outcome of a dose-finding study showing substantial 
levels of virus replication in the upper respiratory tract (URT) and lower respiratory tract 
(LRT) as well as lung damage, but no mortality during a four day follow up. Nasal and 
pharyngeal swabs were taken prior to influenza virus inoculation (day 0) and on day 2 and 
4 post inoculation (p.i.) and stored in transport medium (Hanks medium (MEM) with 
lactalbumin, glycerol, penicillin, streptomycin, polymyxin B, nystatin, gentamicin) at -70ºC 
until use. Four days p.i. all animals were euthanized. From the time point of influenza virus 
inoculation onwards the animals were housed in bio-safety level 3 containment facilities 
and were monitored for clinical signs.  
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Serology 
The serum samples collected prior to immunization and on day 21 and 49 post 
immunization were tested for the presence of influenza A/H7N9 virus specific antibodies 
in the hemagglutination inhibition (HI) assay with a 6+2 reassortant strain of influenza 
virus A/Anhui/1/2013 (containing the HA and NA of the H7N9 virus and the remaining 6 
gene segments of influenza virus A/Puerto Rico/8/34 (A/PR/8/34)) [270]. Sera were also 
tested for the presence of virus-neutralizing antibodies using a virus microneutralization 
(VN) assay, performed as described previously and using the reverse genetics virus 
described above [271]. Rabbit serum raised against influenza virus 
A/Seal/Massachussets/1/80 (H7N7) was used as positive control in both assays. For 
calculation purposes serum samples with an antibody titer of <10 were arbitrarily assigned 
a titer of 5. Seroconversion is defined as a post-vaccination  titer  of    ≥40  or  a  fourfold  rise  
in the antibody titer when the baseline   titer   was   >10.   Antibody   titers   of   ≥40   were  
considered to be seroprotective. 
 
Virus replication in the respiratory tract and the central nervous system (CNS)  
Upon necropsy of the animals on day 4 p.i. samples were collected from their right lung 
lobes and accessory lobe, nasal turbinates, trachea, bronchi and tracheobronchial lymph 
nodes and stored at –70°C until further processing. In addition to the respiratory tract, the 
cerebrum and olfactory bulb were also sampled. Tissue samples were homogenized and 
processed as described previously [140]. Ten-fold serial dilutions of nasal and pharyngeal 
swab supernatants (quadruplicate) and the homogenate supernatants of lungs 
(quintuplicate), other respiratory tract samples (triplicate; quadruplicate) and the CNS 
(triplicate; quadruplicate) were used to determine the presence of infectious virus titers in 
confluent layers of MDCK cells as described previously [198]. 
 
Pathological examination and Immunohistochemistry  
Necropsies were carried out according to standard protocols. The trachea was clamped 
prior to opening the thorax and inflated lungs were assessed visually to determine the 
percentage of lung grossly affected. Lungs were weighed and relative lung weight was 
calculated as a percentage of total body weight. Nasal turbinates, nasal septum, trachea, 
tracheobronchial lymph node, bronchus, lung, cerebrum (including the olfactory bulb) and 
cerebellum were sampled and fixed in 10% neutral buffered formalin. To optimize 
histological assessment, the right lung was inflated with formalin prior to fixation and, 
after fixation, right cranial and caudal lung lobes were sectioned in a longitudinal and 
cross-sectional plane in a standardized manner. Formalin fixed tissues were embedded in 
paraffin, cut to 4μm and either stained with haematoxylin and eosin (HE) for 
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histopathological evaluation or with an immunoperoxidase method using a primary 
monoclonal antibody (Clone HB65 IgG2a (American Type Culture Collection)) against the 
nucleoprotein of influenza A virus and a secondary goat-anti-mouse IgG2a HRP antibody 
(Southern Biotech, Birmingham, Alabama, USA), for immunohistochemical (IHC) 
evaluation. A positive control and IgG2a isotype controls of each slide were included. All 
slides were evaluated without prior knowledge of the identity of the animals and HE slides 
were assessed semi-quantitatively using previously described criteria (Table 3) [272]. IHC 
was evaluated qualitatively to confirm association of histological lesions with the presence 
of viral antigen. 
 
Statistics 
Differences in antibody titers and virus titers were tested for statistical significance using  
unpaired Student T-tests. Differences were considered significant at p<0.05. 
 
RESULTS 
 
Influenza virus specific immune responses 
After one immunization with 108 pfu MVA-H7-Sh2, 92% of the animals (Group A and B) 
seroconverted upon vaccination as measured in the HI assay (Table 1). In these groups 
75% of the animals reached titers of >40, which are considered to be protective.   
A second vaccination boosted the serum antibody titers as seen in animals of group B. The 
HI GMT increased from 31.7 (SD=2.8) to 127 (SD=2.0).  All animals in this group reached 
antibody titers >40. In general the results obtained with the HI assay were in agreement 
with those obtained in the VN assay. After two immunizations, a GMT of 160 (SD=3.5) was 
achieved.   
To assess if dose sparing was possible with MVA-H7-sh2 ferrets were also immunized 
twice with 100-fold lower dose. However, only one out of these six animals (group F) 
seroconverted after the first immunization and GMT of the group was 6.3 (SD=1.8). The 
second immunization with 1:100 diluted vaccine dose increased the GMT to 12.6 (SD=2.8), 
but out of six ferret only three seroconverted and two reached HI serum antibody titers of 
>40.  Again, similar results were obtained with the VN assay, in which a GMT of 17.8 
(SD=2.0) was reached. Antibodies directed to influenza virus A/Anhui/1/2013 were not 
detectable in any of the control animals that received wtMVA (Group C, D) or PBS (Group 
E) by HI or VN assay. 
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Table 1 Serology after MVA-H7-Sh2 immunization 
Group Serology 
HI  VN 
1st 
imm. 
2nd 
imm.  1
st imm. 2nd imm. 
A MVA-H7-Sh2 108 pfu1 
Seroconverted2 
Seroprotected3 
GMT (SD) 
6/6 
5/6 
50.4 (1.8)* 
d.n.a. 
d.n.a. 
- 
 
6/6 
3/6 
28.3 (1.5) 
d.n.a. 
d.n.a. 
- 
B 
2x 
MVA-H7-Sh2 
108 pfu 
Seroconverted 
Seroprotected 
GMT (SD) 
5/6 
4/6 
31.7 (2.8)* 
6/6 
6/6 
127.0 (2.0)* 
 
6/6 
4/6 
44.9 (2.0)* 
6/6 
5/6 
160.0 (3.5)* 
F 
2x 
MVA-H7-Sh2 
106 pfu 
Seroconverted 
Seroprotected 
GMT (SD) 
1/6 
0/6 
6.3 (1.8) 
3/6 
2/6 
12.6 (2.8) 
 
2/6 
0/6 
7.9 (2.0) 
5/6 
1/6 
17.8 (2.0) 
 
1Animals were immunized at the moment of the second immunization in group B and F. Post-immunization sera 
were obtained four weeks post immunization. The sera after the first immunization in group B and F were 
obtained three post immunization (on the day of the second immunization). 
2Seroconverted:  when  an  animal  has  a  ≥  four-fold increase in antibody titer after immunization. The numbers for 
seroconversion are cumulative: an animal that seroconverted after the first immunization is also accounted for 
as seroconverted after the 2nd immunization. 
3 Seroprotected: when an animal has an antibody titer of  ≥40 
*Titer is significantly higher than that of group F; d.n.a.= does not apply 
No HI or VN antibody titers were detected against the H7N9 influenza A/Anhui/1/2013 virus in the sera from the 
animals in the PBS and wtMVA groups. 
 
 
Clinical signs 
Two days post inoculation with influenza virus A/Anhui/1/13, all animals but those 
immunized once or twice with 108 pfu MVA-H7-Sh2 had loss of appetite. No other signs of 
disease were noticeable. On day 4 post challenge inoculation three different clinical 
phenotypes were observed: Group B (2x MVA-H7-Sh2 108 pfu) animals did not display any 
signs of disease (ate well, normal posture and normal breathing), Group A (1x MVA-H7-
Sh2 108 pfu) and Group F (2x MVA-H7-Sh2 106 pfu) animals ate slightly less, were a bit 
lethargic but displayed normal posture and normal breathing, Group C (1x wtMVA 107 
pfu), D (2x wtMVA 107 pfu) and E (PBS) animals were lethargic, showed heavy breathing 
and alternately showed hunched or flat-stretched posture. Most animals that experienced 
clinical signs also suffered from weight loss with mean values of 9.7% (SD=5.1) in group C, 
14.1% (SD=3.5) in group D and 8.3% (SD=3.4) and 8.6% (SD=3.7) in group E and F, 
respectively. In contrast, animals in group A (mean weight gain: 2.8% (SD=8.0)) and group 
B (mean weight gain: 4.3% (SD=5.5)) were protected from weight loss.  
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Figure 2 Virus replication in the trachea (A) and lung (B). MVA-H7 is an abbreviation for the 
MVA-H7-Sh2 vaccine. * indicates that the virus titers in the trachea of the animals in the two 
indicated groups are significantly lower than those of the other four groups. ** indicates that the 
virus titers in the lung of the animals in the two indicated groups are significantly lower than 
those of the other groups except the single shot wtMVA group. 
 
Virus replication in the upper and lower respiratory tract  
Swabs were taken on day 0, 2 and 4 p.i. from the nose and pharynx to asses viral shedding 
from the upper respiratory tract. All samples on day 0 were negative. Apart from one 
animal in group E that had a virus titer in its nose on day 2 p.i. (104.8), no virus was present 
in any of the other nasal swabs on day 2 and 4. The pharyngeal swabs on day 2 p.i. were 
virus-positive for animals from all six groups. In the groups A, B and F, all immunized with 
MVA-H7-Sh2, virus titers were lower on day 4 p.i. and in groups C, D and E pharyngeal 
virus titers increased between day 2 and day 4 p.i. (Table 2). 
Highest virus titers were observed in the trachea and lung samples (Figure 2). Mean virus 
titers in groups A and B were significantly lower for both organs and 50% and 67% of the 
animals in these respective groups tested negative for the presence of infectious virus in 
their trachea. Also in the lungs of two out of six animals of group B, virus was 
undetectable. In addition, in none of the animals of this group virus was detectable in the 
nasal turbinates  whereas in the other groups 17-100% of the animals virus was detectable 
in that anatomic  site (Table 2). In the bronchi of animals from all groups virus was 
detectable but the lowest titers were observed in the bronchi of animals in groups A and 
B: and 105.0 (SD=101.9) and 103.1 (SD=102.2) respectively. Sporadically, low virus titers were 
detected in the tracheabronchial lymphnodes and the central nervous system (cerebrum 
and olfactory bulb) of some animals, but there was no clear pattern regarding the 
distribution of animals that tested positive over the experimental groups (Table 2). 
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Histopathological changes and immunohistochemistry  
Macroscopically observed lesions consisted of multifocal to coalescing consolidation of 
pulmonary parenchyma, characterized by depressed areas of increased consistency and 
(dark) red discolouration. The total percentage of lung tissue affected varied between 
groups, with group B showing only minimal lesions and group D most severely affected 
(Table 3). All infections resulted in a similar expression of pulmonary pathology 
characterized by alveolitis, bronchiolitis, and to a lesser extent, bronchitis. Alveolar lesions 
consisted of thickening of septae and filling of alveolar spaces with variable quantities of 
(alveolar) macrophages and neutrophils, in severe cases accompanied by karyolytic and 
karyorrhectic (necrotic) cellular debris, red blood cells (haemorrhage),  proteinaceous fluid 
(edema) and eosinophilic fibrillar material (fibrin) (Figure 3). In addition, multifocally 
alveolar epithelium showed hyperplasia of type II pneumocytes. Bronchiolar lesions 
consisted of necrosis of epithelial cells, luminal accumulations of aforementioned 
inflammatory cells and cellular debris, frequently accompanied by peribronchiolar 
accumulations of lymphocytes and fewer plasma cells, macrophages and neutrophils. 
Bronchi were similarly affected but to a far lesser extent and variably showed hyperplasia 
of bronchial associated tissue (BALT). Infrequently, perivascular spaces were infiltrated 
with predominantly lymphocytes (perivascular cuffing).  
Remarkable differences between groups predominated in the extent and severity of 
alveolar lesions, with groups C, D and E showing significantly more extensive and more 
severely affected alveolar tissue. Severity of lesions in bronchioli was remarkably similar 
between groups. Groups A, B and F showed slightly more BALT hyperplasia (consistent 
with an active immune response)(Figure 3). Semi-quantitative assessment of IHC stain 
showed little positive nuclear staining in alveolar tissue of especially group C, F and, to a 
lesser extent, E when compared with remaining groups. Bronchioli showed fewer 
differences in IHC scores among groups, a finding that was consistent with the histological 
findings. 
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Table 3 H
istopathological and im
m
unohistochem
istry scores 
Histopathological and Im
m
unohistochem
istry scoring system
                
1 Percentage of lung affected w
as determ
ined by exam
ination of the intact lungs looking at consolidation of pulm
onary parenchym
a, characterized by depressed areas of increased consistency and (dark) red 
   discolouration 
2 Extent of alveolitis and alveolar dam
age: 0, 0%
; 1, 1%
–25%
; 2, 25%
–50%
; 3, > 50%
   
3 Severity of alveolitis, bronchiolitis, bronchitis, and tracheitis: 0, no inflam
m
atory cells; 1, few
 inflam
m
atory cells; 2, m
oderate num
bers of inflam
m
atory cells; 3, m
any inflam
m
atory cells.  
4 Presence of alveolar edem
a, alveolar hem
orrhage, and type II pneum
ocyte hyperplasia: 0, no; 1, yes.  
5 Extent of peribronchial, peribronchiolar and perivascular infiltrates: 0, none; 1, 1–2 cells thick; 2, 3–10 cells thick; 3, m
ore than 10 cells thick.  
6 IHC score: 0, 0%
; 1, <1%
; 2, 5-10%
; 3, 10-25%
; 4, 25-50%
; 5, <50%
 cell show
ing positive nuclear staining 
Bold values indicate a m
arked difference in the respective score for the indicated group(s) com
pared to score of the others groups. 
Group 
A 
B 
C 
D 
E 
F 
M
VA-H7-Sh2 
10
8 pfu 
2x M
VA-H7-Sh2 
10
8 pfu 
w
tM
VA 
10
7 pfu 
2x w
tM
VA 
10
7 pfu 
2x 
PBS 
2x M
VA-H7-Sh2 
10
6 pfu 
 
n=6 
n=6 
n=3 
n=3 
n=3 
n=6 
Score 
M
ean 
(SD) 
M
ean 
(SD) 
M
ean 
(SD) 
M
ean 
(SD) 
M
ean 
(SD) 
M
ean 
(SD) 
Percentage Lung Affected
1 
17.5 %
 
(22.3) 
5.2 %
  
(2.9) 
30.0 %
 
(15.0) 
41.7 %
  
(17.6) 
33.3 %
 
(27.5) 
24.2 %
 
(15.9) 
Relative Lung W
eight 
1.1 %
 
(0.2) 
1.0 %
 
(0.2) 
1.5 %
 
(0.1) 
1.7 %
 
(0.1) 
1.5 %
 
(0.1) 
1.5 %
 
(0.4) 
Extent Alveolitis
2 
1.5 (0.5) 
1.2 (0.4) 
2.3 (0.6) 
3.0 (0.0) 
2.0 (1.0) 
1.5 (0.8) 
Severity Alveolitis
3 
1.3 (0.5) 
1.3 (0.5) 
2.3 (0.6) 
2.3 (0.6) 
2.0 (0.0) 
1.2 (0.4) 
Severity Bronchiolitis 
2.5 (0.5) 
2.2 (0.4) 
2.7 (0.6) 
2.3 (0.6) 
2.3 (0.6) 
2.5 (0.5) 
Severity Bronchitis 
1.2 (0.4) 
1.2 (0.4) 
1.0 (0.0) 
1.0 (0.0) 
0.7 (0.6) 
0.7 (0.5) 
Severity Tracheatis 
1.5 (0.5) 
1.3 (0.5) 
1.3 (0.6) 
0.7 (0.6) 
0.7 (0.6) 
0.8 (0.8) 
Alveolar O
edem
a
4 
0.2 (0.4) 
0.5 (0.5) 
1.0 (0.0) 
1.0 (0.0) 
0.7 (0.6) 
0.7 (0.5) 
Alveolar Hem
orrhage 
0.5 (0.5) 
0.5 (0.5) 
1.0 (0.0) 
1.0 (0.0) 
0.7 (0.6) 
0.7 (0.5) 
Type II Hyperplasia 
1.0 (0.0) 
1.0 (0.0) 
1.0 (0.0) 
1.0 (0.0) 
1.0 (0.0) 
1.0 (0.0) 
Peri-bronchiolar Infiltrates
5 
2.5 (0.5) 
2.5 (0.5) 
2.0 (0.0) 
2.3 (0.6) 
2.3 (0.6) 
2.2 (0.4) 
Peri-bronchial Infiltrates 
2.0 (0.9) 
1.5 (1.0) 
1.3 (0.6) 
1.3 (0.6) 
1.3 (0.6) 
1.0 (0.0) 
Perivascular Infiltrates 
1.7 (0.5) 
1.3 (0.5) 
1.3 (0.6) 
1.3 (0.6) 
1.7 (0.6) 
1.2 (1.0) 
BALT Hyperplasia 
1.5 (0.5) 
1.7 (0.5) 
1.0 (0.0) 
1.0 (1.0) 
1.3 (0.6) 
1.7 (0.5) 
IHC Alveoli 6 
1.0 (0.0) 
1.2 (0.4) 
2.0 (0.0) 
3.0 (0.0) 
2.7 (0.6) 
1.8 (0.8) 
IHC Bronchi(oli) 
1.8 (0.8) 
1.3 (0.5) 
2.0 (0.0) 
2.0 (0.0) 
2.7 (0.6) 
2.0 (0.0) 
i
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Figure 3 Histopathology (HE) and antigen expression (IHC) in bronchioli (x20) and alveoli (x40) of groups A-
F. Histopathology of bronchioli shows peribronchiolar inflammatory infiltrates, epithelial necrosis and 
luminal accumulations of predominantly neutrophils and necrotic debris in all groups. Antigen expression in 
bronchioli is of similar extent for groups A, C-F and mild for group B. Histopathology of the alveoli shows a 
small increase in alveolar macrophages in groups A (MVA-H7-Sh2 108 pfu), B (2x MVA-H7-Sh2 108 pfu) and F 
(2x MVA-H7-Sh2 106 pfu). Groups C (wtMVA), D (2x wtMVA107 pfu) and E (2x PBS) show marked interstitial 
and luminal accumulations of predominantly neutrophils and macrophages, (epithelial) necrosis and edema. 
Antigen expression in alveoli is minimal to mild for groups A, B and F and marked for groups C, D and E. 
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DISCUSSION 
 
Here we describe the construction and preclinical evaluation of the first H7N9 influenza 
vaccine based on the MVA viral vector technology. Ferrets immunized with the MVA-H7-
Sh2 vaccine developed protective antibody titers against the H7N9 influenza virus strain 
A/Anhui/1/2013 that was used for challenge infection. Animals that received one or two 
doses of 108 pfu seroconverted and after two immunizations all animals developed HI 
antibody   titers  of  ≥40,  which  are   considered   to   be  protective.   Indeed animals with post 
vaccination   HI   titers   of   ≥40   displayed   reduced   virus   replication   in   the   respiratory   tract,  
especially in the lungs. The histopathological changes caused by challenge infection were 
less severe in these animals in particular of the alveoli. Thus, MVA-H7-Sh2 immunization 
protected animals against weight loss and respiratory symptoms and the development of 
interstitial pneumonia and alveolitis but to a lesser extent against the development of 
bronch(iol)itis. A few animals in the control groups and the group that received a single 
immunization with MVA-H7-Sh2 had low virus titers in the CNS (olfactory bulb and brain). 
Spreading to the CNS, although to a minimal extent may be the result of infection of cells 
in the olfactory epithelium as was described previously [186, 273] after intranasal 
inoculation of ferrets with A/H5N1 viruses. In the present study, the ferrets were 
inoculated via the intratracheal route to model H7N9 induced pneumonia. Since the nasal 
turbinates also tested positive for the presence of infectious virus 4 days post inoculation, 
the olfactory bulb may have become infected indirectly.   
Administration of a 100-fold lower dose of MVA-H7-Sh2 proved to be less immunogenic 
than the normal dose. Clearly the MVA-H7-Sh2 induced antibody response is strongly 
dose-dependent, which may be explained in part by the vectors replication deficiency. 
With a lower dose simply less cells become infected and express the transgene. However, 
in mice it was demonstrated that with an MVA-based H5N1 vaccine candidate substantial 
dose–sparing could be achieved [262].     
Recently we have demonstrated that with an MVA-based vaccine partial protection of 
ferrets against infection with a A(H1N1)pdm09 virus could be achieved. Immunization with 
108 pfu MVA-H7-Sh2 seems to afford stronger protection against virus replication in the 
respiratory tract than the MVA-H1 vaccine against infection with the pandemic 
A(H1N1)2009 virus [140].  However, in both models the MVA based vaccines did not 
induce sterile immunity as was observed against challenge infection with A(H5N1) 
influenza viruses in other species, including mice and cynomolgus macaques [136, 261-
263].  
Reduction of A/H7N9 virus titers in especially the upper respiratory tract after challenge 
infection by MVA-H7-Sh2 vaccination may reduce the risk of airborne transmission with 
i
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these viruses [274, 275]. In contrast to the partial protection from virus replication in the 
upper and lower respiratory tract shown here, Chen et al have shown that a live-
attenuated H7N9 vaccine was capable of providing sterile immunity in ferrets against 
homologous and heterologous challenge infection [276]. Although it was not tested, 
mucosal IgA antibodies most likely have contributed to the protective capacity of the 
vaccine in their model in which vaccine and challenge virus were both inoculated 
intranasally. It would be of interest to test MVA-H7-Sh2 in a similar model to test if it can 
be used for the induction of mucosal immunity. 
Apart from vaccines based on the actual novel H7N9 strain also vaccines based on historic 
H7Nx viruses have been shown to induce cross-reactive antibodies that are able to 
neutralize the novel H7N9 virus [250]. Goff et al demonstrated that a Newcastle disease 
virus expressing the HA gene of a historic H7N3 virus induced cross-reactive antibodies in 
mice that afforded protection against infection with an A/H7N1 influenza virus isolated in 
1993 [253]. Chu et al demonstrated that a historic H7N9 virus-derived vaccine partially 
protected mice against infection with influenza virus A/Anhui/1/2013. Furthermore, live-
attenuated H7N3 and H7N7 vaccines provided partial protection against the novel H7N9 
strain in ferrets [277].  
These examples illustrate the benefits of virus repositories containing prototypic strains of 
the respective HA and NA subtypes found in nature. Such a repository should be updated 
regularly based on influenza surveillance data in poultry, swine and humans. The HA 
nucleotide sequence of a prototypic strain is already enough to produce a viral-vector 
vaccine for viruses of that particular subtype and a logic next step would be to not only 
have an influenza virus repository [278] but to also establish a vaccine repository based 
for example on a versatile vaccine production platform such as MVA. To accelerate the 
further clinical development of MVA-based influenza vaccines, further expansion of the 
safety and efficacy track record of MVA as a viral vector is required. Finally, once advanced 
regulatory frameworks are in place, reaching beyond the national guidelines (e.g. 
pandemic influenza vaccines registration by EMA in Europe) MVA-based vaccine 
production technology could facilitate rapid availability of vaccines for emerging novel 
influenza viruses including those of the H7N9 subtype. 
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ABSTRACT 
 
Middle East respiratory syndrome coronavirus (MERS-CoV) may cause severe pneumonia 
in humans. To study the pathogenesis of this virus, young adult cynomolgus macaques 
were inoculated with MERS-CoV. Viral replication in the upper respiratory tract was 
limited as evidenced by relatively low levels of viral RNA in nasal and throat swabs and the 
absence of MERS-CoV nucleocapsid protein in nasal respiratory epithelium. Lack of MERS-
CoV replication in the upper respiratory tract was consistent with the absence of its host 
receptor, dipeptidyl peptidase-4 (DPP4), in the nasal epithelium. In the lower respiratory 
tract, limited pathological changes were noted and infectious virus was eliminated by four 
days post inoculation. Consistent with the rapid clearance of MERS-CoV, IFN-β   and  
phosphorylated STAT1 (pSTAT1) expression levels were enhanced in the lungs of infected 
animals. Different from SARS-CoV, which inhibits phosphorylation and translocation of 
STAT1, co-localization of pSTAT1 and MERS-CoV antigen indicates that virus-infected cells 
respond to interferon signaling. Therefore, DPP4 expression and the activation of 
interferon signaling pathways might be critically involved in controlling MERS-CoV 
replication in vivo. 
 
INTRODUCTION 
 
There are six coronaviruses (CoVs) known to cause respiratory illness in humans with 
clinical manifestations ranging from mild to fatal. Four of them, 229E-CoV, OC43-CoV, 
HKU1-CoV, and NL63-CoV commonly cause mild upper respiratory tract infection [279, 
280]. The other two CoVs have been reported to cause severe lower respiratory tract 
infection [281]. One of them, severe acute respiratory syndrome coronavirus (SARS-CoV), 
rapidly spread across continents in 2003. However, the pandemic was contained within a 
year due to well-coordinated and stringent public health measures. By the end of the 
outbreak, SARS-CoV had affected ~8000 people resulting in ~800 fatal cases [281, 282]. 
Another CoV was isolated from a 60-year-old Saudi Arabian man with acute pneumonia. 
This virus, currently known as Middle East respiratory syndrome coronavirus (MERS-CoV), 
has infected more than 1500 people [32, 283]. Approximately 35% of infected patients 
succumb to severe infection with life-threatening complications, such as septic shock, 
acute kidney failure, and acute respiratory distress syndrome. These patients are mostly 
over 50 years of age and have underlying comorbidities, such as diabetes, 
immunocompromised state, chronic renal failure, and heart disease. The remaining two 
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thirds of MERS cases are either asymptomatic or develop mild pneumonia. This group 
mostly consists of young immunocompetent individuals without comorbidities but with 
close contact to MERS patients, such as family members and health-care personnel [283-
286]. It is currently unclear how MERS-CoV infection can cause such differences in clinical 
manifestations. Our lack of understanding how MERS-CoV infection can cause such 
differences in clinical manifestations is due in part to the dearth of data on the 
pathogenesis of MERS infection in the respiratory tract. 
To better understand MERS pathogenesis, we analysed experimental MERS-CoV infection 
in healthy young adult cynomolgus macaques. The replication capacity of this virus in both 
upper and lower respiratory tract tissues was thoroughly assessed. Distribution of the 
MERS-CoV host receptor, dipeptidyl peptidase-4 (DPP4) [287], was evaluated and 
compared to MERS-CoV tropism in the respiratory tract. Innate immune signaling in 
response to MERS-CoV infection, focusing on the expression of interferon-beta (IFN-β)  and  
its surrogate marker pSTAT1, was also analyzed in lung tissue samples. In addition, the 
capacity of MERS-CoV to induce upper respiratory tract infection was compared to NL63-
CoV, while MERS-CoV infection in the lower respiratory tract was compared to SARS-CoV. 
Unlike MERS-CoV, both NL63-CoV and SARS-CoV use angiotensin converting enzyme-2 
(ACE2) as their host receptor [288, 289]. Our observations provide novel insights in the 
pathogenesis of MERS-CoV.  
 
MATERIALS AND METHODS 
 
Virus preparation 
MERS-CoV (EMC/2012 isolate) [32] was passaged six times on Vero E6 cells. NL63-CoV was 
passaged four times on Vero E6 cells. All cell cultures were performed under biosafety 
level (BSL) 3 conditions. 
 
In-vivo infection experiment  
Experiments were performed under BSL 3 conditions at the Erasmus Medical Centre in 
Rotterdam using an animal research protocol approved by the Institutional Animal 
Welfare Committee (EMC2808, nr 122-12-32) . Young adult cynomolgus macaques 
(Macaca fascicularis) seronegative for coronaviruses were purchased from commercial 
breeders (Harlan, Indianapolis, IN, USA), maintained in standard housing and provided 
with commercial food pellets and water ad libitum until the start of the experiment. Two 
weeks prior to inoculation with MERS-CoV, a telemetric sensor (DST micro-T ultra-small 
i
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temperature logger, Star-Oddi, Reykjavik, Iceland) was placed in the peritoneal cavity of 
only three macaques in the MERS-CoV inoculated group to record body temperature 
every 15 minutes. Before the inoculation, the macaques were examined clinically and 
determined as healthy by a registered veterinarian and were placed in negatively 
pressurized glove boxes. During the experiment, animals were checked daily for clinical 
signs, including assessment of appearance, behavior, weight, presence of any nasal or 
ocular secretions, food and water consumption.  
All inoculations were performed under anesthesia ((ketamine® (Nimatek, Eurovet Animal 
Health BV, Bladel, the Netherlands) and domitor® (Orion Pharma, Espoo, Finland)). Ten 
macaques were inoculated intratracheally (4.5 ml) and intranasally (0.5 ml) with 1 x 106 
50% Tissue Culture Infectious Dose (TCID50) MERS-CoV. Prior to infection and at days 1, 2, 
4, 8, and 11 pi, animals were anesthetized with ketamine, and oral and nasal swabs were 
taken and placed in 1 ml Dulbecco's modified Eagle's medium supplemented with 100 IU 
penicillin/ml   and   100   μg   streptomycin/ml   (virus   transport   medium).   The   swabs   were  
frozen  at  −70°C  until  analysis  (see  below).  Four macaques were euthanized at each of days 
1 and 4 pi, while the last two were euthanized at day 21 pi  by exsanguination under 
anesthesia. Autopsies were performed according to a standard protocol. One lung from 
each monkey was inflated with 10% neutral-buffered formalin by intrabronchial 
intubation and suspended in 10% neutral-buffered formalin overnight. Samples were 
collected   in   a   standard   manner,   embedded   in   paraffin,   cut   at   3   μm,   and   used   for  
immunohistochemistry (see below), in situ hybridization (see below) or stained with 
hematoxylin and eosin (H&E) for examination by light microscopy. Tissue samples were 
also collected in virus transport medium (Hanks balanced salt solution supplemented with 
10%   glycerol,   200   U   of   penicillin   per   ml,   200   μg   of   streptomycin   per   ml,   100   U   of  
polymyxin  B  sulphate  per  ml,  250  μg  of  gentamycin  per  ml,  and  50  U  of  nystatin per ml). 
Tissue samples were weighed prior to homogenization in 2 ml virus transport medium, 
using Polytron PT2100 tissue grinders (Kinematica). After centrifugation, the homogenates 
were  frozen  at  −70°C  until  virus  titration  (see  below)  and  RT-qPCR (see below).  
NL63-CoV and SARS-CoV infections were used as a contrast to further understand the 
pathogenesis of MERS-CoV infection. Experimental NL63-CoV infection was performed in 
four macaques. They were inoculated intratracheally (2.5 ml) and intranasally (0.5 ml) 
with 1 x 105 TCID50 of HCoV-NL63. Two animals were euthanized at each of days 4 and 21 
pi. All animals were euthanized by exsanguination under anesthesia. Meanwhile, 
experimental SARS-CoV infection had been previously performed in our center also in 
healthy young adult cynomolgus macaques [68].  They were infected intratracheally with 1 
× 106 TCID50 SARS-CoV (strain HKU-39849) and euthanized at day 4 pi. Left over lung tissue 
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samples from this experiment were analyzed together with lung tissue samples from 
MERS-CoV experiment. 
 
Ex-vivo infection experiment 
Nasal tissue and one entire lung lobe were harvested from a healthy 8 year-old 
cynomolgus macaque and transferred immediately to ice. Lung tissue was prepared as 
described previously [290]. Nose and lung tissue were sliced and transferred to 24-well 
plates (Corning, Wiesbaden, Germany) containing culture medium and incubated 
overnight at 37°C in 5% (v/v) CO2. Each tissues were prepared in triplicate. Either 3 x 10
6 
TCID50 MERS-CoV or culture medium (mock infected group) was added to the wells under 
BSL3 conditions. After 1 hour incubation at 37°C, 500 µl fresh medium was added to each 
well and incubated overnight at 37°C in 5% (v/v) CO2. All tissue pieces were then fixed in 
formalin and embedded in paraffin. MERS-CoV was detected using 5 µg/ml mouse IgG1 
anti-MERS-CoV nucleocapsid protein (Sino Biological Inc, Beijing, China) and 1:100 
peroxidase labeled goat anti-mouse IgG1. Red signal was revealed using 3-amino-9-ethyl-
carbazole substrate [77]. 
 
Virological analysis 
Viral RNA was isolated using viral RNA Mini kit (Qiagen, Hilden, Germany) and 
subsequently measured for viral load using reverse transcription-quantitative polymerase 
chain reaction (RT-qPCR) (Roche, Mannheim, Germany). Each MERS-CoV samples was only 
considered positive if both E and N gene were detected [291]. Meanwhile, NL63-CoV 
samples were detected by RT-qPCR targeting N gene [292]. Samples were also titrated on 
Vero E6 cells to further confirm the results of RT-qPCR. Ten-fold serial dilutions of the 
homogenates were prepared in Lonza IMDM medium containing 5% fetal bovine serum 
(FBS) for virus titration assay on Vero E6 cells [293]. The amount of infectious virus in lung 
homogenates was calculated according to the Spearman-Karber standard equation [294]. 
The limit of viral detection for this assay was 0.5 log10 TCID50/ml.  
 
Bacteriological analysis 
One macaque developed severe suppurative bronchopneumonia in our study. Lung tissue 
samples of this macaque were used to isolate RNA and bacterial typing as described 
previously [295]. 
 
 
 
i
i
i
i
i
i
i
i
92 | MERS-CoV Infection in Non-Human Primates 
 
Immunohistochemistry  
For immunohistochemistry (IHC), MERS-CoV antigen was detected using rabbit serum 
against SARS-CoV nucleocapsid (N) protein, which is known to cross-react with MERS-CoV 
[287]. NL63-CoV was detected using rabbit serum against its nucleocapsid protein (kind 
gift from Lia van den Hoek). Normal rabbit serum was used as negative control for both. 
Distribution of DPP4 and ACE2 expression was evaluated on the non-infected macaque 
tissues using polyclonal goat IgG anti-human DPP4 (R&D systems, Abingdon, UK) and 
polyclonal rabbit IgG anti-human ACE2 (Abcam, Cambridge, UK), respectively. Normal goat 
serum and rabbit IgG was used as a control. Peroxidase-labeled goat anti-rabbit IgG 
(DAKO, Glostrup, Denmark) was diluted 1:100 and used as secondary antibody for NL63-
CoV, MERS-CoV, and ACE2 staining. Goat anti-rabbit IgG (Southern Biotech, Alabama, USA) 
diluted 1:200 was used as secondary antibody for DPP4 staining. For MERS-CoV, 
peroxidase was revealed using diaminobenzidine substrate, while other antigens were 
revealed with 3-amino-9-ethyl-carbazole substrate. Counterstaining was performed with 
hematoxylin. 
We studied co-localization between pSTAT1 and nucleocapsid protein of either MERS-CoV 
or SARS-CoV in the infected lungs of macaques sacrificed at day 1 pi. Lung tissues derived 
from non-infected macaques were included as negative control tissues. Monoclonal 
antibodies against MERS-CoV nucleocapsid protein (SinoBiological, Beijing, China) and 
SARS-CoV nucleocapsid protein (Imgenex, Littleton, USA) were used in 5 µg/ml 
concentration [77, 296]. Goat anti-mouse IgG1 labeled with alkaline phosphatase was 
used as secondary antibody (DAKO, Glostrup, Denmark). The dark blue signal was revealed 
with BCIP/NBT substrate (DAKO, Glostrup, Denmark). Phosphorylated STAT1 protein was 
detected using rabbit anti-human pSTAT1 (ThermoScientific, Rockford, USA) at a 1:200 
dilution [297]. Rabbit IgG in similar concentration was used as a negative control. 
Peroxidase labeled goat anti-rabbit IgG diluted at 1:100 was used as secondary antibody 
staining. Red signal was revealed using 3-amino-9-ethyl-carbazole substrate followed by 
hematoxylin counterstaining. 
 
In situ hybridization 
In situ hybridization (ISH) was performed according to the RNAScope platform [298]. 
Probes targeting the nucleocapsid gene of MERS-CoV and NL63-CoV were designed by 
Advanced Cell Diagnostics (Hayward, CA, USA). 
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Cytokine measurements 
RT-qPCR was performed as described previously to detect cellular gene expression 
changes for IFN-β,  IL-6, IL-8, CCL3, CCL20, and osteopontin [68, 296]. Differences in gene 
expression are represented as the fold change in gene expression relative to a calibrator 
and normalized to a reference, using the 2−ΔΔCt method [299]. GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) was used as a reference endogenous control. The samples 
from the mock-infected macaques were used for calibration [299]. Data distribution was 
evaluated  with  D’Agustino  and  Pearson  omnibus  normality  test.  The  data  were  presented  
either in mean ± standard error of mean or median ± interquartile range. Statistical 
analysis was performed with unpaired t test or Mann-Whitney test.  
 
RESULTS 
 
Clinical signs and gross pathology of MERS-CoV infected healthy young adult 
macaques 
Ten young healthy adult cynomolgus macaques were inoculated both intranasally and 
intratracheally with MERS-CoV. Clinical signs, fever and body weight loss were minimal in 
all animals during the experiment (Fig. 1a). Upon autopsy, the macroscopic lung lesions 
were found to be generally mild, consisting of focal to multifocal consolidation in 
approximately 5% area of lung tissue, except for one macaque that developed severe 
suppurative bronchopneumonia (Fig. 1b). This macaque also showed elevated body 
temperature up to 40°C around day 4 post inoculation (pi) (Fig. 1a). Histological 
examination on the lung sample of this macaque revealed myriad intralesional small rod-
shaped bacteria. Bacterial typing analysis on the lung sample of this animal revealed the 
presence of Escherichia coli, which suggests bacterial co-infection in this animal. The 
bronchial lymph nodes and tonsils were enlarged in all animals. 
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Limited MERS-CoV infection in the upper and lower respiratory tracts  
Nasal and throat swabs were collected at multiple time-points to assess MERS-CoV 
replication over time. MERS-CoV RNA was detected from day 1 pi but levels were in 
general relatively low (Fig. 2). This observation was consistent with the fact that all swabs, 
except for one throat swab sample from the macaque with bacterial co-infection (10 
TCID50/ml, labelled with asterisk in Fig. 2), were found negative in the virus titration assay. 
In lung homogenates, infectious virus was only observed at relatively high levels shortly 
after inoculation (Fig. 2). Other respiratory and extra-respiratory tissues tested did not 
contain infectious virus. However, MERS-CoV RNA was detected in the lungs of all animals 
(Fig. 2), and in the urine, large intestines, and kidney of only one macaque sacrificed at day 
1 pi (data not shown). These results demonstrate that MERS-CoV replication in 
experimentally infected cynomolgus macaques is efficiently restricted; only when lung 
tissue samples were taken at very early time points post inoculation infectious virus was 
detected.   
Replication of MERS-CoV in the upper and lower respiratory tract tissues was further 
analysed using immunohistochemistry (IHC). MERS-CoV nucleocapsid protein was 
detected mainly in the bronchiolar and the alveolar epithelial cells at day 1 pi (Fig. 3). In 
Figure 1 Body temperature and gross lesions of MERS-CoV infected macaques. All animals 
developed elevated body temperature (body temperature >38°C) post MERS-CoV inoculation (a). 
One macaque (number 3) developed bacterial co-infection during the experiment. This macaque 
developed elevated temperature up to 40°C around day 4 pi (a) and had severe gross lesions (b, 
bottom right) compared to the other macaques. Gross pathology pictures were taken of four 
macaques sacrificed at day 4 pi.   
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situ hybridisation with a MERS-CoV nucleocapsid probe confirmed the IHC results (Fig. 3). 
Consistent with the replication of MERS-CoV in the lungs, expression of dipeptidyl 
peptidase-4 (DPP4), the MERS-CoV receptor [287], was also observed in the bronchial and 
alveolar epithelial cells, although mainly in the type 2 alveolar epithelial cells. However, 
DPP4 expression gradually became undetectable from the lower to the upper respiratory 
tract. Whereas epithelial cells in the submucosal gland along the respiratory tract, 
terminal bronchioles, and trachea were DPP4 positive, both the olfactory and respiratory 
nasal epithelial cells were found to be DPP4 negative (Fig. 4). The lack of DPP4 expression 
in the upper respiratory tract corresponds with undetectable MERS-CoV replication in this 
location (Fig. 4). In addition to the lower respiratory tract, DPP4 is also widely expressed in 
other organs, including liver, kidney, and intestines (Fig. 5). MERS-CoV nucleocapsid 
protein, however, was not detected in these tissues. In addition, ex-vivo MERS-CoV 
infection of macaque nasal and lung tissues was performed. As shown in figure 6, both 
type I and II alveolar epithelial cells were successfully infected, while nasal respiratory 
epithelium was not. Together, these results reveal that MERS-CoV tropism in the 
respiratory tract corresponds to the distribution of DPP4.  
 
Figure 2 Detection of MERS-CoV in the nasal swabs, 
throat swabs, and lung homogenates using quantitative 
PCR and virus titration.   MERS-CoV RNA was detected in 
the nasal and throat swabs of all macaques up to day 11 pi. 
None of the samples showed detectable infectious virus 
titres, except for  one throat swab (*) taken from the 
macaque that developed bacterial co-infection. In the lung, 
large amounts of MERS-CoV RNA were detected at day 1 
and 4 pi, but infectious MERS-CoV was only largely 
detected at day 1 pi. Three out of four lung homogenate 
samples from day 4 pi were negative in virus titration. 
Dotted lines indicate detection limit of the assays. 
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Figure 4 Immunohistochemistry staining of MERS-CoV, NL63-CoV, and their receptors in the nasal 
epithelium. Neither MERS-CoV nucleocapsid protein nor MERS-CoV receptor, DPP4, were detected in 
the nasal epithelium. In contrast, NL63-CoV nucleocapsid protein was detected in the nasal olfactory 
epithelium and NL63-CoV receptor, ACE2, was detected in both nasal olfactory and respiratory 
epithelium. All pictures were taken at 40x objective magnification. 
 
Figure 3 MERS-CoV and DPP4 
were detected in the lower 
respiratory tract. MERS-CoV 
nucleocapsid protein and RNA 
was detected in the alveolar 
epithelium. Nucleocapsid protein 
and DPP4 were detected using 
immunohistochemistry staining, 
while MERS-CoV RNA with in-situ 
hybridization. Pictures were taken 
from macaques sacrificed at day 1 
pi. DPP4 was also expressed in 
the alveolar epithelium. HE 
staining of the lungs showed mild 
histopathological changes. All 
pictures were taken at 40x 
objective magnification. 
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Figure 5 DPP4 expression in other macaque tissues. DPP4 was expressed on the apical surface of the nasal 
submucosal glands (A), the tracheal submucosal glands and their secretory ducts (B). It showed limited 
expression on the apical surface of the trachea (C). The expression was gradually increased in the bronchi 
(D), the bronchioles (E), and the terminal bronchioles (F), as it reached the lungs. In the tonsils, it was mainly 
detected in the paracortex and medulla, but not inside the lymphoid follicles (G). In the liver, it was 
predominantly found in the endothelium of the hepatic sinusoids (H). In the intestine, it was detected on the 
apical surface of small intestine (I) and colonic crypts (J). In the kidney cortex, it was mainly found in the 
apical surface of proximal tubules but not in the glomeruli (K). Negative control staining on kidney tissues 
showed no background in our staining (L). Small intestine and colon pictures were taken at 10x objective 
magnification; tonsil, liver, and kidney at 20x; while the rest at 40x.  
 
 
 
 
 
Figure 6 Ex-vivo MERS-CoV 
infection in the nasal and lung 
tissues. MERS-CoV nucleocapsid 
protein was detected in type I and 
II alveolar epithelial cells but not 
in the nasal epithelial cells. Non-
infected tissues (mock) were used 
as negative control. All pictures 
were taken at 400x magnification.  
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Similar to DPP4, ACE2, the entry receptor of SARS-CoV and NL63-CoV [288, 289], is 
expressed in the alveolar epithelial cells [300]. Meanwhile in the upper respiratory tract 
epithelium, ACE2 is also expressed, unlike DPP4; ACE2 is present in the apical layer of both 
nasal respiratory and olfactory epithelium (Fig. 4). We subsequently performed 
experimental NL63-CoV infection of cynomolgus macaques. They showed mild clinical 
signs and no gross lesions upon autopsy, but did seroconvert (virus neutralization titres of 
40-80). NL63-CoV antigen was detected by IHC in the nasal olfactory epithelial cells (Fig. 
4), but not in the other tissues. This result was confirmed with ISH (data not shown). 
Localized replication of NL63-CoV was consistent with very low NL63-CoV RNA levels (Ct 
value above 36) in the lungs, nasal and pharyngeal swabs taken from days 1 to 4 pi and 
with the inability to culture virus from these samples (not shown). In line with the clinical 
signs and gross pathology data, histopathological evaluation of the lung tissues of NL63-
CoV-infected macaques only showed mild increase of alveolar macrophages and 
neutrophils, and minimal hypertrophy and hyperplasia of type II cells. Based on these 
results, we conclude that NL63-CoV predominantly induces mild upper respiratory tract 
infection in cynomolgus macaques. Differences in tropism between MERS-CoV and NL63-
CoV in the upper respiratory tract correspond with differences in the distribution of their 
receptors, DPP4 and ACE2, respectively. 
 
MERS pathogenesis in the lower respiratory tract 
MERS-CoV infected macaques showed minimal histopathological changes in the lungs. 
There was mild increase of alveolar macrophages and neutrophils in the alveolar lumina, 
and moderate type II hyperplasia and hypertrophy as compared to control mock 
inoculated animals (Fig. 3). Few syncytial cells were also seen in the alveolar lumina. 
MERS-CoV RNA was detected in the lungs at high levels at day 1 and 4 pi, but almost no 
infectious virus was found at day 4 pi (Fig. 2). This was consistent with the MERS-CoV 
nucleocapsid protein immunohistochemistry results, showing less viral antigen at day 4 pi 
compared to day 1 pi. This rapid clearance of MERS-CoV from the lungs might be 
associated with expression of type I interferon (IFN) and its downstream cellular signalling. 
It has been shown in vitro that MERS-CoV is highly sensitive to type I interferon [301]. We 
observed high level expression of IFN-β   in   lung  tissue  samples  collected  at  day  1  pi   (Fig.  
7a). However this high expression was only observed in some lung tissue samples, 
suggesting localized expression of IFN-β   in   the   lungs,   consistent   with variable levels of 
MERS-CoV RNA detected in different tissue samples. IFN-β  expression  has  been  reported  
to be correlated with presence of SARS-CoV in the lung [296]. Nevertheless, IFN-β  levels  in  
the lungs dropped significantly at day 4 pi, similar to other cytokines like IL-6, CCL3, and 
CCL20 (Fig. 7a). 
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In order to better contrast our MERS-CoV data with other CoV infections in cynomolgus 
macaques, samples from previous experimental SARS-CoV infections [68] were reanalysed 
together with samples obtained in this study. At day 4 pi, SARS-CoV RNA levels were  ~2 
log10 higher in the lungs compared to MERS-CoV. Infectious SARS-CoV also could be 
cultured at this time point [300]. IFN-β  mRNA  expression  in  the  lungs  of  SARS-CoV infected 
macaques was also ~2 log10 higher compared to MERS-CoV infected macaques (Fig. 7b). 
This may reflect a strong correlation between IFN-β   expression   and   virus   titre [296]. 
Besides IFN-β,  IL-6 and CCL3 expression levels were also significantly higher, while CCL20 
was significantly lower in the SARS-CoV infected macaques (Fig. 7b). 
To further characterize the type I IFN production in both MERS-CoV and SARS-CoV 
infections, pSTAT1 immunohistochemistry was performed on the lung tissues of the 
infected macaques. STAT1 becomes phosphorylated as a result of downstream IFN 
signalling [296]. We observed that pSTAT1 was expressed in nuclei of alveolar epithelial 
cells at day 1 pi, both in MERS-CoV- and SARS-CoV-infected macaques, but not in mock-
infected macaques (Fig. 8a,b). pSTAT1 expression was localized to areas near blood vessels 
and virus infected cells consistent with localized IFN-β  expression.  MERS-CoV infected lung 
explants did not show staining for pSTAT1, suggesting that the type I IFN is initially 
produced by infiltrating immune cells (Fig. 8c). Interestingly, pSTAT1 translocation was 
observed in MERS-CoV-infected cells (Fig. 8a), but not in SARS-CoV-infected cells (Fig. 8b). 
It has been reported that SARS-CoV infection does block pSTAT1 translocation to the 
nucleus both in vitro and in vivo [296, 301]. Our results suggest that MERS-CoV infection 
does not block pSTAT1 translocation in the lungs of cynomolgus macaques, confirming 
previous in vitro findings [301]. 
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Figure 7 IFNβ,  IL-8, IL-6, osteopontin, CCL3, and CCL20 mRNA expression in the lungs of MERS-
CoV infected macaques at day 1 and 4 pi (a); Viral  RNA  and  mRNA  expression  of  IFNβ,  IL-8, IL-
6, osteopontin, CCL3, and CCL20 in the lungs of MERS-CoV and SARS-CoV infected macaques 
at day 4 pi (b). In figure (a), all data were presented in fold change unit as described in the 
methods section. Osteopontin and CCL3, were displayed in mean ± standard error of mean and 
analysed with unpaired t-test due to their normal distribution. IFNβ, IL-8, IL-6, and CCL20 were 
presented in median ± interquartile range and analysed with Mann-Whitney test. Significant 
difference was found in IL6, CCL3, and CCL20. In figure (b), viral   RNA,   IFNβ,   and  osteopontin 
were displayed in median ± interquartile range and analyzed with Mann-Whitney test. The 
graphs of viral  RNA  and  IFNβ  are    in  the  log10 scale, while that of osteopontin, IL-8, IL-6, CCL3, 
and CCL20 were presented in mean ± standard error of mean, graphed in linear scale, and 
analysed with unpaired t-test. Significant difference was detected in the viral RNA, IFNβ, IL-6, 
CCL3, and CCL20 (***p  value  ≤  0,001;  **p  value  ≤  0,01;  *p  value  ≤  0,05;    n.s.  =  not  significant). 
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Figure 8 Double immunohistochemistry staining of pSTAT1 and virus nucleocapsid protein in the lungs of 
MERS-CoV infected macaques (A), the lungs of a SARS-CoV infected macaque (B), and MERS-CoV infected ex 
vivo lung tissues (C). pSTAT1 signal is shown in red, while MERS-CoV and SARS-CoV nucleocapsid protein are 
shown in dark blue. In the top row (200X magnification), pSTAT1 was abundantly detected in the lungs of MERS-
CoV infected macaques at day 1 pi. Lung from mock infected macaques was used as negative control (A). Similar 
result were found in the lungs of SARS-CoV infected macaques (B), but not in the MERS-CoV infected ex vivo 
lung tissues (C). In the middle (40x objective magnification) and bottom row (100x), several MERS-CoV infected 
alveolar epithelial cells were positive for pSTAT1 (arrows) (A). Co-localization of pSTAT1 and virus nucleoprotein 
was not found in the lungs of SARS-CoV infected macaques (B) and in the MERS-CoV ex vivo infected lung 
tissues (C).  
 
 
DISCUSSION 
 
The pathogenesis of MERS is still not well understood, partly because of the lack of human 
lung tissue from MERS cases. Experimental infection in healthy young adult cynomolgus 
macaques was performed to gain some insights in the host factors that may restrict MERS-
CoV replication in vivo. MERS-CoV-infected cynomolgus macaques developed a virtually 
asymptomatic infection, mimicking mild human MERS cases mostly observed in healthy 
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young individuals without comorbidities [285, 286]. We speculate that MERS-CoV 
replication in the respiratory tract of such individuals might be restricted in a similar 
manner as we observed in macaques. Limited MERS-CoV replication in the upper 
respiratory tract epithelium of the non-human primates corresponded with the absence of 
DPP4. The expression pattern of DPP4 is different from ACE2, another ectopeptidase, that 
serves as the NL63-CoV receptor [289]. In fact, ACE2 is expressed in the nasal epithelium, 
providing NL63-CoV the possibility to enter the upper respiratory tract. NL63-CoV 
preference to infect nasal olfactory instead of respiratory epithelium might be due to 
another attachment factor [302, 303]. On the other hand, DPP4 is expressed in the lower 
respiratory tract, predominantly in type II alveolar epithelial cells. This distribution of DPP4 
therefore corresponds with the tropism of MERS-CoV in the respiratory tract. Together 
these data suggest that receptor expression in vivo is an important determinant for these 
coronavirus infections. 
In the lower respiratory tract, both MERS-CoV RNA and infectious virus were detected at 
day 1 pi. In some of the lung tissue samples that were MERS-CoV positive, IFN-β  
expression was also observed. The pSTAT1 staining in the lungs of MERS-CoV infected 
macaques at day 1 pi also supported this observation; pSTAT1 could be used as a 
surrogate marker of IFN expression [296]. We speculate that type I IFN plays a significant 
role in the rapid clearance of MERS-CoV from the lungs of the infected cynomolgus 
macaques. This is consistent with in vitro studies showing that MERS-CoV is highly 
sensitive to the antiviral action of type I IFNs [301]. Therefore, time-dependent sampling is 
important in the analysis of host responses to MERS-CoV in cynomolgus macaques. Only 
by analyzing very early time points after inoculation could the presence of infectious virus, 
interferon, and pSTAT1 be revealed. Experimental MERS-CoV infections have been 
previously performed in rhesus macaques. These macaques developed lower respiratory 
tract infection but the earliest time point after inoculation that animals were sacrificed 
was day 3 pi. Dependent on the inoculation route, MERS-CoV RNA was detected in the 
nasal and oropharyngeal swabs [64, 65]. In the lower respiratory tract, MERS-CoV mainly 
infected alveolar epithelial cells and induced mild-to-moderate interstitial pneumonia but 
infectious virus hardly could be detected [64, 65]. Thus, MERS-CoV replication and the 
ensuing host response in both rhesus and cynomolgus macaques seem to peak early in the 
infection. Additionally we provide evidence that although MERS-CoV RNA was shed in 
nasal and throat swabs up to day 11 pi, virus titration and immunohistochemistry staining 
showed that there is no evidence of upper respiratory tract infection, suggesting that the 
source of the excreted virus was the lower respiratory tract.   
To further gain insight in the pathogenesis of MERS, historic samples from cynomolgus 
macaques inoculated with a similar dose of SARS-CoV through identical routes were used 
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for comparison. Unlike what we observed for MERS-CoV, SARS-CoV RNA is detected at 
much higher levels and infectious SARS-CoV is still present in the lungs at day 4 pi [300, 
304]. SARS-CoV infectious virus is also continuously shed in the macaque upper 
respiratory tract for at least a week after virus inoculation [304, 305]. These in vivo 
observations are different from the growth characteristics of both viruses in vitro. 
Compared to SARS-CoV, MERS-CoV induces more severe cytopathology in both monkey 
and human cell lines [301], and is capable of infecting various cell lines, suggesting a broad 
tissue tropism [306]. MERS-CoV also replicates more efficiently in primary human airway 
epithelium cell culture compared to SARS-CoV [306, 307].  
SARS-CoV most likely more efficiently circumvents the host immune response and 
therefore able to replicate and persist longer in the lungs of cynomolgus macaques. This is 
supported by observations showing partial resistance of SARS-CoV to IFN type I [301], and 
its capacity to block pSTAT1 translocation [296, 301]. Here we show that unlike SARS-CoV, 
MERS-CoV infection does not block pSTAT1 translocation in vivo, confirming our previous 
in vitro findings [301]. Together these data indicate that MERS-CoV is less pathogenic 
compared to SARS-CoV in macaques. Since MERS-CoV infection might be rapidly 
controlled by the host innate IFN response, healthy young adult macaques might not be 
the most appropriate animal to test therapeutic measures evaluating the therapeutic 
potential of IFN-α2b [308].  
Our study showed that MERS-CoV replication is limited in both upper and lower 
respiratory tract infection, associated with the distribution of DPP4 expression and type I 
IFN response. In comparison to SARS-CoV, MERS-CoV seems to be less pathogenic and 
possibly also less transmissible because of limited replication in the upper respiratory 
tract. This might be one reason why MERS-CoV has not spread as quickly and widely as 
SARS-CoV did in 2003 [282]. However, this does not exclude the possibility that some 
MERS infected patients transmit MERS-CoV efficiently. It is currently difficult to identify 
these individuals, since factors that could influence MERS-CoV transmission are still 
unknown. In our study, the only throat swab sample that was positive in virus culture 
came from a macaque that developed bacterial co-infection. This observation suggests 
that bacterial co-infection might increase the MERS-CoV infection. Age on the other hand 
is another important risk factor for fatal MERS infection in human [284]. We have 
previously reported that aged cynomolgus macaques developed much fatal SARS-CoV 
infection compared to the young ones, due to the incapacity of aged macaques to yield 
sufficient innate immune response post SARS-CoV inoculation [68]. Future studies 
dedicated to identify factors influencing MERS-CoV transmission would be important to 
pursue.
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OVERVIEW 
 
The objective of the work presented in this thesis was to improve understanding of, and 
response to, emerging zoonotic respiratory viruses. To this end, various animal models 
were employed to represent respiratory viral infections in humans. In the normal 
situation, humans are vaccinated and/or infected with respiratory viruses multiple times 
throughout life, resulting in a complex infection history shaping an intricate immunological 
landscape. It is virtually impossible to adequately mimic this situation in animal models. 
Nonetheless, animal models can provide valuable insights into the interplay between viral 
characteristics and host responses. The viruses that were studied in most depth, influenza 
A/H7N9 and MERS-CoV, were selected rather opportunistically as they both emerged in 
real-time during the conception of this manuscript. As such, very little was known about 
them at the time, making them particularly pertinent subjects for further study. 
 
In the introduction of this document, the relevance of the presented work was outlined; 
the high rate of emergence of novel human viruses and the relative lack of (timely) 
intervention strategies justify our continued efforts in this field. In addition, available 
animal models and intervention strategies were discussed to outline the tools we 
presently have at our disposal and to place our work in its current context. 
 
Animal models were used in three rather different ways, underlining that the choice of 
animal model depends largely on the research question. In Chapter 2-4 a new model was 
developed that provides unique features compared to established influenza virus models. 
In Chapter 5, an established model was used to test a novel intervention strategy for an 
emerging influenza subtype. Finally in Chapter 6, a new model was explored to gain 
understanding of the pathogenesis of a recently emerged coronavirus. 
 
Developing a new model that provides unique features  
In Chapter 2, 3, 4 the groundwork was laid for a new model for influenza virus infection. 
Although numerous functional influenza virus models exist, studying particular aspects 
such as transmission and cellular immunity simultaneously has so far not been possible. 
Strain 2 guinea pigs provide unique features (isogenicity and the ability to transmit 
unadapted avian and human influenza viruses) that would make such studies achievable. 
However, before proceeding to more complex work, the baseline parameters of such a 
model must be explored to truly ascertain its suitability for the envisioned experiments. 
Firstly, in Chapter 2, viral replication and pathogenesis of infection with a pandemic 
influenza virus of zoonotic origin that now circulates seasonally (A/H1N1pdm09), was 
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described in this model after intranasal or intratracheal inoculation.  It was concluded that 
viral replication peaked at 2 d.p.i and that virus continued to replicate only in the nose by 
day 7. When studying influenza in outbred guinea pigs, the intranasal route is used 
exclusively because intratracheal administration is technically more demanding. However 
our experiments showed that intratracheal inoculation is the preferable route when 
attempting to mimic human lower respiratory tract disease, as intranasal inoculation 
resulted in viral replication that appeared to be limited to the nasal cavity only.  
 
Chapter 3 shows the replication kinetics of H7N9 virus after intratracheal inoculation, 
which was more severe and resulted in more protracted viral shedding than following 
H1N1pdm09 virus infection. In addition, infection with H7N9 caused more inflammation 
and necrosis particularly in the lower respiratory tract. This predilection for the lower 
respiratory tract may be explained by the receptor distribution as H7N9 is an avian virus 
that is thought to preferentially use the α2,3 receptor that is expressed to a greater extent 
in the lungs.  
 
Chapter 4 shows that H1N1-primed animals showed decreased disease manifestation and 
viral shedding when challenged with H7N9 compared to unprimed animals, thus 
establishing the existence of heterosubtypic immunity in this model. The absence of cross-
reactive neutralizing antibodies leads us to conclude that this observed protective effect is 
best explained by the induction of more broadly reactive (cellular) immune responses, but 
the exact correlates of protection remain to be identified. 
 
The experiments described in Chapter 2, 3 and 4 pave the way for use of the guinea pig 
model in elucidating the role of cell mediated immunity on transmission dynamics. 
However to fully develop this model, further experiments are required. Although outbred 
guinea pigs are traditionally used for transmission studies and the high viral titres in nasal 
turbinates that were found in our experiments suggests that transmission would indeed 
be possible, the exact transmission dynamics of this particular model should be fully 
elucidated before proceeding. Transmission experiments should preferably be performed 
using the configuration that was developed by Herfst et al. to study airborne transmission 
in ferrets [19]. Some preliminary work (unpublished) that has been carried out shows that 
isolation and transfer of lymphocytes is indeed possible in strain 2 guinea pigs, but 
additional experiments are needed to optimize the methods. The final application of this 
model should include an experimental design in which infected recipient animals, either 
with or without transferred lymphocytes (ideally also assessing CD4+ and CD8+ subsets 
separately), are evaluated for their ability to transmit influenza to naive animals. 
i
i
i
i
i
i
i
i
108 | Summarizing Discussion 
 
Information obtained from these experiments will help to better understand immune 
correlates of transmission, which can, in turn contribute to refining our approach in design 
of novel vaccines. If decreased transmission of heterologous subtypes can indeed be 
effectuated by adoptive transfer of CD4+ and/or CD8+ lymphocytes, this would provide 
further evidence to support the development of vaccines that induce both humoral and 
cellular immune responses. 
 
Using an established model to test a novel intervention strategy  
In Chapter 5, we showed how established animal models can be used in real-time to test 
novel vaccines in the face of the emergence of a novel zoonotic influenza subtype.  During 
the 2009 H1N1 pandemic, the conventional production of (pre)pandemic vaccines fell 
short. Therefore when H7N9 emerged in 2013 and concerns arose regarding its pandemic 
potential, efforts focused on demonstrating the potential efficacy of alternatives to 
conventional production methods. 
 
The ferret model is considered the gold standard for influenza research and the 
pathogenesis of many influenza subtypes (including H7N9) is well known in this species. 
The purpose of this paper was therefore not to use the model to characterize the disease, 
but rather to assess potential intervention strategies. A newly sythesized MVA-H7-Sh2 
viral vector was used to immunize ferrets that were subsequently challenged with H7N9 
virus via the intratracheal route. Unprotected animals that were mock-vaccinated or that 
received empty vector, developed interstitial pneumonia characterized by a marked 
alveolitis, accompanied by loss of appetite, weight loss and heavy breathing. In contrast, 
MVA-H7-Sh2 immunized animals were protected from severe disease, even after a single 
immunization.  
 
As was discussed in more detail in the introduction, much progress has been made on the 
way to the development of universal influenza vaccines but many new, theoretically 
promising approaches still have to be verified in animal models and/or humans. In the 
development of the holy grail of influenza research, the universal influenza vaccine, 
candidates that induce both broad humoral and cell mediated responses show 
considerable promise. However until true universal vaccines become reality, attention 
must also be paid to pandemic preparedness and thus to increasing the speed of vaccine 
production. Platforms such as MVA are potentially very useful for inducing both arms of 
the adaptive immune system, as well as for decreasing response time in an outbreak 
situation. However clinical trials are needed as MVA-vectored vaccines are not yet 
i
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licensed for use in humans and at present their actual deployment in the face of a 
pandemic is still hampered by a number of logistical limitations [133]. 
 
A new model to gain understanding of pathogenesis  
In Chapter 6, we explored the macaque as a model for (emerging) coronaviruses and 
elucidated some of the mechanisms responsible for its limited success.  Since MERS-CoV 
emerged, much effort has focused on finding an appropriate animal model to study the 
disease and test interventions. Several groups have attempted to use the macaque model, 
but to little avail as it does not appear to faithfully reproduce the severe disease seen in 
humans. We delved deeper to better understand what may be responsible for the 
observed limited viral replication. 
 
Young adult cynomolgus macaques were inoculated intranasally and intratracheally with 
MERS-CoV. Viral replication was limited to the lower respiratory tract and therefore 
corresponded to MERS-CoV receptor (DPP4) distribution. However, although the virus was 
able to replicate in the lower respiratory tract, it was cleared rapidly and appeared to 
cause only mild pathological changes. IFN-β  and  phosphorylated  STAT1  expression levels 
were enhanced in the lungs of infected animals, indicating that virus infected cells respond 
normally to interferon signaling, in contrast to what is known for SARS-CoV. 
 
According to our results, both receptor distribution and innate immunity have an 
important effect on restricting MERS-CoV replication. However, there are likely more than 
just these factors at play. Considering the relatively mild disease manifestation in young, 
immunocompetent individuals and the profile of severely affected patients, it is likely that 
the host response is the pivotal factor in the pathogenesis and the outcome of coronavirus 
infections. MERS-CoV affects predominantly middle-aged males with co-morbidities 
(WHO). Similarly, for the other human coronaviruses, host immunity appears to play a 
crucial role in disease manifestation [309-311]. To better understand host immunity to 
coronaviruses, some of the techniques that have been used in influenza research may 
prove interesting to extrapolate and explore, as will be further discussed below.  
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INFLUENZA AND CORONAVIRUSES, POTENTIAL PARALLELS AND FUTURE 
DIRECTIONS  
 
Evidently, the field of influenza virology is significantly more advanced than the field of 
corona-virology, but we must consider that the first human coronavirus of (perceived) 
significant public health impact, SARS, emerged in 2003, whereas research on influenza 
has been ongoing since its discovery by veterinarian Richard Shope in 1931 [312]. Not only 
does influenza have a significant head start; it also has a far greater public health impact, 
which is reflected in the intensity of research and the allocated funding. Also, as discussed 
in this thesis, animal models for influenza viruses are more established, more 
representative of human disease and, as demonstrated by the isogenic guinea pig model, 
potentially more versatile. However in order not to re-invent the wheel for each different 
virus, we might ask if lessons learned from influenza can be of use to improving our 
understanding of coronaviruses. 
 
Despite obvious differences in these pathogens, epidemiologically influenza and 
coronaviruses share some characteristics. Both comprise viruses or subtypes that circulate 
seasonally (coronaviruses NL63-CoV, 229E-CoV, OC43-CoV and HKU-1-CoV and, currently, 
Influenza A subtypes H3N2 and H1N1) affecting large numbers of people [313, 314].  Also, 
both are capable of causing pandemics when new viruses or subtypes emerge (for 
example SARS-CoV and MERS-CoV or Influenza A/H1N1pdm09). Hence in the face of a 
pandemic, the population is naive for the emerging virus but may have been exposed and 
developed immunity to the circulating viruses. In such situations, humoral immunity (in 
the form of neutralizing antibodies) provides little or no cross-protection between 
different subtypes or viruses. However this may not be the case for cell-mediated 
immunity (CMI). Following influenza virus infection, the induction of cross-reactive T cells 
by circulating subtypes has frequently been demonstrated and their protective role in CMI 
to (emerging) heterologous subtypes (including H7N9) is now well established [222]. 
Preliminary results obtained for α-coronaviruses 229E-CoV and NL63-CoV (unpublished) 
show that these viruses appear to be capable of inducing cross-reactive T cells. However, 
much remains to be answered about T cell responses to coronaviruses and equally, T cell 
responses to influenza viruses merit further attention, especially in the context of 
vaccination strategies and novel (universal) vaccines.  
 
One of many fundamental questions that remain to be answered in the understanding of 
coronavirus infections regards the correlates of protection. It is as yet unclear whether 
pre-existing (cellular) immunity to homologous and heterologous coronaviruses is 
i
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protective or detrimental. Immune responses to coronaviruses are complicated and 
excessive or dysregulated reactions by pro-inflammatory cells appear to play a key role in 
their pathogenesis [315]. This information is not only important in understanding natural 
infection dynamics, it must also be taken into consideration when designing vaccines that 
may induce such responses.  
 
Although we now have some evidence for the existence of α-coronavirus cross-reactive T 
cells, it would be of even more interest to establish whether cross-reactive T cells can also 
be demonstrated for β-coronaviruses (OC43-CoV, HKU-1-CoV, SARS-CoV and MERS-CoV). 
Influenza specific cross-reactive T cells have repeatedly been demonstrated using ELISPOT 
INF-ϒ assays [104, 111]. To ascertain whether these methods can be extrapolated and 
adapted for use with for β-coronaviruses, we performed pilot experiments. Unfortunately for such experiments, effective antigen presentation is required and SARS-CoV is known 
to interfere with such presentation [316, 317].  According to results of our pilot 
experiments, this may also be the case for MERS-CoV. Another important factor that 
hampers progress in this direction, is the lack of availability of PBMCs from known-
exposed individuals and indeed the difficulty in even ascertaining such previous exposure. 
As with any well-designed experiment, results can only be interpreted in any meaningful 
way after the inclusion of appropriate controls. In this case, controls should ensure that 
the measured responses are indeed virus specific, and finding the ideal control has been 
another stumbling block in our efforts.  
 
Further effort in optimizing such assays is justified as establishing the presence (or 
absence) of cross-reactive T cells would be useful not only to understand natural disease 
dynamics but is also essential information if diagnostic T cell assays for coronaviruses are 
to be developed. As for serological assays, a diagnostic T cell assay should be specific for 
the pathogen, and the existence of cross-reactivity would therefore interfere with the 
accuracy of such tests. Developing T cell assays for MERS-CoV could be of interest as it has 
been shown that in confirmed MERS-CoV infected individuals, a humoral immune 
response does not always develop. That is to say: several confirmed MERS-CoV infected 
(PCR-positive) individuals never seroconverted (personal communication) and therefore if 
surveillance is based on serology only, this would create an under-representation of the 
actual number of MERS-CoV cases.  
 
The future experiments should ascertain the presence of MERS-CoV specific T cells in 
(recovered) patients and to further understand the exact epitopes targeted. For SARS-CoV, 
the presence of such cells has already been shown repeatedly and responses have been 
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mapped to epitopes on mostly the spike, nucleocapsid and membrane proteins [318] and 
the importance of CD8+ T cells has even been verified in vivo by adoptive transfer in the 
mouse model [319].  
 
As for intervention strategies, MVA vaccines have shown effectiveness against influenza as 
demonstrated in Chapter 5 and there are indications that they may also be the key to 
control of emerging coronaviruses. For MERS-CoV, quite possibly vaccination of the 
intermediate host, the camel, is a more favorable approach than vaccinating humans. In 
the absence of an appropriate animal model as well as in the absence of financial 
incentive, a human vaccine is unlikely to be developed in the near future but fortunately 
recent experiments (in press) have shown that MVA-vectored MERS-CoV vaccines are safe 
and effective for use in camels. Another advantage of using such MVA vectored vaccines 
in this species is that they can potentially be deployed as dual efficacy MERS-
CoV/Camelpox virus vaccines. Although MERS-CoV may not always be perceived as a 
problem in camel owners, camelpox is a known (zoonotic) threat and vaccines for this 
disease are already in use. A dual vaccine could thus face fewer barriers to being adopted.  
Although the presence of camelpox virus in the camel population also means that there 
may be pre-existing immunity to the vector, it has been shown for influenza that MVA 
vectored vaccines can be effective even in the face of such pre-existing immunity [135]. 
 
To conclude, the experiments suggested and the questions raised above represent only a 
tiny fraction of what remains to be answered, and will undoubtedly provide both fun and 
frustration for many generations of PhD candidates to come. Equally, work described in 
this thesis only constitutes a minute contribution to solving the colossal puzzle of 
emerging human respiratory viral infections, but as we all know;  
Rome wasn't built in a day.  
i
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COMMON ABBREVIATIONS 
 
ACE2   Angiotensin-converting enzyme 2 
ADE  Antibody dependent enhancement 
AI   Avian influenza 
APC   Antigen presenting cells 
BSA   Bovine serum albumin 
BSL-3  Biosafety level-3 
CPE   Cytopathic effect 
DEC   Dierexperimenten commissie 
DNA  Deoxyribonucleic acid 
dpi   Days post-inoculation 
DPP4  Dipeptidyl peptidase-4 
ELISPOT  Enzyme-Linked ImmunoSpot 
FFPE   Formalin fixed paraffin embedded 
HA   Haemagluttinin 
HCoV   Human Coronavirus 
HE   Haematoxylin and Eosin 
IFN-ϒ  Interferon gamma 
IHC  Immunohistochemistry 
IMDM   Iscove's Modified Dulbecco's Medium 
IN   Intra-nasal 
ISH   In-situ hybridisation 
IT   Intra-tracheal 
MDCK   Madin- Darby Canine Kidney 
MERS   Middle Eastern Respiratory Syndrome 
mRNA   Messenger RNA 
MVA   Modified Vaccinia Ankara 
NA   Neuraminidase 
NP   Nucleoprotein 
PBMC  Peripheral blood monocyte 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
RNA  Ribonucleic acid 
RT-PCR    Reverse transcriptase PCR 
SA   sialic acid 
SARS   Severe Acute Respiratory Syndrome 
SD  Standard deviation 
TCID50   Tissue Culture Infective Dose 50 
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NEDERLANDSE SAMENVATTING 
 
INLEIDING 
 
Nieuwe virale luchtweginfecties bij de mens worden de laatste jaren steeds vaker 
gerapporteerd. Tijdens de totstandkoming van dit proefschrift zijn twee belangrijke, 
nieuwe, opkomende pathogenen beschreven: het Influenza A H7N9-virus uit pluimvee in 
China en het Middle East Respiratory Syndrome (MERS) -coronavirus uit dromedarissen in 
Saoedi-Arabië. De opkomst van deze pathogenen is voor een groot deel te wijten aan 
veranderingen in menselijk gedrag, waaronder toenemende landbouw en veehouderij, 
groeiende populaties en stijgende globale mobiliteit. 
 
Om deze zoönotische ziekteverwekkers zo goed mogelijk te bestuderen, zijn diermodellen 
die de ziekte in mensen zo nauwkeurig mogelijk nabootsen vooralsnog onmisbaar. Het 
uiteindelijke doel hiervan is het ontwikkelen van effectieve interventiestrategieën, in dit 
geval vooral vaccins. Diermodellen en de toepassing daarvan voor het bestuderen van 
Influenza A en coronavirussen, zijn dan ook het onderwerp van dit proefschrift. 
 
Influenza A-virussen, beter bekend als griepvirussen, zijn negatiefstrengs RNA-virussen 
met een gesegmenteerd genoom dat uit acht (PB2, PB1, PA, HA, NP, NA, M en NS) delen 
bestaat die meerdere eiwitten coderen. De virussen worden onderverdeeld in subtypes op 
basis van hun oppervlakte-eiwitten HA en NA. Er zijn achttien HA subtypen en 11 NA 
subtypen bekend, waarvan H1N1 en H3N2 momenteel verantwoordelijk zijn voor jaarlijkse 
griepepidemieën bij de mens. Om deze griepepidemieën te beperken, bestaan 
verschillende soorten vaccins. Dode vaccins induceren humorale immuniteit, oftewel 
antilichamen, die voornamelijk gericht zijn tegen de kop van de HA, en in mindere mate de 
NA, eiwitten van de op dat moment circulerende subtypes. Aangezien het huidige proces 
van vaccinvervaardiging zeer traag is, moet reeds zes maanden voor het griepseizoen de 
keuze gemaakt worden welke virussen als vaccinstammen gebruikt zullen worden. 
Doordat de polymerase van influenza niet erg nauwkeurig is, kunnen mutaties echter 
zodanig snel optreden dat de bescherming die geboden wordt door deze vaccins, tegen de 
tijd dat de griepepidemie begint, soms niet meer van toepassing is op het inmiddels 
veranderde virus. In deze gevallen is de bevolking niet beschermd en zal er in dat seizoen 
een verhoogde morbiditeit en mortaliteit optreden. Naast het feit dat de huidige dode 
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vaccins dus niet voldoen voor seizoensgebonden griep, gaat de productie van vaccins ook 
te traag wanneer een geheel nieuw subtype opkomt. Het virus kan niet alleen 
overspringen vanuit een dierlijk reservoir maar kan tevens recombineren door 
gensegmenten van verschillende virussen uit verschillende gastheren (bijvoorbeeld vogels 
en varkens) uit te wisselen. Bestaande levende vaccins bieden enig voordeel ten opzichte 
van dode vaccins, omdat ze naast humorale ook cellulaire immuniteit kunnen induceren. 
Een zeer wenselijke eigenschap, aangezien cellulaire immuniteit een bredere bescherming 
biedt, omdat het tevens tegen geconserveerde eiwitten gericht is. Levende vaccins zijn 
echter onderhevig aan dezelfde beperkingen als de reeds beschreven dode varianten en 
bieden daarom geen goed alternatief. 
 
De focus van de influenzawetenschap richt zicht al enige tijd op het ontwikkelen van 
nieuwe vaccins die idealiter een dusdanig brede bescherming bieden dat jaarlijkse 
vaccinatie overbodig wordt en de bevolking beschermd is tegen alle mogelijke 
(opkomende) subtypes; een universeel vaccin. Er zijn talloze manieren getest die 
immuniteit zouden kunnen verbreden en/of gebruik maken van nieuwe formuleringen om 
dit te bereiken. Een voorbeeld daarvan is het Modified Vaccinia Ankara (MVA) vaccin dat 
gebruik maakt van een vaccinia virus vector om de gekozen influenza eiwitten te 
vervaardigen in de gastheer. Deze vaccins zijn effectief, veilig en relatief snel te maken en 
zijn dus, in combinatie met de juiste eiwitten, een veelbelovende combinatie. 
 
Diermodellen zijn van groot belang, zowel om meer te weten te komen over het 
samenspel tussen het influenzavirus en de gastheer, als voor het testen van nieuwe 
vaccins. De meest gebruikte diermodellen voor influenza zijn muizen, fretten en cavia's. Al 
deze diersoorten hebben voor- en nadelen maar tot op heden wordt de fret beschouwd 
als de gold standard voor influenzaonderzoek. In hoofdstuk 5 van dit proefschrift hebben 
wij dan ook gebruik gemaakt van dit diermodel om een nieuw MVA-vaccin tegen het 
recent opgekomen influenza A/H7N9-virus te testen. Isogene fretten zijn echter niet 
verkrijgbaar en daarom is dit diermodel niet optimaal voor het bestuderen van cellulaire 
immuniteit, waarvoor voornamelijk muizen gebruikt worden. In tegenstelling tot fretten 
zijn muizen echter geen goed model voor het bestuderen van transmissie van influenza-
virussen. In hoofdstuk 2, 3 en 4 worden de eerste stappen voor het ontwikkelen van een 
nieuw diermodel beschreven. Het betreft de isogene stam-2-cavia, die uitzonderlijk 
geschikt zou zijn voor gelijktijdig onderzoek naar transmissie en naar cellulaire immuniteit. 
Coronavirussen (CoV) zijn positiefstrengs RNA-virussen die bedekt zijn met conisch 
gevormde oppervlakte-eiwitten (het S-eiwit) die rondom het viruspartikel de kroon 
vormen waaraan het virus zijn naam verleend. Deze S-eiwitten zijn belangrijk voor het 
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binden van het virus aan de receptoren op de gastheercel en deze eiwitten zijn dan ook 
bepalend voor welke diersoorten door het virus geïnfecteerd kunnen worden. Er zijn 
momenteel  zes  humane  coronavirussen  bekend,   twee  α-coronavirussen (229E- en NL63-
CoV)  en  vier  β-coronavirussen (OC43-, HKU-1-, SARS- en MERS-CoV), die alle voornamelijk 
respiratoire klachten veroorzaken. 
 
Het eerste humane coronavirus dat beschouwd werd als belangrijk voor de 
volksgezondheid, het Severe Acute Respiratory Syndrome (SARS)-CoV, sprong rond 2002 
over van de civetkat naar de mens en veroorzaakte een uitbraak in meer dan 8000 
mensen waarvan er ongeveer 800 stierven. Voor het opkomen van SARS-CoV, waren 
alleen OC43-CoV en 229E-CoV bekend als veroorzakers van overwegend milde bovenste 
luchtweginfecties bij de mens. Na de SARS-CoV-uitbraak werden nog twee virussen 
ontdekt, NL63-CoV en HKU-1-CoV, die eveneens voornamelijk milde bovenste 
luchtweg-infecties veroorzaken. Het was enige tijd stil rondom coronavirussen tot in 2012 
MERS-CoV werd geïdentificeerd als de veroorzaker van ernstige lagere luchtweginfectie bij 
mensen in het Midden-Oosten. Na uitvoerig onderzoek werd de dromedaris als 
tussengastheer voor dit virus aangewezen. Door de genetische verwantschap met 
coronavirussen die in vleermuizen gevonden zijn, wordt aangenomen dat zowel SARS- als 
MERS-CoV oorspronkelijk voort zijn gekomen uit deze diersoort. 
 
Gezien de relatief recente ontdekking van coronavirussen als pathogenen bij de mens, is 
veel minder bekend over de pathogenese vergeleken met influenza. Ondanks meerdere 
veelbelovende kandidaten (waaronder wederom MVA-vaccins, ditmaal op basis van het S-
eiwit) is er op dit moment dan ook nog geen vaccin op de markt. Dit komt deels door het 
feit dat het zeer uitdagend is gebleken om representatieve diermodellen te ontwikkelen 
voor deze virussen. Diermodellen voor SARS-CoV zijn wel ontwikkeld, onder andere 
fretten en (na aanpassing van het virus) muizen kunnen geïnfecteerd worden, maar geen 
van deze modellen bootst het ziektebeeld in mensen goed na. Ziekteverschijnselen in 
oudere makaken leken tot nu toe het best overeen te komen met de ziekte in mensen, 
maar om ethische en praktische redenen is dit model van weinig nut voor algemeen 
onderzoek. In Hoofdstuk 6 worden diermodellen voor MERS-CoV en NL63-CoV onderzocht 
en vergeleken met historische informatie over SARS-CoV. Naast een transgene muis, en 
mogelijk het penseelaapje, zijn diermodellen voor MERS-CoV tot nu toe helaas weinig 
representatief.  
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DIERMODELLEN VOOR INFLUENZAVIRUSSEN 
 
Isogene stam-2-cavia's lijken een veelbelovend diermodel om transmissie en cellulaire 
immuniteit gelijktijdig te bestuderen, iets wat niet mogelijk is in fretten of muizen. Om een 
diermodel te ontwikkelen, moeten echter eerst de basisprincipes vastgesteld worden. 
Zoals beschreven in hoofdstuk 2, zijn ten eerste cavia's intra-nasaal of intra-tracheaal 
geïnoculeerd met de pandemische stam van influenza A H1N1 (H1N1pdm09). Hieruit 
bleek dat intra-tracheale inoculatie meer longontsteking veroorzaakt en dat het virus na 
intra-nasale inoculatie vrijwel uitsluitend in de neus te vinden is. Omdat het model 
toegepast zal worden om de immuunreactie op ernstige longontsteking te onderzoeken, is 
intra-tracheale inoculatie dus een betere methode. Uit dit experiment bleek ook dat de 
piek van virusreplicatie reeds op dag 2 plaatsvond en deze informatie is eveneens 
belangrijk voor toekomstige experimenten. 
 
In hoofdstuk 3 zijn de lessen die geleerd zijn uit hoofdstuk 2 toegepast om een soortgelijk 
experiment  uit   te  voeren   in   isogene  cavia’s,  ditmaal  met  het   Influenza  A  H7N9-virus. Dit 
virus bleek ernstiger laesies te veroorzaken, met name in de longen. Dit komt overeen met 
de verwachtingen, aangezien dit virus van aviaire herkomst is, dus   aan   α-2,3-siaalzuur 
gekoppelde receptoren bindt, die zowel bij de cavia als bij de mens in hogere mate 
aanwezig zijn in de lagere luchtwegen. Het H7N9-virus bleek eveneens langer via de neus 
uitgescheiden te worden dan H1N1pdm09. 
 
Nadat gegevens over het gedrag van deze twee virussen (H1N1 en H7N9) in dit model 
verzameld waren, was de volgende stap om de basisprincipes van de immuniteit tegen 
influenza in isogene cavia's vast te stellen door het aantonen van heterosubtypische 
immuniteit. Heterosubtypische immuniteit treedt op wanneer een infectie met een 
influenza -subtype (gedeeltelijke) bescherming biedt tegen infectie met een ander 
subtype. Zoals in hoofdstuk 4 wordt beschreven, werden cavia's hiervoor eerst 
geïnoculeerd met H1N1pdm09 of met een zoutoplossing (controledieren). Vier weken 
later werden de dieren wederom geïnoculeerd maar ditmaal met H7N9- virus. De virale 
kinetiek en de laesies werden vergeleken en het bleek dat dieren die eerder een H1N1 
virusinfectie doorgemaakt hadden deels beschermd waren tegen H7N9- virus. Er werd 
aangetoond dat antilichamen niet verantwoordelijk waren voor de geobserveerde 
bescherming en dus is het aannemelijk gemaakt dat dit een manifestatie van cel 
gemedieerde heterosubtypische immuniteit is. 
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In hoofdstuk 5 werd het belang aangetoond van het gebruik van bestaande diermodellen 
om nieuwe interventiemethoden preklinisch te testen. Het vaccin werd samengesteld uit 
MVA in combinatie met het HA-eiwit van het H7N9-virus. Fretten werden op verschillende 
wijze gevaccineerd, meerdere malen en/of met verschillende dosis, en hieruit bleek dat 
een enkele vaccinatie met een hoge dosis al genoeg is voor bescherming. Tweemaal 
vaccineren met een lage dosis bleek daarentegen minder effectief. MVA vaccins lijken 
interessante vaccinkandidaten, aangezien ze effectief en veilig zijn en daarnaast in relatief 
korte tijd in grote hoeveelheden geproduceerd kunnen worden. 
 
DIERMODELLEN VOOR CORONAVIRUSSEN 
 
Voor de humane coronavirussen die voornamelijk milde symptomen in de bovenste 
luchtwegen veroorzaken, is vooralsnog niet veel bekend over mogelijke diermodellen, 
mede omdat er weinig stimulans is om deze virussen in meer detail te onderzoeken. 
Terwijl er voor SARS-CoV aanzienlijk meer inspanning is geleverd, heeft dat relatief weinig 
opgeleverd. In hoofdstuk 6 wordt het makaakmodel gebruikt om beter te begrijpen 
waarom MERS-CoVreplicatie in dit diermodel zo beperkt is en worden de verkregen 
resultaten vergeleken met andere coronavirussen NL63-CoV en SARS-CoV. De receptor 
voor MERS-CoV, DPP4, wordt vrijwel uitsluitend in de lagere luchtwegen gevonden wat 
zou kunnen verklaren waarom dit virus vooralsnog niet eenvoudig overspringt van mens 
naar mens. ACE-2, de receptor voor SARS- en NL63-CoV, is aanwezig in zowel de bovenste 
als de lagere luchtwegen en longen, maar waar SARS-CoV in het gehele respiratoire 
systeem lijkt te repliceren, wordt NL63-CoV voornamelijk in de bovenste luchtwegen 
gevonden. Ook wordt aangetoond dat, in tegenstelling tot wat bekend is voor SARS-CoV, 
MERS-CoV geïnfecteerde cellen wél vatbaar zijn voor de antivirale werking van IFN-β  en  
dat het aangeboren (innate) immuunsysteem op die manier de infectie beperkt. 
  
DISCUSSIE 
 
De tot nu vergaarde kennis over coronavirussen loopt achter op het influenza 
onderzoeksveld, maar in beide disciplines zijn nog vele vragen onbeantwoord. Het is van 
belang dat onderzoek voortgezet wordt omdat het risico dat nieuwe virussen uit deze 
families in de toekomst op zullen komen zodanig is dat het eerder een kwestie van 
wanneer dan of  het zal gebeuren. 
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Een universeel vaccin blijft het hoogste doel van influenzaonderzoek, maar voordat dit 
vaccin daadwerkelijk ontwikkeld en klaar voor gebruik is, zullen nog vele jaren verstrijken. 
Gedurende deze periode is het belangrijk , mede door middel van diermodellen, aandacht 
te besteden aan zowel het virus als de gastheerrespons. Daarnaast kunnen bestaande 
interventiestrategieën zoals MVA geoptimaliseerd worden om zo beter en sneller 
voorbereid te zijn mocht een nieuwe influenzapandemie zich voordoen. 
 
Voor het bestuderen van coronavirussen liggen nog veel meer vragen open, niet in het 
minst hoe de ziektes adequaat bestudeerd kunnen worden in de afwezigheid van goede 
diermodellen. Mogelijk kunnen experimenten met humane witte bloedcellen, zoals die 
uitgevoerd zijn voor influenza, uitkomst bieden voor in vitro studies naar immuniteit. Het 
is vooral van groot belang om meer informatie te vergaren over de exacte rol van het 
immuunsysteem, want tot dusver is het niet altijd duidelijk wanneer en hoe het bijdraagt 
aan bescherming en wanneer het juist ziekteverschijnselen bevordert. Deze informatie is 
van groot belang voor vaccinontwikkeling. 
 
Dit proefschrift omvat slechts een minuscuul deel van een kolossale globale puzzel, maar 
alle beetjes helpen; Rome is immers ook niet op een dag gebouwd. 
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antwoord op al mijn stomme vragen. Miranda, toen je eenmaal ontdooid was bleek je eigenlijk 
een gewoon lieverdje (daar gaat je reputatie als b*tch). Nella, dank voor al je hulp en de mooie 
momenten, ben blij dat het zo goed met je gaat! Arwen, heel veel succes, het is over voor je 
het weet. Mark, overleef tussen de dames! Joost, zonder jou geen hoofdstuk 5 en zonder 
hoofdstuk 5 geen proefschrift dus ik ben je dankbaar en vond het super relaxed werken met je 
:) Rogier, gast, wij komen elkaar vast nog wel tegen; jij gaat volgens mij hele gave dingen doen, 
of anders ga je op 40ste met pensioen maar wat het ook is, altijd met een big smile. 
De andere (ex-)leden van FLU-II: Gerrie, Tiny, Heidi, Marine en Ruud, dank jullie voor het delen 
van al jullie kennis en voor de hulp, het was een plezier om met jullie te werken.  
De wildlife groep, mijn tweede thuis :) Peter, wat heb jij ontzettend veel voor me gedaan en je 
was nooit gestrest en altijd vrolijk, maakt het leven een heel stuk prettiger! Lonneke en Marco, 
ook jullie bedankt voor alle hulp. Jurre, life's a trip, have a good one! Debby, superwoman, 
dank voor de gezelligheid, de steun en het optimisme, ben benieuwd wat jij allemaal nog gaat 
doen.  Edwin,   ik  ben  geloof   ik   langer  collega’s  met   jou  geweest  dan  wie  dan  ook,  en  gelukkig  
maar want ik vond het super fijn om met je samen te werken. 
Bart’s  group,  Do,  dude,  you’re  a  unique  combination  of  the  grumpiest  and  the  most  cheerful  
person I know. Thank you for the life-saving shoulder massages, the unsolicited  and often 
unflattering appraisals of how I looked  and everything you did for the MERS paper. Just hang 
in there, there is light at the end of the tunnel I promise! Stalin, Saskia, Debby S., en Lisette 
dank jullie voor de fijne samenwerking! 
Mathilde ma belle, thanks for being there, even if we never managed to meet up as much as 
we intended, it was great having you around for chats, dinners and moral support. Kirsty and 
Keng, thanks for all the delicious dinners and the wonderful evenings of randomness, hope to 
make it to Australia one day to see you. Ramona thanks for the fun dinners and chats. 
Leslie, thank you for pancakes, barbeques, EWDA meetings, dog walks, visits to Annecy and 
philosophical chats. I look forward to working with you in the future, not sure how or when but 
I sense it will happen. 
Dear Stefanie and Mechtild, thank you and your lovely team at the BfR so much for all you help 
and wonderful coordination. I enjoyed our meetings and although I am happy not to do any 
animal experiments anymore, I will miss my visits. I hope our paths will cross in the future and I 
wish you the very best. Dear Hubert, thank you for the support of the guinea pig project, I 
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sincerely hope that my work will help justify the maintenance of the colony, in Berlin or 
elsewhere. 
Theo, dank je voor alles wat ik van je geleerd hebt, voor alle keren dat je me (uit de brand) 
geholpen hebt en er voor me was. David, bedankt voor hulp met cijfertjes. Rik bedankt voor 
het lenen van proefdier gadgets. Ron bedankt voor je scherpe oog. Sarah bedankt voor ISH. 
Oanh, bedankt voor virus transport medium. Marco bedankt voor Viruskenner, wat heb je dat 
gaaf gedaan, ik hoop dat het blijft groeien!  
Exotics groep, Byron, Penelope, Petra, Jeroen, Stephanie, bedankt voor de goeie borrels. 
Andere fijne collegas, ook bedankt, Brooke, Bri, Monique, Mart, Gijs, Hans, Robert, Stefan x2, 
Pascal x2, Jonneke, Bjorn, Bernadette, Kim, Kleine Sander, Martin, Chantal, Cox, Sumeyra, 
Lennert, Wesley, Colin, Judy en de mensen van ViroClinics. 
Dames van het secretariaat: Loubna, Maria, Anouk, Simone, dank jullie voor alle moeite en alle 
gezelligheid. Ik hoop dat ik niet te vervelend ben geweest, ik ben jullie in ieder geval erg 
dankbaar! 
Everyone from the EWDA student chapter, the EWDA board and the one health/wildlife 
community; it has been great working with you. Christian and Marianna, gracias por todo, 
espero que nos veamos a Roma. Bieneke en Aniek, jullie zijn mooie dames en ik hoop in de 
toekomst nog vaak met jullie te werken. 
Fellow pathologists / marine mammal buddies Mark, Andrew, Lonneke, Tilen and Thierry and 
of course my honorary older sister Johanna, thanks for all the fun, parties and support. Ex-
collegas uit Utrecht, dank voor de mooie tijden. 
And then friends, you all know what you mean to me but I have to keep saying it, you guys kept 
me afloat over the years even if we are in different countries. Ainhoa, Amaia, Liza, Diane, Line, 
Pablo, Dimi and Sergio, you guys are the best! 
All my acro buddies from around the globe, acrobatics is what kept me going while writing this 
and so you guys were indispensable. Gemma y Diana, guapas, espero que coincidimos en algún 
lugar del mundo para entrenar, y espero que os vaya muy bien con la tesis. Paul, Hans en 
Fedde dank jullie wel, ik mis de dinsdagavond vreselijk en ik mis jullie als maatjes, samen 
spelen was precies wat ik nodig had voor balans, jullie zijn me zo dierbaar! Sabine ik denk niet 
dat een vliegende proefschrift verdediging er nog in zit, maar alle lol die wij in de lucht hebben 
gehad heeft ook dit boekje mogelijk gemaakt.  
Tango friends, Cherif, Dragan and Derek, thank you so much for teaching me how to lose 
control and be led. 
Extended family, Tobias&Lisette en Fons&Jorijn dank voor jullie steun en onvoorwaardelijke 
vriendschap. 
Cat, thank you for being being you. You make me feel less weird :) You were part of making this 
thesis in many ways. My trips to Berlin to pick up a new load of unfortunate experimental 
animals were made so much better by knowing that I got to hang out with you. You always 
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took such great care of me. You helped me so much both in real support with the layout and in 
moral support. Just knowing you're there makes everything better :)  
Carlo and Gilda, I'm so glad you guys came back home to Rome, you have no idea how happy I 
am that you're here. You've been amazing, I hope there are more many barbeques and 
bullsh*t to come. Thank you most of all for introducing me to my Prince in the White Fiat 
Panda aka il Pangolino Gigante, the only man who is both tall enough and weird enough for 
me. By doing this, you have changed my life forever and I am so grateful for that. 
Soph, I was so hoping to share this with you. I know you would have been my only friend who 
would have actually read it and then asked me a million questions about it. Words fail me to 
describe how empty it feels now you are gone... Your beautiful girls will always be safe with 
me. I love you. 
En dan mijn Marius, DIT PROEFSCHRIFT WERD MEDE MOGELIJK GEMAAKT DOOR MARIUS VAN 
DER PLOEG ;) Je bent m'n enige grote broer en je hebt me altijd en op iedere manier 
ondersteund, je hebt achter me gestaan en me een veilige plek gegeven. Je bent zo lief en 
genereus, zorg alsjeblieft goed voor jezelf. 
Dan mijn familie. Hier kom ik echt woorden tekort. Ik krijg niet zo vaak de kans om op papier te 
zetten hoe ontzettend veel ik van jullie allemaal hou. Ik heb zo'n geluk dat ik uit zo'n veilig 
warm nest kom, dat heeft me alle kansen gegeven om ver uit te vliegen. Ik heb altijd een 
vangnet en ik weet dat wat er ook gebeurt en waar ik ook ben, jullie stuk voor stuk altijd 
allemaal achter me staan en als het nodig is, in het eerste vliegtuig stappen om bij me te zijn. 
Mijn paranimf, zusje en beste vriendinnetje Rienke, ik hou zo ontzettend veel van je en ben je 
zo dankbaar voor alles. Ik ben blij dat je nu ook Eelco hebt voor alle mooie en moeilijke tijden, 
maar ik blijf ook voor je klaar staan. Marijn en Tos en jullie ontzettend mooie lieve Sacha, 
Tijmen, Mila en Ytsa, ik weet dat jullie trouwen belangrijker vinden dan promoveren en ik ga 
zorgen dat ik in al jullie wensen voorzie ;) Fem en Jan, ik heb zo vaak bij Fem aangeklopt voor 
praktische dingen en je staat altijd klaar, ik weet niet of ik je daar wel vaak genoeg voor 
bedankt heb? En dan Pap en Mam, ze zeggen dat je je eigen dromen aan je kinderen doorgeeft, 
en dus misschien dat ik daarom nu promoveer en met een Italiaan ga trouwen? Gelukkig maar 
dat jullie zulke mooie dromen hadden.... 
Pango mio, I know you hate PDA (oh my gosh) but I have to say, thank Carlo we met! You are 
the man I thought didn't exist, the last surviving unicorn. You have changed everything, and I 
am so happy with you. Your family is like my family and that is the biggest compliment I can 
give; grazie per tutto Vitti e Paolo!) Pangolone, thank you for your infinite patience and 
understanding while I was doing this. It helps that you know what it feels like. I love you so 
much and I am so happy that we will be Dr. Pango and Dr. Panga aka da Pangooooooos 
(whistle the song). 
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